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ABREVIATIONS 
 
 
MUC1  mucine 1 
RNA   ribonucleic acid 
VNTR  variable number of tandem repeats 
GalNAc  N-acetylgalactosamine 
GlcNac  N-acetylglucosamine 
MHC   Major histocompatibility complex 
HLA-A,B,C human leukocyte antigen 
H2Kb   mouse MHC class I allele 
CTL   cytotoxic T lymphocytes 
IgG, IgM  Immunoglobuline G, Immunoglobuline M 
APC   antigen presenting cells 
DC   dendritic cells 
IPs   immunoproteasomes 
INF γ   Interferon gamma 
IL-4   Interleukin-4 
TNF-α  Tumor Necrosis Factor-alpha 
GM-CSF  Granulocyte-Macrophage Colony Stimulating Factor 
ER   Endoplasmatic Reticulum 
ERAD  Endoplasmatic Reticulum Associated Degradation 
Tg mice  transgenic mice 
HPLC   high pressure liquid chromatography 
 
 
Units of Measure and Prefixes 
°C   degree Celsius 
Da   Dalton 
g   gram 
h   hour 
L   litre 
m   meter 
min   minute 
s   sec 
V  volt 
MW   molecular weight 
 
Symbol Prefix (Factor) 
k kilo (103) 
c centi (10-2) 
m milli (10-3) 
µ micro (10-6) 
n nano (10-9) 
p pico (10-12) 
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1.1 Breast cancer 
Breast cancer is the primary cause of death of women in the western countries, accounting 1 
out of 10 women. Just over 1 million of people per year get diagnosed with breast cancer and 
around 400.000 die. Despite a 60% survival rate 1100 persons die daily due to breast cancer 
(Parkin DM et al.,2001).  
The small size of most cancer nodes (below two centimetres) results in late detection, and 
localisation in the proximate neighbourhood of lymph nodes increases the metastatic 
probability. The best prognosis for breast cancer patients is still dependent on an early 
detection. Although many efforts have been made to develop new diagnostic and therapeutic 
tools, surgery with chemotherapy and radiation are still the methods of choice for breast 
cancer treatment.  
Breast cancer is actually a common name for different malignant incidences which can be 
classified in ductal, lobular, medular, tubular and mucinous carcinoma or as inflammatory 
breast cancer, Paget’s disease of the nipple and phyllodes tumor (Berg JW et al., 1995).  
Ductal carcinoma originates in the milk ductus and after 
conveying metastatic potential, it can spread through the body. 
Around 80% of all breast cancers are invasive ductal 
carcinoma.  
Lobular carcinoma originates in the milk producing glands. In 
invasive form it spreads to surrounding fatty tissue and can 
metastasize. 10-15% of all breast cancers are of invasive 
lobular type.  
Other types of breast cancer are rare and represent between 1 
and 5% of all breast cancer cases. 
A large number of tumor markers in the sera of patients indicate breast cancer. These include 
MUC1 (e.g. CA15-3), CEA, HER-2oncogene, p53 tumor-suppressor, glycolytic enzymes and 
cytokeratins. Compared to healthy individuals and patients with benign breast diseases, 
patients with breast cancer have elevated levels of breast antigens circulating in their plasma 
and/or serum.  
  
 
Figure 1: Brest anatomy 
showing ducti and lobule. 
From the web site 
http://www.breastbiopsy.com/bi
oresults_typesofbreastcancer2
.jsp 
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1.2 MUC1 and mucins 
Mucins are high-molecular weight glycoproteins, representing the main constituents of mucus 
and the glycocalix of epithelial and some non-epithelial cells. Common functions of mucins 
are lubrication and protection. The family of mucin proteins consists of up to now 19 defined 
proteins (Entrez-Protein database, Table 1), MUC1-MUC20. Their MW of 100.000 till 
1.000.000 is by 50-90% contributed by carbohydrates.  
Mucin-
Name 
Secretory 
Membraneous 
Chromosomal 
localisation 
Expressing tissue Literature 
Mucin 1 m,s 1q21-q24 Ubiquitous Gendler et al., 1990 
Mucin 2 s 11p15 GI tract, respiratory tract Gum et al., 1994 
Mucin 3 m,s 7q22 GI tract van Klinken et al., 1997 
Mucin 4 m,s 3q29 GI tract Nollet et al., 1998 
Mucin 5AC s 11p15 Respiratory tract Guyonnet Duperat et al., 1995 
Mucin 5B s 11p15 Respiratory tract, Stomach Meerzaman et al., 1994 
Mucin 6 s 11p15.5-15.4 Bile duct Toribara et al., 1993 
Mucin 7  s 4q13-q21 GI tract Bobek et al., 1993 
Mucin 8 / 12q24.3 Saliva gland Shankar et al., 1994 
Mucin 9 / 1p13 Trachea Lapensee et al., 1997 
Mucin 11 / 7q22 Oviduct Williams et al., 1999 
Mucin 12 m,s 7q22 GI tract, Uro-genital tract Williams et al., 1999  
Mucin 13 m 3q13.3 GI tract, Uro-genital tract Williams et al., 2001 
Mucin 15 / 11p14.3 GI tract Pallesen et al., 2002 
Mucin 16 m 19p13.3 Genital tract, GI tract, 
lymph organs 
Yin et al., 2001 
Mucin 17 m 7q22 Ovaries Gum et al., 2002 
Mucin 19 / 12q12 Trachea, Saliva gland Chen et al., 2003 
Mucin 20 / 3q29 Kidneys, Placenta, Lungs, 
Prostate, Liver  
Higuchi et al., 2004 
 
Table 1. The list of currently identified mucins, with chromosomal localisation, tissue expression 
and the mark about secretory or transmembrane form of the protein 
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The currently known MUC species can be subdivided into two groups based on their 
structural aspects and biosynthetic routes: membrane bound and secretory mucins. 
Membrane bound mucins (MUC1, MUC3, MUC4, MUC12) are essential components of the 
glycocalix. Their hydrophobic transmembrane domains are anchoring the protein within the 
lipid bilayer with C-terminus oriented toward the cytosol (Table 1). Most of the membrane 
bound mucins show tissue-specific expression patterns (Hanisch FG et al., 2000).  
Secretory mucins are the main constituents of the visco-elastic mucus gel and are mainly 
coded by a gene cluster on chromosome 11p15.5. All secretory mucins (MUC2, MUC5AC, 
MUC5B, MUC6) except MUC7 possess one or several von Willebrandt factor-like D domains 
(Hanisch FG et al., 2000), cysteine-rich peptides, which function in the oligomerization of 
mucin monomers and in the packaging into secretory vesicles (Perez-Vilar J et al., 1999). 
Other mucin genes are randomly scattered over the genome.  
The special characteristic of all mucins is the presence of a “tandem repeats domain”, several 
tens till hundreds of repeats of a peptide (Fowler J et al., 2001). The number of tandem 
repeats varies due to the diversity of mRNA length from 0,4 to 20kb transcribed from the 
single gene. Tandem repeats are heavily O-glycosylated by long glycan chains (up to 20 
monosaccharides per chain) on numerous serines and threonines. At terminal position 
negatively charged sugars, like sialic acid or sulphated sugars, are often found. The sugar 
chain composition and length are tissue specific. Because of the high proline content, the 
complete molecule is extended and protruding from the cell surface (Figure 2).  
 
Figure 2. Model of mucins and other cell surface glycoproteins/proteoglycans. The figure 
schematically portrays structures of four size classes of mucins as well as consensus structures for 
syndecans and integrins. All extracellular portions of these molecules are roughly drawn to scale. Blue 
squiggles represent O-linked oligosaccharides while red squiggles represent glycosaminoglycans. 
Integrins, syndecans and most other surface receptors do not extend beyond 50 nm from the cell 
surface; however, with the exception of MUC13, mucins extend much further due to the extended 
structures contributed by the proline-rich heavily O-glycosylated tandem repeat domains. MUC1 and 
MUC4 are the largest transmembrane mucins, extending >200 nm from the cell surface. The 
ectodomain structures of MUC16 and MUC17 are considerably shorter than those of MUC1 and 
MUC4, but still much larger than those of other surface glycoproteins. Soluble mucins, such as MUC2, 
5AC, 5B and 19 are even larger, reading 500–100 nm in length (Brayman M et al., 2004). 
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The functions of mucins are mainly influenced by sugar presence.  The major common 
function of mucins is protection of the cellular surface of mechanical injuries and micro-
organisms, prevention of dehydration as well as lubrication, especially in the gastrointestinal, 
respiratory or reproductive tracts (Perez-Vilar et al., 1999). These functions are contributed 
mainly by secretory forms of mucins, which reside close to the apical surface of epithelia cells 
in the form of oligomers connected by disulfide bridges. Membrane bound mucins are as 
monomers attached to the cell membrane, where beside protective functions they influence 
cell-cell interactions. The long, protruding structure of mucins (Bramwell ME et al.,1986) 
introduces anti-adhesive effects and prevents cell-cell and cell-extracellular matrix contacts 
(Ligtenberg MJ et al., 1992), thereby taking part in epithelial morphogenesis (Hilkens J et al., 
1992), migration, proliferation of cells, carcinogenesis and metastasis. Specific interactions 
with E-selectine and integrins involve mucins in inflammation, development and lymphocytes 
homing (Walz et al., 1990; Yuen CT et al.,1992; Schimizu Y et al.,1993).  
1.2.1 MUC1 
The first mucin characterized during the 80ies was MUC1, a large glycoprotein existing in 
both secretory and transmembrane forms. It was described under numerous names: 
Polymorphic epithelial mucin, PEM, PEMT, Episialin, Tumor-associated mucin, Carcinoma-
associated mucin, Tumor-associated epithelial membrane antigen, EMA, H23AG, Peanut-
reactive urinary mucin, PUM, Breast carcinoma-associated antigen DF3, CD227 antigen. 
Finally it was systematically designated as MUC1 (Figure 3).  
 
Figure 3. The structure of MUC1. The 72 amino acids cytosolic domain is shown in purple. The 28 
amino acids domain is shown in green. The VNTR region is shown in blue while the rest of the protein 
is shown in tan. The extensive O-linked glycosylation in the VNTR region is indicated with the stick 
figures. 
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1.2.1.1 MUC1 localisation 
MUC1 exhibits a ubiquitous organ distribution (Fig. 4), (Zotter et al., 1988) including 
mammary gland acini and ducts, salivary gland ducts and serous acini, but not mucinous acini; 
squamous epithelium of the esophagus; parietal cells, canaliculi and peptic cells of the 
stomach; acini and ducts of the pancreas; bile ducts in the liver; enterocytes of the duodenum, 
but not the large intestine; respiratory and ciliated epithelium of the lungs, serous bronchial 
glands, but not mucinous ones; distal tubules of the kidney and collecting ducts, but not 
proximal tubules; bladder urothelium; prostate gland epithelium; resting endometrium of the 
uterus; rete testis; (activated) mesothelium. Important negative tissues are the skin epithelium 
and all kinds of mesenchymal tissues. Beside epithelial tissues, MUC1 was found on 
lymphoid cells and lymphomas, especially on plasma cells and myelomas (Zotter et al., 1988; 
Treon et al., 1999) as well as on erythroblasts. MUC1 presence is moreover reported for 
activated T cell and mature dendritic cells, but not on resting T cells and immature dendritic 
cells.(Clossen S et al.,2004; Agrawal et al., 1998)   
 
Figure 4. Structure of MUC1 in the transmembrane form and the list of MUC1 positive tissues 
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1.2.1.2 MUC1 Gene 
MUC1 is coded by a gene localised on the long arm of chromosome 1 in the 1q21-q24 region. 
The gene is composed of seven exons that together comprise 4,2 to 7,0 kb of genomic DNA. 
The alternative splicing of mRNA gives rise to transcripts of 3.7 to 6.4 kb coding for the 
different isoforms of the MUC1 protein, transmembrane, secretory, and MUC1 X/Y/Z isoforms.  
1.2.1.3 MUC1 protein structure 
The alternative splicing results in the generation of several isoforms of MUC1 protein, and 
therefore we speak of MUC1 polymorphism. Several forms of MUC1 are formed: 
1. MUC1/REP: heterodimeric complex of a large tandem repeat ectodomain component 
and a small transmembrane component (Ligtenberg MJ et al., JBC 1992) 
2. MUC1/SEC that contains tandem repeat but no transmembrane domain (Smorodinsky 
N et al., 1996)  
3. Short MUC1/X/Y/Z membrane anchored isoforms generated by alternative splicing 
and devoid of tandem repeats. (Zrihan-Licht S et al., 1994; Baruch A et al., 1997; 
Oosterkamp HM et al., 1997) 
Figure 5. MUC1 protein isoforms. Domains re-occurring in various MUC1 isoforms are marked with 
the pattern. N and C represent amino and carboxy termini of the protein, TM – transmembrane 
domain; CYT-cytoplasmic domain, SP – signal peptide. The proteolytic cleavage site in the 
MUC1/REP protein is indicated by the open arrow. Cleavage divides the protein into the large tandem 
repeat array (VNTR)-containing extracellular domain and the smaller proteolytic cleavage product, 
which contains the cytoplasmic domain. 
                Wreschner DH  
VNTR 
VNTR 
VNTR 
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The best characterized MUC1 gene product is a long membrane associated protein, named 
also a MUC1/REP. It is a type 1 transmembrane mucin-like protein (Fig. 5) consisting of two 
sub-domains: large extracellular domain and short cytoplasmic tail. After a translation of 
MUC1 mRNA, the MUC1/REP protein is autolytically cleaved in the endoplasmatic 
reticulum. This cleavage generates two peptide chains that get noncovalently re-associated in 
the proximity of the cleavage site (Ligtenberg MJL et al., 1992). The larger of the cleavage 
products is the ectodomain component, mainly built by the variable number of tandem repeats 
(VNTR), flanked by short degenerate sequences and non-repetitive sequences at both sides of 
the protein (Wreschner DH et al., 1990; Ligtenberg MJL et al., 1990; Gendler SJ et al., 1990; 
Abe M et al., 1993). The VNTR region contains 20-125 repeats of the 20-meric amino acid 
sequence PAPGSTAPPAHGVTSAPDTR repeat which represents 50-80% of the peptide mass 
(reviewed in Gendler SJ et al., 1995; Lagow E et al., 1999). MUC1 protein is highly 
polymorphic in the population with respect to the number of tandem repeats as well as the 
presence of sequence variations within the tandem repeats (major being DT>ES). Shorter 
cleavage product carries the cytoplasmic and transmembrane domain.  
The MUC1/REP extracellular domain can be shed from the cell by a yet not completely 
understood mechanism and found in the sera of breast cancer patients at increased levels 
(Baruch A et al., 1999). During its biosynthesis, the MUC1/REP protein is extensively 
modified by O- and N-glycosylation. O-glycosylation takes mainly place within tandem 
repeats of the VNTR region.  Further on, MUC1/REP proteins can be subdivided into four 
variants A-D, which arise from the single nucleotide polymorphisms. 
The MUC1/SEC protein contains full length sequence corresponding to the extracellular 
domain of MUC1/REP, but lacks the membrane anchoring hydrophobic domain as well as the 
intracellular domains. (Fig. 5) 
In contrast to MUC1/SEC, short MUC1/X/Y/Z splice isoforms contains a transmembrane and 
cytoplasmic domains identical to the MUC1/REP, but their extracellular part contains neither 
the repeat array domain nor its flanking region and, hence, are devoid of the hallmark mucin-
like features (Fig. 5). (Baruch A et al., 1999) 
Due to the abundant glycosylation of the VNTR region with frequent negatively charged 
terminal sugars and because of the high number of proline residues, MUC1 has an extended, 
rigid form protruding 200-500 nm from the cell surface into the lumen. (Fig.2  Brayman et al., 
2004). 
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1.2.1.4 MUC1 functions 
Beside functions common to all glycocalix-building proteins, like lubrication, hydration, and 
protection from microbes, MUC1 fulfils several other more complex roles. So is MUC1 
reported to take part in signal transduction, binding of actin cytoskeleton and it influences 
cell-cell and cell-matrix contacts and metastases. 
It has been shown that MUC1 mucin undergoes phosphorylation on both tyrosine and serine 
residues of the cytosolic domain and, as a consequence, can potentially bind second 
messenger or adaptor proteins such as Grb2 (Wreschner DH et al., 1994, Zrihan-Licht S et al., 
1994). Kufe D has reported the participation of MUC1 in the Grb2/Sos/ras signalling 
pathway, whereas interaction of MUC1 with erbB1 during lactation was reported by 
Gendler SJ (Pandey P et al., 1995; Schroeder JA et al., 2001). Moreover, high levels of MUC1 
in mammary gland promote MAPK (ERK1/2) signal transduction (Schreder JA et al., 2001). 
Also, the cytoplasmic domain of the MUC1 protein interacts directly with ß-catenin and 
therefore with the actin cytoskeleton (Yamamoto M et al., 1997). Besides this, the secretory 
MUC1 can interact with MUC1/Y and trigger Ser/Thr phosphorylation of its cytoplasmic part 
which involves MUC1 in signal transduction (Baruch A et al., 1999). These results suggest 
that MUC1 protein participates in signal transduction and may well play an active role in the 
oncogenic process.   
The tandem repeat domain is reported to interact with ICAM-1 of endothelial and epithelial 
cells (Hayashi T. et al., 2001), and therefore to participate in cell migration and metastasis. 
MUC1 has also influence on the cell-cell and cell-ECM contacts by sterically introducing 
anti-adhesive effects (Hilkens J et al., 1992, Wesseling J et al., 1995) or promoting adhesion 
by specific interaction of carbohydrate moieties with adhesion molecules like selectines 
(Zhangh K et al., 1996).  
1.2.1.4.1 MUC1 glycosylation 
MUC1 is post-translationally modified by both N- and O- type of glycosylation.  
MUC1 has five potential N-glycosylation sites, three of which are located in the C terminal 
transmembrane component of MUC1, and two proximate to the VNTR domain. However, the 
major type of MUC1 glycosylation is O-glycosylation on numerous Ser and Thr residues 
within the VNTR region. Each 20-meric tandem repeat contains five possible glycosylation 
sites (Gendler SJ et al., 1995; Hanisch FG et al., 2000), two serines and three threonines (Fig.6). 
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   H G V T S A P D T R PA P G S T A P PA  
 
     Potential O-glycosylation sites 
Figure 6. MUC1 tandem repeat amino acid sequence with label potential O-glycosylation sites 
The average glycosylation density and structure vary in vivo and are cell and tissue specific. 
O-glycosylation is performed by the ordered action of glycosyltransferases adding 
carbohydrates to the protein backbone. The reaction initiates with addition of    
N-acetylgalactosamine on side chains of hydroxyl-amino acids Ser or Thr by one isoform of 
the 20 different polypeptide N-acetylgalactosaminyltransferases. The product, peptide linked 
GalNAc, is named Tn antigen and presents a starting point for the generation of more complex 
glycan chains. The elongation of the carbohydrate chain is performed by one of the numerous 
glycosyltransferases isoforms (Varki A). Based on the structure of two or three sugars attached 
to the Tn antigen eight basic core structures can be defined. Core structures are further 
elongated by sialylation, acetylation, sulphatation and (poly)lactosamine extension. The 
membrane attached protein appears as incompletely glycosylated form on the membrane and 
is repetitively re-internalised for additional glycosylations probably in the trans Golgi network. 
The mature form of the protein can remain attached to the membrane or become shed without 
the short, membrane attached subunit. The secretory form of MUC1 is not re-internalised and 
reaches the extracellular space via secretory vesicles with only one passage of the Golgi. 
The subcellular location where O-glycosylation initiates is the Golgi, since the up to 20 
polypeptide GalNAc-transferases are localized throughout the cis to trans compartments. The 
O-glycosylation position within the polypeptide chain is not easily predictable and depends on 
the availability of GalNAc-transferases, the amino acids sequences around the putative 
glycosylation site and already existing glycosylation on proximal Ser/Thr residues. 
(Elhammer AP et al., 1999). Up to now, at least 14 polypeptide GalNAc-transferases 
potentially involved in glycosylation of MUC1 are cloned and available for in vitro 
glycosylation (Clausen H et al., 1996; Bennett EP et al., 1998; Ten Hagen KG et al., 1999). 
Each of these enzymes has a specific site preference, but some overlapping between them 
exists.  
The complexity of glycan chains is tissue specific, and characteristic patterns were described 
for a number of organ sites and tissue specific secretions. So the predominant presence of 
core2-based linear or branched glycan chains was detected in lactation-associated MUC1 
compared to short glycans, mainly of core 1 type, found in urine associated MUC1. 
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1.2.1.5 MUC1 as a tumor antigen 
MUC1, as well as ovarian tumor antigen CA-125, HER2neu and Carcinoembrynic Antigen 
(CEA), are glycosylated tumor antigens with proven potential in clinical diagnostics or in 
immunotherapy.  
Tumor antigens are those antigens that are produced predominantly or exclusively by tumor 
cells and are recognised by the immune system. When presented only by tumor cells, but 
never by normal cells, they are called tumor-specific antigens and typically result from a 
tumor specific mutation. More common are antigens presented by both tumor and normal 
cells, named tumor-associated antigens. Cytotoxic T lymphocytes that recognize these 
antigens may be able to destroy the tumor cells before they proliferate or metastasize.  
Two research groups showed by using specific monoclonal antibodies that sera from tumor 
patients were positive for MUC1/SEC and MUC1/REP (Smorodinsky N et al., Hilkens J et 
al., 1986). Thus, both the MUC1/SEC protein and the MUC1/REP extracellular cleavage 
product can be secreted or shed from breast cancer cells and used for monitoring during the 
patients recovery. Beside this, it was shown that the MUC1/Y protein is expressed by various 
human secretory epithelial tumors, but is not detectable in the adjacent normal tissue (Zrichan-
Licht S et al., 1994; Hartman M et al., 1999; Baruch A et al., 1997) 
In the mid 80ies it was shown that the tumor-associated MUC1 is over-expressed in a non-
polarised manner and shed into the circulation in increased amounts (Hilkens J et al., 1986; 
Wesseling J et al., 1996). Due to pericellular expression of the several hundred nanometre 
long ectodomain, the MUC1 on carcinoma cells represents a primary immune target in anti-
cancer strategies.  
During the 90ies the MUC1-specific immune response in human sera was detected. Natural B 
cell responses were detected in breast cancer patients as well as in pregnant women or in 
women after passage of one lactation phase. These weak humoral responses were shown to 
provide a certain degree of survival benefit for breast cancer patients (Kotera Y et al., 1994). 
More specific, cellular responses of MUC1 specific T lymphocytes were detected in the 
cancer patients. These T-cells were able to lyse the cancer cell, but in an MHC unrestricted 
manner (Jerome KR et al., 1991). Due to their low efficiency, these detected immune 
responses to MUC1 are not sufficiently strong to eradicate the growing tumor. 
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Both humoral and cellular immune responses found in cancer patients were directed toward 
the tandem repeat domain of MUC1, mainly to its PDTR motif. Over 50 monoclonal 
antibodies were generated in mice and more than half of these were directed to this 
immunodominant motif (von Mensdorff-Pouilly S et al., 2000). Initially regarded as non-
glycosylated, the PDTR peptide motif turned out to be O-glycosylated on the tumor-
associated MUC1 (Muller S et al., 1997). Many of the peptide-specific antibodies bind with 
higher affinity to the glycosylated PDTR motif (Karsten U et al., 1998, 2004), indicating a 
glycosylation-induced stabilisation of the epitope. 
The antibodies and T lymphocytes detected in cancer patients were specific for the cancer 
associated MUC1. Cancer associated MUC1 differs from lactation-associated MUC1 on the 
level of O-glycosylation (Muller S et al., 1999). The aberrant glycosylation is the structural 
difference that characterises the cancer-associated MUC1 as a tumor-specific antigen (Fig 7). 
It is visible in the form of three structural changes: 
Glycans of the tumor-cell associated MUC1 are shorter than the polylactosamine-type chains 
found on lactation-associated MUC1. They are predominantly core 1-based, with numerous 
Tn (core1-GalNAc) or T antigen (core1-disaccharide Gal-GalNAc) and in particular their 
sialylated derivatives. The percentage of sialylated glycans is higher in cancer- than in 
lactation-associated glycoform. 
This tumor-associated truncation could be caused by reduced levels of core2-specific 
enzymes, ß-N-acetylgalactosaminyltransferase or by the increased sialylation (over-expression 
of 3GalST) (Dalziel M et al., 2001; Brockhausen I et al., 1995), which presents the stop signal 
for further addition of sugars (Whitehouse C et al., 1997).  
The third remarkable difference in MUC1 glycosylation occurring on tumor cells is the 
increased glycosylation density. The density of glycosylation is significantly higher on tumor-
associated MUC1 than on lactation-.associated MUC1. The number of glycosylated Ser/Thr 
in the tumor MUC1 VNTR domain is remarkably increased with 4,8 glycan chains per repeat 
found in breast carcinoma cell lines compared to 2,6 glycan chains per repeat in 
lactation-associated MUC1 (Muller S et al., 1997,1999). The shortening of sugar chains 
directly correlated with the density of glycosylation in the different breast cancer cell lines.  
Together with increased and unpolarized expression, this deviation unmasks the core peptide 
epitopes and exposes otherwise (sterically) hidden glycan epitopes. (Karsten U et al., 2005). 
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Figure 7. Glycosylation of lactation- and tumor-associated MUC1. Glycosylation positions within a 
tandem repeat are bolded. Glycan chains attached to Tn antigen characteristic for lactation- or tumor-
associated MUC1 are depicted on opposite sites of the figure.  
1.2.1.5.1 MUC1 functions in tumor cells 
The aberrant expression and glycosylation levels of MUC1 have consequences for the 
functions and interactions of the protein. 
The pericellular expression of tumor-associated MUC1 protein plays a distinctive role in 
sterically reducing cell-cell and cell-extracellular matrix interactions. It has been postulated 
that MUC1 may be involved in the metastatic spread of cancer cells from the initial tumor site 
(Ligtenberg MJ et al., 1992; Hartman M et al., 1992; Wesseling J et al., 1995). It was 
demonstrated that MUC1 expression positively correlates with tumor formation and 
progression in knock out mice (Spicer W et al., 1995). Also the short form of MUC1 protein, 
MUC1/Y is reported to stimulate oncogenesis and tumor progression (Baruch A et al., 1997). 
The negative charge of abundant sialyl groups present on the terminal ends of MUC1 sugar 
chains facilitates the interaction of tumor cells with E-and P-selectine, promoting the adhesion 
to endothelial cells and extravasation into the surrounding tissue during metastasis. Moreover, 
the negative charge is supporting spreading and dissemination of tumor cells by introducing 
repulsing force between them. 
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The over-expressed MUC1 on tumor cells shields the cell from immune recognition by the 
cellular part of the immune system, and thus favours tumor cell survival and metastasis. 
Therefore role played by MUC1 in cancer progression represents two sides of one coin: On 
the one end, loss of polarity and over-expression of MUC1 in cancer cells interferes with cell-
adhesion and shields the tumor cell from immune recognition by the cellular arm of the 
immune system, thus favouring metastases. On the other hand, MUC1, in essence a self-
antigen, is displaced and altered in malignancy and induces immune responses to it. Tumor-
associated MUC1 has short carbohydrate side-chains and exposed epitopes on its peptide 
core; it gains access to the circulation and comes in contact with the immune system 
provoking humoral and cellular immune responses to it. 
1.2.1.6 Immunity to MUC1 
Natural antibodies to MUC1 are present in the circulation of cancer patients, both as free 
antibodies and as immune complexes, bound to MUC1. Both IgM and IgG antibodies were 
detected in breast cancer patients and their early appearance is connected with good prognosis 
(Fig 8).  
Natural MUC1 antibodies from breast cancer patients reacted more strongly to the MUC1 
peptides with cancer-specific glycosylation (GalNAc) than to the naked VNTR sequence.  
Therefore, as the naturally existing tumor-related 
MUC1 is glycosylated, the immune response against 
breast cancer should be directed toward glycosylated 
MUC1 epitopes. 
Initially, the glycosylation was considered to prevent 
antibody binding to the peptide backbone. Besides 
this, it was shown that circulating tumor MUC1 
antigen found in tumor patients can not be processed 
by dendritic cells and does not elicit either 
MHC class II- (Hiltbold EM et al., 2000) nor CTL 
response (Hiltbold EM et al., 1999).  
These findings were shown to be related to heavy 
glycosylation (Hiltbold et al., 2000) and not to a 
tolerance to MUC1 (Hiltbold et al., 1998). 
 
 
Figure 8. MUC1 VNTR specific 
antibodies. 
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The high avidity interaction of MUC1 glycan chains with the mannose receptor residing in 
early endosomes prevents the protein to traffic to late endosomes after endocytosis where 
processing occurs (Hiltbold EM et al., 2000).  
Additionally, the digestion of densely glycosylated MUC1 by the enzyme Cathepsin L, 
involved in MHC class II epitope generation is prevented or restricted by site-specific O-
glycosylation (Hanisch FG et al., 2003). Consequently, under-glycosylation was regarded as 
the prerequisite for an effective immune response against tumor MUC1. In particular, it was 
postulated that the immunodominant domain within tandem repeats, the PDTR sequence, was 
not glycosylated. As a consequence, cancer vaccines were developed based on unglycosylated 
MUC1 (Karsten U et al., 2005). 
MUC1 positive tumors were targeted in a series of vaccination attempts in mouse models and 
in clinical trials. The clinical trials comprised  
• gene-based vaccine approaches, where MUC1 is encoded by a highly attenuated 
vaccinia virus vector (Scholl SM et al., 2000),  
• antibody-based vaccines (Heuser C et al., 2003, Wilkinson RW 2000 ),  
• peptide-based vaccination (Ramanathan RK et al., 2005; Wierecky Y et al., 2006; 
Yamamoto K et al., 2005; Kohlgraf KG et al., 2004 ; Plamer M et al., 2001), 
• MUC1/interleukins synthetic chimera (Snyder LA et al., 2006),  
• fusion of tumor and dendritic cell (Tanaka Y et al., 2005) or 
• vaccination based on autologous, peptide-pulsed dendritic cells (Loveland BE et al., 
2006; Wierecky Y et al., 2006).  
The peptide-based strategies stimulated strong humoral IgM and IgG responses, but with no 
or with weak cellular immune response (Soares MM et al., 2001; Stepensky D et al., 2006). 
The developed IgM and IgG reactivities were peptide-specific and therefore failed to 
recognize glycosylated tumor related MUC1. The approach using autologous dendritic cells 
loaded with nonglycosylated-MUC1 stimulated peptide-specific CTL in 50% of the patients 
with metastatic renal cell carcinoma (Wierecky Y et al., 2006).   
Such a moderate success of peptide vaccines can presumably be ascribed to the structural 
discrepancy between nonglycosylated epitopes used as immunogens and the glycosylated 
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antigen of targeted cancer cells.  As glycosylation, albeit aberrant, is still present in the tumor-
associated mucin the optimal MUC1 vaccine is not a peptide, but a glycopeptide. 
1.2.1.7 Immunity to tumor and MUC1 tumor vaccines 
The theory of immune surveillance claims that the immune system continually recognizes and 
eliminates tumor cells.  Immune surveillance is most likely to be successful against virus-
induced tumors, which express foreign antigens. But even the tumors with antigens which can 
be recognized by the host immune system can evade immune elimination. There are 
numerous mechanisms used by tumor cells to evade immune elimination: (1) expression of 
anti-apoptotic genes blocking the activity of CTLs and NK cells as well the effects of 
chemotherapy, (2) secretion of inhibitory cytokines TGFβ, IL-10, VEGF which prevent 
maturation of dendritic cells and recruit regulatory T lymphocytes inhibiting activation of 
helper and cytotoxic T cells that arrived at the tumor site. (3) reduction / lack of MHC 
expression, (4) lack of co-stimulation, (5) antigen shedding, (6) sequestration of tissue from 
surveillance , (7) lymphocyte killing… 
To overcome these sabotaging mechanisms of the tumor, efforts are made to develop tumor 
vaccines for the induction of a stronger and more specific anti-cancer cell response. Tumor 
vaccines should utilize tumor specific antigens and stimulate dendritic cell maturation and T 
lymphocyte activation outside of the tumor micro-surrounding and thereby overcome some of 
the possible evasion mechanisms. Therefore, for the design of anti-breast cancer vaccine the 
best MUC1-derived antigens and glycosylation forms have to be known and interaction of 
glycopeptides with the immune machinery has to be elucidated.  
Processing of glycosyalted MUC1 antigen is one of the crucial steps in generation of MHC 
epitopes and stimulation of MUC1 specific T-cells. Previously, Vlad et al (2002) showed that 
O-linked glycans are not removed from MUC1 during processing in the MHC class II 
pathway in dendritic cell. The glycans control the extent of MUC1 proteolysis in endosomes 
and site specificity of Cathepsin L, the major endosomal protease involved in MHC class II 
antigen processing (Hanisch FG et al., 2003). T-helper cell responses specific for MUC1 
glyco-peptides were reported by Vlad et al (2002).  A MUC1 glycopeptide was also shown to 
bind to MHC class I and to induce activation of CTLs which was not glycopeptide specific 
(Apostolopoulos V et al., 2003).  
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1.2.2 Antigen presenting cells 
The most potent antigen-presenting cells (APCs) involved in the tumor defence are dendritic 
cells. Their role is to internalise circulating antigens and present them on MHC class II and I 
molecules. During the process of internalisation and processing of antigen, immature dendritic 
cells undergo maturation, expressing high amounts of MHC and co-stimulatory molecules. 
Co-stimulatory molecules are necessary for the activation of naïve T lymphocytes, in the T 
cell areas of lymph nodes.  
Dendritic cells are able to present endocytosed antigens in MHC class II and class I fashion. 
This process of presentation of extracellular antigens in the MHC class I pathway is called 
cross-presentation of antigen or cross-priming of APCs. It refers to two possible situations of 
processing of endocytosed extracellular antigen: (1) antigen can escape from endosomes and 
enter the cytosol where it reaches proteasomes and other cytosolic enzymes (Hearn AR et al., 
2004; Seifert U et al., 2003) or (2) antigen gets processed within endosomes by cathepsins 
residing there and loaded onto recycled MHC class I molecules (Chen L et al., 2004, Shen l 
2004 immunity). Both of these pathways can generate 8 to 11-meric peptides potentially 
fitting to the groove of MHC class I molecules.  
1.2.3 Proteasome  
Proteasomes are multi-enzyme complexes that digest proteins. They were discovered by 
Alfred Goldberg and Martin Rechtsteiner in 1980s. The average human cell contains 20.000 
to 30.000 proteasomes present in both cytoplasmic and nuclear compartments, which in 90% 
degrade missfolded proteins, but also proteins with high turnover rates are degraded by IPs. 
By degrading antigen, proteasomes create immune 
epitopes, which is their second function.  
The general structure of a proteasome involves three 
subunits: two regulatory 19S particles and catalytic 
20S core particle (Fig. 9). At both ends of the 20S 
core are 19S caps, also known as regulatory units 
since they recognise proteins to be degraded by the 
attached polyubiquitin chain and unfold the proteins 
before it can enter the cavity of the 20S core for 
active hydrolysis of peptide bonds.  Figure 9. Structure of 26S proteasome 
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The dimensions of the proteasome cavity (148 Å) and entrance (131 Å) are such that only 
unfolded proteins can enter (Unno M et al., 2002). The unfolding of polypeptide chains of 
native proteins by cap is ATP driven.  
The basic 20 S core is evolutionary conserved from archebacteria through yeast down to 
humans, whereas the associated ubiquitin system is found only in eukaryotes. The 20S core 
consists of a barrel shaped cylinder made of four annular rings of protein subunits: the end 
ones known as alpha rings sandwich the two beta rings (Fig 10).  Beta rings contain 
proteolytic enzymes on the inner side of the cylinder; the alpha rings have no known enzyme 
activity.  
 
Figure 10. Structure of the Saccharomyces cerevisiae 20S proteasome 
A. Slightly tilt side view in space-filling mode showing the overall subunit arrangement, which results in 
a C2 symmetry of the particle. All seven α- and β-type subunits are marked and shown in different 
colors. 
B. Surface view of the proteasome molecule clipped along the cylinder axis shows the central active 
chamber (formed by two face to face-oriented β-rings) which is separated from two antechambers 
(formed by the β- and α-ring) by narrow constrictions. The catalytic Thr1 residues of active subunits in 
the central active chamber have calpain inhibitor molecules bound (shown as space-filling models in 
yellow). 
There are two kinds of proteasomes existing: constitutive and immuno-proteasomes. 
Constitute proteasomes are expressed in each cell type. Immunoproteasomes are found mainly 
in antigen-presenting cells after stimulation of these by INF-γ. Human immunoproteasomes 
represent a subset of inducible 20S proteasomes, occurring by substitution of three 
proteolytically active subunits LMP2, LMP7 and MECL-1 upon interferon-γ induction. 
Due to their cytosolic and nuclear localisation, immuno-proteasomes are digesting mainly 
non-glycosylated proteins and the only glycosylation form they come into contact with is the 
O-linked GlcNAc, a substoichiometric modification at the monosaccharide level that is 
involved in the regulation of protein function, similar to, but mostly antagonistic to 
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phosphorylation. It was demonstrated that proteasome can process O-GlcNAc modified 
proteins. Although no data showed that proteasomes can deal with longer glycan chains, this 
information indicated that proteasomes have some sort of tolerance to at least short glycan 
moieties. As the cancer related MUC1 is glycosylated with short glycan chains, there is a 
possibility that MUC1 glycopeptides or complete glycoprotein can be substrates of 
immunoproteasomes.  
1.2.3.1 The proteasome specificity 
The two central β rings of proteasomes have six threonine protease catalytic active sites. Two 
of these active sites have a chymotrypsin like activity and digest the peptide after hydrophobic 
amino acids, two sites have trypsin like activity digesting after basic amino acid residues, and 
the residual two sites cleave behind acidic amino acid residues similar to caspase activity. The 
active sites take part in antigen degradation and production of immune-epitopes. The 
efficiency of immune-epitope generation is rather low, and requires digestion of 1000 
molecules for production of a single MHC binding epitope (Boes M et al., 2004). Short 8 to 
11-meric peptides leave proteasome and with the help of TAP protein (transporter associated 
with antigen processing) enter ER where they are loaded onto empty MHC class I proteins. 
The proteasome is a threonine protease (Seemuller E et al.,1995). Its active centre is build by 
an N-terminally located threonine, one lysine, two aspartic acids and two serines. The two 
serines and one aspartic acid carry electronegative oxygen atoms that are attracting hydrogen 
of the amino group of the terminal threonine. The lysine with its positive charge makes a salt 
bridge with second aspartic acid, and this positive charge lowers the pKa value of the 
hydroxyl group of terminal Thr (Chen P et al., 1996; Schmidtke G et al., 1996; Seemüller E et 
al., 1996; Heinemeyer Wet al., 1997). The hydrogen of the Thr-OH group is transferred to its 
amino group, probably with the help of water molecule, and a reactive oxygen can 
nucleophilically attack the peptide bond of the substrate. The cleavage is terminated by 
degradation of generated acyl-ester intermediate mediated by water molecules. Thereby is 
proteasomal threonine released for the next catalytic cycle. 
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1.2.4 MHC molecules 
The Major Histocompatibility Complex (MHC) is a set of molecules displayed on cell 
surfaces of all nucleated cells. Their main function is a presentation of “self” and “non-self” 
antigens and activation of T lymphocytes. There are app. 50,000 - 100,000 MHC molecules 
on a typical cell and most of them (class I) are occupied by self peptides.  
MHC molecules can be divided in two classes: MHC class I and class II. MHC class I 
molecules are present on all nucleated cells, whereas MHC class II are restricted to antigen- 
presenting cells. Each class of human MHC is represented by three gene loci that are called 
“HLA” for Human Leukocyte Antigen. The class I loci are HLA-A,-B and -C and the class II 
loci HLA-DR, -DQ and -DP. In the human genome more than 200 MHC alleles that spread 
over HLA loci are described. This polymorphism allows a variety of peptide antigens to bind 
to MHC molecules. The population of app. 100.000 MHC class I molecules on a somatic cell 
displays >1000 different peptides. One single peptide-MHC complexe can be represented in 
widely different amounts from 1 - 5000 molecules/cell (mean~100).  
The allelic variation of MHC molecules is functionally reflected in the selection of peptides, 
which can bind; each allelic product has a unique set of peptides, which it can bind with high 
affinity (though rarely particular peptides may bind to more than one MHC allele). 
 
Figure 11. MHC class I molecule from top with peptide bound to the protein groove. Yellow 
spirals present two alpha helixes, green bands – beta-plated sheet. Between two alpha helixes is 
green/blue/red peptide chain (antigen). 
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MHC Class I is a heterodimeric membrane molecule consisting of a heavy alpha chain and a 
light beta-microglobulin chain (Fig. 11). The alpha chain can be divided into three 
extracellular domains, alpha1, alpha2 and alpha3, in addition to the transmembranous and 
cytoplasmic domains. Between the alpha-1 and alpha-2 domains a peptide binding groove is 
located that is formed by beta-pleated sheet on the bottom and two alpha helices on the sides. 
This region has several pockets and is capable of binding a small peptide via non-covalent 
interactions. The beta subunit, a beta-Microglobulin, associates primarily with the alpha-3 
domain and is necessary for MHC stability.  
Class I molecules usually bind nonapeptides, and less frequently octapeptides or decapeptides. 
The peptides are anchored within "pockets" in the peptide-binding groove of MHC class I 
only at a few positions of the peptides, which are called "anchor residues". Other side chains 
of the bound peptide also make contact with the groove, but apparently not constrained by any 
specific pocket. Nonapeptides bind in an extended conformation with a kink near P4 (fourth 
amino acid of the peptide). Octapeptides bind with less acute kink, whilst decapeptides and 
longer peptides bind with more pronounced kinks or “zigzags” in the extended conformation.  
The MHC/peptide complexes play a fundamental role in regulation of immune responses. T- 
cells can recognize antigens normaly as a complex with MHC molecules. Rare MHC-
independent activation of T-cells was also reported. T-cells vary in the need for number of 
specific MHC/peptide complex from a few complexes per cell to a few thousand, depending 
on the affinity or activation state of the T-cell and on the antigen presenting cell. Recognition 
of MHC/peptide complex by T-cells requires antigen to be processed by unfolding and 
proteasomal digestion before it complexes with the MHC molecule. Once formed the complex 
of antigenic peptide and MHC is generally very stable (half life ~ 24h). 
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1.3 Aim of the study 
Breast cancer patients often develop weak but helpful immune response directed toward the 
tumor antigen MUC1. This protein is in cancer cells expressed in increased and unpolarized 
manner. Moreover, it is aberrantly O-glycosylated with shorter, denser and more often 
sialylated sugar chains than those of normal epithelial cells. These structural changes make 
MUC1 a tumor antigen with diagnostic and therapeutic potential. Several studies showed that 
the most immunodominat part of the protein is exactly this aberrantly O-glycosylated domain 
with tandem repeats of a 20-meric peptide sequence. The stimulation of immune responses 
against the cancer-related form of MUC1 is rationalized to have therapeutic effects in breast 
cancer patients. For the development of a breast cancer vaccine, those glycoforms should be 
identified, which are able to induce the strongest cytotoxic and humoral response to the 
natural target. Hence, we attempted in this study to: 
• Identify the influence of glycan structure and position on antigen processing by 
immunoproteasomes of antigen-presenting cells 
• Identify the structure of MUC1 derived glycopeptides that are the best substrate for 
immunoproteasomes 
• Define those MUC1 glycopeptides which are processed to MHC class I binding glyco-
epitopes 
• Identify glycosylated peptides with high binding capacity to the most frequent MHC 
class I allele in the human population (HLA-A0201) 
• Understand the weak immunogenicity of natural glycoforms of tumor-associated 
MUC1.  
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MATERIAL 
o 2,5-Dihydroxybenzoic acid, DHB,         Bruker Daltonics 
o 2-mercaptoethanol 50mM,         Gibco, UK 
o Accutase         PAA Laboratories GmbH, 
              Germany 
o Acetic acid,           Fluka Chemie, Germany 
o Acetone HPLC grade,      JT Baker, Germany 
o Acetonitrile Chromasolv for HPLC,      Sigma-Aldrich, Germany 
o Alpha-dithiotreithol, DTT, minimum 98%,      Sigma-Aldrich, Germany 
o Beta-2 micro globulin from human  urine, 90%,  
           Sigma-Aldrich, Germany  
o BSA Bovine serum albumin fraction V,             Carl Roth GmbH, Germany 
o Cacodylic acid sodium salt, 98%,          Sigma Chemical 
o Chloroform, anhydrous, 99+%,        Aldrich, Germany 
o Cholesterol, min 99%,        Sigma-Aldrich, Germany  
o Citric acid monohydrate,         KMF optichem, Laborchemie Handels 
o Dimethyl sulphoxide, DMSO, hybrid-max,         Sigma, Germany 
o Ethanol, Absolut Chromasolv,                  Sigma-Aldrich, Germany  
o Ethylendiaminetetraacetic acid, EDTA, disodium salt dihydrat,  
            Fluka Chemie, Germany 
o FITC Fluorescein isothiocyanate isomer I,      Sigma-Aldrich, Germany 
o Foetal Bovine Serum, FCS, heat inactivated,  
              Gibco, Invitrogen Corporation 
o Formaldehyde solution, min 35%, extra pure,  
                                   Merck, Germany 
o HEPES pufferan, >99,5%,              Roth, Germany 
o Hydrochloric acid, HCl, 1 mol/l, volumetric solution,  
           Sigma-Aldrich, Germany 
o Magnesium chloride, MgCl2, 99%,       Sigma-Aldrich, Germany 
Manganese (II) chloride dehydrate, MnCl2,        Merck, Germany 
o Methanol dried,          Sigma-Aldrich, Germany 
o Sodium hydroxide solution, NaOH                Fluka 
o Nonessential amino acids, 100X,               Biochrom AG 
o Nonidet-P40,         Fluka BioChemika  
o PBS Dulbeco,                Biochrom AG 
o PEG-PE 2000 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-
[Methoxy(Polyethylene glycol)-2000], sodium salt,  
          Avanti Polar Lipids, USA 
o Penicillin-Streptomycin solution,        Sigma Aldrich, Germany 
o Phosphoric acid, orto-phosphoric acid 85%,       Merck, Germany, KGaA 
o Poly-lactic acid                Fluka Chemie GmbH 
o Polyvinyl alcohol                      Sigma Chemicals 
o POPC, 1-Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphocholine,  
           Avanti Polar Lipids, USA 
o Potasium chloride, KCl, >99,5%,            Roth, Germany 
o Potasium hydroxide, KOH,          Carl Roth GmbH 
o Primulin,                        Sigma, Germany 
o Protein A Sepharose 4 Fast Flow       Amersham Pharmacia Biotech, Sweden 
o Sodium azide,              Fluka Chemica 
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o Sodium chloride, NaCl,              KMF Laborchemie Handels 
                                 GmbH, Germany 
o Sodium hydrogen phosphate, dehydrate,              Merck  
o Trifluoroacetic acid, TFA               Fluka Chemie 
o Tris-(hydroxymethyl)-aminomethan,               Merck 
o Trypsin/EDTA solution, 0,5%/0,2% (w/v) in PBS (10x),  
                   Biochrom AG 
 
SPECIFIC CHEMICALS 
o 20S immunoproteasomes,                  Immatics;Germany 
o Albumin from hen egg white,                   Fluka Biochemika 
o Ficoll-Paque PLUS,           Amersham Bioscience, Sweden 
o Fluorescent mounting medium,              Dako Cytomation;Danemark  
o GM-CSF, Recombinant human,         BD Bioscience, Pharmingen, Germany 
o IL-4, recombinant human,         Cell Genix Tecnologie Transfer GmbH 
                          Germany 
o Peptides,           Mimotopes/Perbio 
o Protease inhibitor cocktail tablets, Complete Mini,  
           Roche Diagnostics GmbH 
o Proteasome inhibitor Ada(Ahx)3-(Leu)3-vinyl sulphone,  
                   Biomol 
o Sepharose 4b,                Pharmacia Bioscience 
o TNF alpha, Tumor necrosis Factor-alpha, Recombinant,  
            Sigma-Aldrich, Germany 
 
SOFTWARE 
o Confocal Microscope software,           Leica confocal software 
o ESI/MS/MS software MassLynx 4.0                  Waters 
o FACS software, Expo 32 ADC XL4 Colour/Analysis,  
               Bruker Daltonics 
o Find Pep              http://expasy.org/tools/findpept.html 
o HPLC software Gold chromatography data software,  
               Beckman Coulter 
o MALDI software Flex Control /Analysis,          Bruker Daltonics 
o NetChop      http://www.CBS.dtu.dk/services/NetChop/ 
o Syfpeithi              http://www.syfpeithi.de 
 
PARTICULARS 
o Cell culture plates: 6 well, 48 well, 150cm², 300cm²,  
           TPP Technoplastic Products AG, 
                                            Switzerland 
o Chromabond HR-P glass column,                Carl Roth, Germany 
o Cryo-tube vials, NUNC 
o Glass coverslides, microscope cover glasses,            Marienfeld, Germany 
o Glass slides, microscope slides, precleaned polysine tm ,  
                        Menzel GmbH, Germany 
o Maldi plate MTP 384 massive Au coated,                    Bruker Daltonics 
o Membrane for extruder, polycarbonate membrane pore diameter 100nm, 
             Avestin Inc 
o MACS separation column,      Miltenyi Biotech, Germany 
o Preseparation Filters,      Miltenyi Biotech, Germany 
o Midi-MACS separation unit,     Miltenyi Biotech, Germany 
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o Nanospray needle, spray capillaries, Medium, for Micromass Qtof,  
          Poxeon Biosystems 
o Nanospray source, Qtof II,                    Micromass 
o Previal C18 5u rpHPLC column, 150mm x 10mm,  
         Alltech, Munich, Germany 
o Solid phase extraction backerbond C18 SPE 200mg/3ml,  
                 JT Baker 
o Syringe sterile filter 0,22µm fast flow PES membrane,  
           TPP Technoplastic Products AG, 
                                             Switzerland 
o Thin layer chromatography plates HPTLC aluminium sheets silica gel 60 20x20cm, 
                   MERCK, Germany 
o Ultrafiltration tubes, Centriprep centrifugal filer devices,  
                  Millipore Corporation, USA 
o Ultrasphere HPLC ODS column, 2 mm x 15 cm,  
              Beckman Coulter 
 
MASHINES 
o Centrifuge Z323K               Hermle 
o Confocal microscope,         Leica CTR MIC, Leica Microsystems 
                                                             GmbH 
o ESI/MS/MS Qtof II,                    Micromass  
o Extruder, Lipofast with stabilisator,      Avestin Inc 
o FACS- flow cytometer EPICS XL4C,       Beckman Coulter 
o HPLC system, Beckman system gold,       Beckman Coulter 
o Incubators- cell culture, Heraeus 6000            Heraeus Instruments 
o Incubators- dry , Function line,              Heraeus Instruments 
o MALDI-TOF system, Reflex IV,                  Bruker Daltonics 
o Peristaltic pump P-1,                            Pharmacia, Biotech 
o pH-Meter pH 538            Multical Wisseschaflich-Technische 
                       Werkstätten GmbH, Germany 
o Sonicator,                    Brandsonic  
o Ultracentrifuge Optima-L70                   Beckman Coulter 
o UV lamp UVIS multipurpose equipment for UV254/366 nm  
              Desaga, Heidelberg,Germany 
o Vacuum centrifuge, DNA plus,        Heto 
 
CELL CULTURE MEDIA 
o CellGrow DC medium,    Cell Genix Technologie Transfer GmbH, 
                       Germany 
o DMEM Dulbeco’s MEM with stabile glutamine,  
                Biochrom AG 
o IMDM, basal Iscove medium with stabile glutamine,  
                 Biochrom AG 
o Phenol-red free RPMI 1640 medium,            Biochrom AG 
o RPMI 1640 medium,              Biochrom AG 
 
ANTIBODY 
o Alexa Fluor 488, goat anti-mouse IgG,                 Molecular Probes 
o Anti-CD14 microbeads, human,             Miltenyi Biotech, Germany 
o W6/32 monoclonal anti-human HLA class I antigen clone W6/32,  
            Sigma; Germany 
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2.1 Cell-biological methods                                                                               
2.1.1 Culture of mouse dendritic cell line 
DC2.4 cell line was obtained from the American Type Culture Collection and grown in 
DMEM medium supplemented with 10% FCS, penicillin/streptomycin (200 IU/ml-
200 µg/ml), 1% nonessential amino acids, 50 µM 2-mercaptoethanol at 37°C and 5% CO2. 
Cells were detached by 10 min incubation in PBS containing 2 mM EDTA, centrifuged at 
180xg / 5min and split 1:10. In all experimental procedures followed by mass spectrometric 
analyses, cultivation of cells was carried on in media without phenol red. 
2.1.2 Culture of T2 cell line 
The T2 cell line is a negative mutant for “Transporter associated with antigen processing” 
(TAP protein), expressing empty HLA-A0201 allele of MHC class I molecule on the cell 
surface. The cell line was a kind gift from Prof. Jonathan Howard and Dr. Michael Knittler, 
University of Cologne, and was initially grown at 37°C and 7,5% CO2 in IMDM media 
supplemented with 10% FCS and penicillin/streptomycin (200 IU/ml-200 µg/ml). For the 
MHC class I stabilisation experiments, T2 cells were slowly adapted to reduced serum 
conditions: 2% FCS.  
2.1.3 Culture of human mammary carcinoma cell lines 
The mammary carcinoma cell line T-47D and MCF7 were obtained from the American Type 
Culture Collection. T-47D cell line was grown in RPMI 1640 with 10% FCS and 
penicillin/streptomycin (200 IU/ml-200 µg/ml), at 37 °C and 5% CO2. MCF7 cell line was 
grown in DMEM with 10% FCS and penicillin/streptomycin (200 IU/ml – 200 µg/ml). For 
splitting, cells were washed with PBS and detached by incubation with 1x trypsin or Accutase 
solution for 10 minutes in the cell culture incubator. Medium was replaced at intervals of 2-3 
days. In all experimental procedures followed by mass spectrometric analyses, cultivation of 
cells was carried on in media without phenol red. 
2.1.4 Long time storage of cells 
For long time storage cells were frozen in liquid nitrogen. A minimum of one million cells 
were resuspended in 90% fully supplemented medium or in pure FCS (for T2 cells) and 10% 
DMSO. Cells were placed in Cryo Tube vials, gradually cooled to -80°C in Cryo freezing box 
for minimum 2 h but not longer than 24h and stored in liquid nitrogen tanks.  
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2.2 Biochemical methods                                                                                   
2.2.1 MUC1 derived peptides and glycopeptides 
MUC1 derived glycopeptides were chemically synthesised and kindly provided by Prof. Hans 
Paulson (GP1-16; GGP1-4; SGGP1-5). The P1 100-mer peptide and P2 ESR61 were provided 
by Dr. Olivera J. Finn and in vitro glycosylated with GalNAc using purified polypeptide 
GalNAc-transferases T1 and T2 (kindly provided by Dr. Henrik Clausen, School of Dentistry, 
University of Copenhagen, Denmark). Other nonglycosylated peptides were ordered from 
Mimotopes/Perbio and glycosylated in vitro. TAP25 was synthesized in a local facility at the 
Institute of Biochemistry, Cologne, Germany. 
NAME SEQUENCE 
 
P  
E  
P  
T  
I 
D  
E  
P1(DTR100) (HGVTSAPDTRPAPGSTAPPA)x5 
P2(ESR61) A(HGVTSAPESRPAPGSTAPPA)x3 
P3(AHG21DTR) AHGVTSAPDTRPAPGSTAPPA 
P4(AHG21ESR) AHGVTSAPESRPAPGSTAPPA 
G
L
Y
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P
E
P
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I
D
E
S 
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GP1(Tn100) (HGVTSAPDTRPAPGSTAPPA)x5 
GP2 (H11) AHGVTSAPDTRPAPGSTAPPA 
GP3(H12) AHGVTSAPDTRPAPGSTAPPA 
GP4(H13) AHGVTSAPDTRPAPGSTAPPA 
GP5(H14) AHGVTSAPESRPAPGSTAPPA 
GP6(H15) AHGVTSAPESRPAPGSTAPPA 
GP7(H16) AHGVTSAPESRPAPGSTAPPA 
GP8(A4GALNAC) AHGVTSAPESRPAPGSTAPPA 
GP9(SAP20-1) SAPDTRPAPGSTAPPAHGVT 
GP10(SAP20-2) SAPDTRPAPGSTAPPAHGVT 
GP11(SAP20-3) SAPDTRPAPGSTAPPAHGVT 
GP12(SAP20-4) SAPDTRPAPGSTAPPAHGVT 
GP13(SAP20-5) SAPDTRPAPGSTAPPAHGVT 
GP14(SAP20-6) SAPDTRPAPGSTAPPAHGVT 
GP15(A11) HGVTSAPDTRPAPGSTAPPA 
GP16(A12) HGVTSAPDTRPAPGSTAPPA 
D     
I      
S     
A     
C     
C     
H   
         
GGP1(A1) AHGVTSAPDTRPAPGSTAPPA 
GGP2(A2) AHGVTSAPDTRPAPGSTAPPA 
GGP3(A3) AHGVTSAPDTRPAPGSTAPPA 
GGP4(A4) AHGVTSAPDTRPAPGSTAPPA 
 
S    
I   
A  
L  
Y  
L 
SGGP1 (A4ST) AHGVTSAPDTRPAPGSTAPPA 
SGGP2 (A13ST) AHGVTSAPDTRPAPGSTAPPA 
SGGP3 (A14ST) AHGVTSAPDTRPAPGSTAPPA 
SGGP5 (A8ST) AHGVTSAPDTRPAPGSTAPPA 
Table 2. List of MUC1 VNTR peptides and glycopeptides used in processing studies. 
Glycosylated amino acids are labelled with yellow and with bold (GalNAc carrying), underlined bold 
(GalGalNAc carrying) or italic bold underlined (Sialyl-GalGalNAc carrying) 
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2.2.2 Enzymatic glycosylation of peptides in vitro 
For in vitro glycosylation of all five Ser/Thr in the 20-meric tandem repeat peptide a 
minimum of three different polypeptide GalNAc transferases should be used: ppGalNAc-T1, 
ppGalNAc-T2 and ppGalNAc-T4. ppGalNAc-T1 initiates glycosylation of Thr in the VTSA 
sequence of the tandem repeat, but can also glycosylate Ser and Thr in the GST motif 
(Wandall HHet al, 1997; Hanisch FG et al, 1999). ppGalNAc-T2 rapidly initiates 
glycosylation of Thr in the GST motif, and can less efficiently glycosylate Ser in the same 
region and Thr in the VTSA motif. The glycosylation of Thr in DTR and Ser in VTSA can be 
performed by using ppGalNAc-T4, which is exclusively dependent on glycans already present 
on the substrate peptide (Bennett EP et all, 1998).  
The peptide substrates (50 nmol) were dried from solutions in water by vacuum centrifugation 
and solubilized in 368 µl of a 25 mM cacodylat buffer containing 10 mM MnCl2 (final 
pH 7.4). Addition of the cosubstrate UDP-GalNAc (0,28 mg = 112 µl of stock solution 
containing 2,5 mg/ml of cacodylat buffer) was followed by the respective enzyme 
preparations ppGalNAc-T1 and ppGalNAc-T2, 20 µl of ppGalNAc-T1 (2.04  mU/ml) and/or 
ppGalNAc-T2 (4.04 mU/ml) to yield a total volume of 500 µl. The reaction mixtures were 
incubated for 48 h at 37°C by adding fresh aliquots of cosubstrate and enzyme(s) after a 24 h 
interval. The reaction was stopped by acidification with TFA to pH 2. The glycosylated 
peptide was purified from the reaction mixture by reversed-phase HPLC.  
2.2.2.1 Purification of in vitro glycosylated peptides by rpHPLC 
Aliquots (50-100 µl) of the reaction mixtures were injected onto a narrow-bore ODS 
Ultrasphere column (150 × 2 mm) for analytical chromatography or onto a Prevail C18 
column for preparative chromatography. Chromatography was performed on an HPLC system 
by gradient elution in a mixture of Solvent A (H2O with 2%ACN and 0,1%TFA, v/v) and 
Solvent B (80%ACN and 20 % H2O with  0,1%TFA, v/v). The gradient for analytical 
chromatography increased from 0% solvent B to 6% solvent B within 3 min, followed by an 
increase from 6% to 36% solvent B within 40 min. The gradient applied in preparative 
chromatography increased from 5% to 50% solvent B within 30 minutes. The glycopeptides 
were run at a flow rate of 0,3 ml/min on the narrow-bore ODS column and at a flow rate of  
2 ml/min on the Prevail column. The photometrical detection was performed at a wavelength 
of 214 nm.  
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2.2.3 Proteasomal processing of MUC1 peptides and glycopeptides  
2.2.3.1 Control of Proteasome Purity 
Proteasome purity was controlled by the incubation of proteasome and substrate in the 
presence of a proteasome specific inhibitor and residual activity was measured by using the 
non-glycosylated reference peptide P1 as substrate. The assay was performed by incubating 
1 μg of human 20S immunoproteasomes with 150 μM proteasome inhibitor Ada(Ahx)3-
(Leu)3-Vinyl sulphone in 10 µl digestion buffer B for 10 min at room temperature, followed 
by the addition of 10 μg of P1 peptide and incubation at  37ºC for 24 h. 
2.2.3.2 Optimisation of In Vitro Proteasomal Processing Assay: 
MUC1 VNTR peptide and glycopeptides P1, GP1 and GP11 (10 µg) were incubated with 1μg 
of human 20S immunoproteasomes in 10 μl of digestion buffer A, B or C.  
Buffer A: 50 mM Tris-HCl, pH 7.6;  25 mM KCl; 10 mM NaCl ; 1 mM MgCl2;1 mM DTT;  
Buffer B: 20 mM HEPES-KOH, pH7.6; 2 mM MgAc2  
Buffer C: 20 mM HEPES/KOH, pH7.6; 2 mM MgAc2; 1 mM DTT buffer. 
The reaction was performed at 37ºC for 48h. 
The processing efficiency was measured by rpHPLC as described above for analytical 
chromatography of glycopeptides (section 2.2.2.1). When the nonglycosylated reference 
peptide P1 was quantitatively fragmented, the digestion was stopped by freezing the sample at 
-80ºC.  
2.2.3.3 Analyses and Separation of the Cleavage Products by rpHPLC: 
Each sample was analysed and cleavage products were fractionated by rpHPLC (as described 
for analytical chromatography (section 2.2.2.1). The gradient elution was performed by 
increasing the proportion of solvent B as described above to 36% (for longer peptides) or to 
26% (for shorter peptides) within a period of 30 min.  
Fractions were collected manually, dried and resolved in 5 μl H2O containing 0,1% TFA.  
Chromatograms were analysed by the Gold Chromatography software Data System, version 1.6.  
Subsequent analyses of collected fractions by positive ion matrix-assisted laser desorption 
ionisation (MALDI/TOF/MS) mass spectrometry and/or by LC/ESI-MS/MS spectrometry 
were performed.  
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2.2.4 Mass spectrometric analyses of processed peptides 
Matrix-assisted laser desorption/ionization (MALDI/MS) is a soft ionisation technique 
used in mass spectrometry, allowing the ionisation of biomolecules such as proteins, peptides 
and sugars. MALDI/MS analyses were perfomed on a Bruker–Reflex IV instrument by 
positive ion detection in the reflectron mode. Ionisation of co-crystallized analytes was 
induced with a pulsed nitrogen laser beam (337 nm) and the ions were accelerated in a field of 
20 kV and reflected at 23 kV. For MALDI/MS analyses 1 μl of the peptide or glycopeptide 
sample, resolved in H2O with 0,1% TFA (v/v), was applied on a stainless steel or gold-plate 
target by mixing with the same volume of matrix. A saturated solution of 
2,5-dihydroxybenzoic acid (DHB)  containing 0,1%TFA in ACN (2:1 v/v) was used as a 
matrix.  
Electrospray mass spectrometry (ESI/MS/MS) was performed on a Q-Tof 2 quadrupole 
time-of-flight mass spectrometer equipped with a Z spray source. Samples were injected into 
nanospray source by nanospray capillary. Results were evaluated by Mascot search engine.   
2.2.5 Amino acid sequence analysis of generated fragments 
Amino acid sequence of generated fragments was elucidated from the series of ions of 
ESI/LS/MS/MS fragmentation spectra or from the molecular masses of ions detected by 
MALDI/MS. The molecular masses detected by MALDI/MS were analysed by the FindPep 
software application from Expasy (www.expasy.org). This software identifies the amino acid 
sequences of peptides from their experimentally measured masses resulting from unspecific 
cleavage of proteins. The program takes into account chemical modifications, post-
translational modifications (PTM) and autolytic cleavage of protease. The experimentally 
measured peptide masses are compared with the theoretical peptide masses calculated from 
the user-entered sequence or from an entry specified in the Swiss-Prot/TrEMBL database.  
The suggested amino acid sequence was assigned to the detected molecular mass, if the 
deviation of the experimental and theoretical mass was not more than 1 Da. If several 
sequences corresponded to the same mass, all of them were taken into consideration. 
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2.3 Mathematical analyses 
2.3.1 Quantification of generated peptide fragments 
To quantify the amount of generated proteasome degradation products, we performed further 
analyses of MALDI/MS spectra and rpHPLC chromatograms. The mass spectrometric 
analyses of the HPLC fractions showed that several fragments co-eluted from the HPLC 
column at the same retention time.  
Principally, we calculated the starting amount of substrate as 100% (Table 3). This amount 
was, due to proteasomal digestion, separated into several rpHPLC peaks. Each rpHPLC peak 
contained several co-eluting ion fractions, and the amount of substrate fragment found in one 
rpHPLC peak was estimated based on their relative intensities. In this way we obtained the 
relative amounts of each proteasome degradation product. 
                100%                                
 
 
Relative HPLC peak area was calculated as :  
= peak area x 100 / sum of peak areas  
Relative MALDI/MS ion peak intensity was calculated as: 
 =MALDI/MS ion intensity x 100/ sum of all ion intensities in analyses HPLC peak 
Relative fragment amount was calculated as: 
 = relative HPLC area x relative MALDI/ MS ion intensity / 100 
For example, the fraction 11 of P1 proteasome degradation HPLC chromatogram contained 
5,74 % of the starting substrate distributed on 9 ion species, of which 5 (MW 1471.4; 
1476.55; 1483.42; 1527.73; 2677.76) could be assigned to the MUC1 sequence (Table 4).  
 
 
Ion masses  Relative MALDI/MS 
ion peak intensity 
Relative fragment amount = Percent 
of the starting substrate amount  
1028Da 10% 2% 
1436Da 50% 10% 
1559Da 40% 4% 
      Sum 100% 20% ( = the amount found in this HPLC peak) 
30% 
50% 
20% 
Table 3. Example of the calculation of relative peptide amount  
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Table 4. Example of HPLC/MALDI/MS based quantification of generated fragments 
The relative amount of fragment 1471,4 Da of relative ion intensity 65,3 can be calculated by 
comparison with total amount of fragments in the HPLC peak (5,74%) as follows: 
5,74:100=x:65,3; resulting in 3,75 units. 
Relative intensities of reaction products were calculated for all 29 processed MUC1 
(glyco)peptide substrates. 
2.3.2 Calculation of the frequency of digestion between two amino acids 
The calculated relative amounts of fragments with identical N- or C-terminal motifs were 
summed up, and the higher one of these two sums (further on referred as “a”) was chosen for 
calculation of cleavage frequency at each peptide bond. The cleavage frequency was 
calculated by expressing the value “a” for each peptide bond as a percent of total “a” values in 
the substrate. 
2.3.3 Calculation of average fragment length 
The average length of generated fragments was calculated as the arithmetic mean of the 
fragment lengths.  
2.3.4 Calculation of peptide length distribution  
All detected fragments within one processed sample were grouped according to their length. 
The relative amounts of fragments within the same length group were summed up and 
expressed as the percentage from the total amount of all detected fragments within the sample, 
not counting the amount of non-processed substrate. 
 
Measured 
MW 
Corresponding MUC1 
VNTR amino acid sequence
MALDI/MS 
ion intensity
Relative 
ion 
intensity 
Relative amount 
of peptide 
1471,40 PDTRPAPGSTAPPAH 11569,85 65,32575 3,749698 
1473,05 not MUC1 related 2125,27 11,99971 0,688783 
1476,55 TAPPAHGVTSAPDTR 316,9 1,789282 0,102705 
1483,42 GVTSAPDTRPAPGSTA 553,3 3,124045 0,17932 
1527,73 PDTRPAPGSTAPPAHG 174,95 0,987804 0,0567 
2286,02 not MUC1 related 1656,85 9,354915 0,536972 
2432,17 not MUC1 related 358,75 2,025576 0,116268 
2677,76 PDT-PAPG 630,35 3,559086 0,204292 
3294,64 not MUC1 related 324,79 1,833831 0,105262 
SUM  17711,01 100 5,74 
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2.3.5 Calculation of relative amounts of short 8 to11-meric peptides  
The relative amounts of fragments 8 to 11 amino acids long were summed up and their 
contribution to the complete amount of fragments expressed as a percentage.   
2.3.6 Calculation of relative amounts of glycopeptides within 8 to 11-mers 
The amount of glycopeptides within the group of 8 to 11mers was expressed as the percent of 
the total amount of 8 to 11meric peptides. 
2.3.7 Analyses of the origin region of 8 to 11mers 
8 to 11mers were sorted in three groups based on their starting motif:  
1. Peptides starting N-terminally of the SAP motif within A-H-G-V  
2. Peptides starting in proximity of the SAP region within T-S-A-P-D-T 
3. Peptides starting within R-P-A-P-G-S- terminating often with unprocessed C terminus of 
the substrate. 
The amounts of fragments for each of these three groups separate were summed up and 
expressed as the percentage of the total amount of 8 to 11mers.  
2.3.8 Algorithm prediction of peptide ligation strength to MHC molecule 
The amino acid sequences of all fragments in the size range of 8 to 11 amino acids (peptides 
and glycopeptides) were analysed by SYFPEITHI software application 
(http://www.syfpeithi.de/) without considering glycosylation. SYFPEITHI is a database 
comprising more than 4500 peptide sequences known to bind class I and class II MHC 
molecules. The entries are compiled from published reports only. The database contains 
information on peptide sequences, anchor positions, MHC specificity, source of proteins, 
source of organisms and publication references.  
The database predicts the ligation strength of epitope to a defined HLA type. The algorithms 
used are based on the book "MHC Ligands and Peptide Motifs" by Rammensee H.G et al. 
The probability of being processed and presented is given in order to predict T-cell epitopes.  
The probability of binding to the most common allele in Caucasian population HLA-A0201 
allele for each MALDI/MS detected 8 to 11 amino acids long fragment sequence was 
screened.  Additionally, the prediction of potential HLA-A0201-ligands from the complete 
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MUC1 VNTR sequence was performed. Peptides with the ligation strength higher than 9 were 
considered as good binders. 
2.4 Immunological methods 
2.4.1 Selection of short peptides 
The peptide fragments predicted by SYFPEITHY to have high ligation strength were 
synthesized by Mimotopes/Perbio and in vitro glycosylated. Both the peptides found in 
proteasomal digests and the peptides that were just theoretically predicted to bind with strong 
ligation strength to HLA-A0201 were included. A group of peptides that could not be in vitro 
glycosylated due to restrictions of ppGalNAc-T4 enzyme was not included into further 
analysis although the peptides were predicted to be good binders. Glycosylation was 
performed as described above at VTSA and GST motifs based on the site-specificity of 
ppGalNAc-T1 and/or ppGalNAc-T2. The ligation strength of glycosylated peptides to HLA-
A0201 was measured by MHC stabilisation assay using the human T2 cell line and compared 
to the ligation strength of their non-glycosylated forms and a viral reference peptide.   
2.4.2 MHC stabilization assay 
MHC stabilisation assay is based on the increased affinity of W6/32 antibody for the 
stabilised conformation of MHC molecules after binding of a peptide-ligand. The T2 cells 
express empty MHC molecules with short half life. Binding of the peptide ligand to the 
groove of MHC molecules stabilizes their tertiary conformation and prevents fast recycling. 
Stabilised tertiary conformation of MHC class I molecules is recognized by 
W6/32 anti-HLA-A, B, C monoclonal antibody. The binding affinity of W6/32 antibody 
directly reflects the number of stabilized MHC molecules upon binding of tested peptide. 
Thereby the affinity of the peptide can be measured and compared to that of negative and 
positive controls. 
For MHC stabilisation assay T2 cells were grown in IMDM medium supplemented with 2% 
FCS. T2 cells were washed in PBS from the residual serum, and resuspended at 1x106/ml of 
IMDM supplemented with 0,1 % FCS and 25mM HEPES. Half of the million of cells were 
incubated in 48-well cell culture plate with 1 µg of ß2-microglobulin and 100 µg of peptide 
for 16 h at 27°C and 8 % CO2. Cells were washed with 5 ml PBS, centrifuged at 180xg for 
5 min and the pellet resuspended in 10µl PBS with 1 µg W6/32 antibody and incubated at 4°C 
for 30 minutes. Subsequently cells were washed in PBS with 1%BSA (3x5 ml) and the pellet 
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resuspended in 50µl of secondary anti-mouse Alexa 488 antibody diluted 1:1000 in PBS with 
0,1% BSA. Cells were incubated for 30 minutes in the dark, washed with PBS (3x5 ml) and 
finally resuspended in 500µl of PBS. Binding of W6/32 antibody to MHC class I molecules 
was analysed by FACS spectrometry, nanometres emission and absorption at the name of 
department. As a positive control hepatitis B virus core antigen HBVc18–27 P6Y~C 
(FLPSDCFPSV) was used. As a negative control T2 cells were used, to which no peptide was added. 
Measured fluorescence stronger than that of the negative control was considered positive and 
its intensity was compared to the positive control. Results for tested peptides were expressed 
as the percent of the fluorescence measured for the positive control.  
2.4.3 Cross presentation  
The experimental approach based on cross presentation of antigen implies the introduction of 
antigen into the cytosol of the antigen presenting cells. As antigen presenting cells we used 
immortalized the mouse dendritic cell line DC2.4. We tested three modes to introduce the 
antigen into the cytosol: liposomes, electroporation, and incorporation of antigen into 
poly-lactic acid vesicles. 
2.4.3.1 Culture of monocyte derived human dendritic cells 
Monocyte derived dendritic cells were generated by positive selection of CD14+ monocytes 
of from human buffy coats on magnet assisted cell sorting system (MACS). Buffy coat is the 
fraction of human blood that contains mainly white cells. 50 ml buffy coat volume was 
separated on 4 fractions, each fraction diluted with PBS/2 mM EDTA till 30 ml and applied 
on 13 ml of Ficol. Upon 30 min centrifugation step on 900xg/18ºC without brake, the 
monocyte layer was collected; fractions merged by two, resuspended with PBS/2 mM EDTA 
up to 50ml and centrifuged for 10 min, 300xg, with brake on 18º. Cell pellet was resuspended 
in 25 ml of MACS buffer (PBS/2 mM EDTA, 0,5% BSA) and two fractions merged, 
centrifuged at 200xg/10 min/18ºC/brake. Pelleted cells were resuspended in 3 ml of ice-cold 
MACS buffer, counted and on 1x109/ml 300 µl of MACS CD14 beads added. After short 
vortexing and 20 min incubation on 4ºC cells were diluted with additional 22 ml of MACS 
buffer, centrifuged (300xg/10 min, 18ºC) and the pellet resuspended in 3 ml of MACS buffer. 
The MACS column was attached to MIDI MACS system and washed with 2 ml of MACS 
buffer. Vortexed cell suspension was applied in 1 ml fractions over pre-wet MACS pre-
separation filter on the column, washed 3x3 ml of MACS buffer. The column was detached 
from the magnet and the attached cells washed away by 3 ml of MACS buffer under the 
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syringe pressure. Vortexed cells were counted, centrifuges at 300xg/10 min and resuspended 
at 2x106 cells/ml CellGro DC medium supplemented with 1xGlutamax, 800 U/ml GM-CSF 
and 500 U/ml IL-4. Cells were cultivated in 5 ml fractions in 6 well plate and on the 3rd and 
5th day half of the media exchanged with fresh with preservation of cells. On the 7th day 
complete media was collected and exchanged for CelGro supplemented with GM-CSF, IL-4 
as previously with addition of 20 ng/ml of TNF-alpha and liposome encapsulated antigen 
(100-400 µg of P1) and matured for 2-3 days. Supernatant was collected and exosomes 
isolated and analysed by mass spectrometry. Adherent cells were acid eluted and eluent 
purified by solid phase extraction and analysed by MALDI/TOF/MS.  
2.4.3.2 Formation of Peptide-Loaded Liposomes 
Liposomes are the smallest artificial vesicles of spherical shape that can be produced from 
natural non-toxic phospholipids and cholesterol. The liposomal vesicles can be used as drug 
carriers and loaded with a great variety of molecules, such as small drug molecules, proteins, 
nucleotides and even plasmids. 
Liposomes were generated by hydration of lipids in round bottom glass flask rinsed with 
chloroform. Following lipids: cholesterol (10 µmol), POPC (15,17 µmol) and PEG-PE 2000 
(1,5 µmol) (combined  at 2 : 3 : 0,3 molar ratio), representing together 25 µmol of polar lipids 
(Ignatius R et al, 2000)) were added in 6 ml of dry chloroform : methanol solution 
(10 : 3 v/v). Lipids stored in chloroform solution were kept on ice to minimize oxidation and 
evaporation. The mixture was gently swirled between additions and sonicated briefly in bath 
sonicator to ensure mixing. The organic solvent was carefully evaporated using a gentle 
stream of dry nitrogen to produce a film on a glass. When the film became white, the flow 
was turned up to spread out last drops. The film was dried without thick clumps of 
precipitated lipid. The round bottom glass flask was dried a in vacuum desicator for 30 min 
and the lipid film resuspended in cyclohexane with 1-2% of ethanol to increase suspension in 
water. The solution was frozen on dry ice and lyophilised until dryness. 
Dry lipid powder was suspended in 2ml of 150mM NaCl solution kept at 64°C (above the 
transition temperature of the lipids) with 10 nmol/ml of P1 peptide (400 µg) resulting in final 
lipid concentration of 2 mg/ml. The mixture was left to hydrate at 64°C for 2 h with slow 
rotation. The hydration procedure formed large multilamellar vesicles that were sized down 
by 4 freeze-thaw cycles (1 min liquid N2 followed by 2 h at 4°C). Formed multilamellar 
vesicles were converted to large unilamellar vesicles by extrusion at 64°C through the pre-
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wetted 100 nm membrane for an odd number of times (more than 11) and the material 
deposited into a buffer rinsed glass vial.  
The liposomes where separated from non-encapsulated antigen by size exclusion 
chromatography with 2 passages over a 15 x 1 cm Sepharose 4B column (section 2.4.3.1.1.) 
and the fractions containing liposomes detected by thin layer chromatography 
(section 2.4.3.1.2). Fractions containing liposomes were applied on 1x107 human monocyte 
derived immature dendritic cells or on 4x107 DC2.4 cells, incubated for 24 h under standard 
conditions, washed with PBS (3x5 ml) and acid eluted. The acidic eluent was collected, 
centrifuged at 3000xg for 10min and, ultrafiltrated over the 3000 Da cut-off membrane. The 
filtrate was purified by solid phase extraction on a C18 column, dried and analysed by 
MALDI/TOF/MS, all as previously described (section 2.2.4). Detected masses were analysed 
by FindPep software as described (section 2.2.5). 
2.4.3.2.1 Size exclusion chromatography 
A glass column (20 x 1 cm, 16 ml volume) was filled to the top with pre-swollen Sepharose 4B 
gel and packed with 50 cm/h flow of 150 mM NaCl for 30 minutes followed by 25 cm/h for 1 h.  
The sample is applied and eluted by 1 ml/min flow of 150 mM NaCl. One ml fractions were 
collected and lipid presence was analysed by thin layer chromatography or by noticing the 
milky appearance of the solution. 
2.4.3.2.2 Thin layer chromatography 
A closed glass chamber was equilibrated for a minimum of 30 minutes by a mobile phase 
solution of a mixture of chloroform, methanol and water (130:50:8, v/v). Ten µl of each 
fraction was applied on the start line of the TLC (2 cm from the end) and air dried. As 
stationary phase silica plate 60WF254S precoated aluminium sheets, 20 x 20 cm were used. 
The plate was placed for 30 minutes in the glass chamber containing 1cm of the mobile phase, 
air dried and sprayed by 0,001% Primulin in 80% Acetone/Water. Detection was performed 
by exposure of dry plates to long-wave UV lamp (354nm). 
2.4.3.2.3 Acid elution 
Acid elution is performed according to a modified protocol from Storkus (Storkus WJ et al., 
1993) with incubation of cells for 30-60 s in citrate-phosphate buffer:  
0,131M citric acid,  
0,066M Na2HPO4, 
Adjusted with 0,1N NaOH to pH 3.3. 
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2.4.3.2.4 Solid phase extraction 
Samples were purified from proteins and salts on one-way C18 columns connected to an 
evacuated chamber: 
The column was equilibrated with 5 ml 80% acetonitrile in water with 0,1%TFA (v/v). The 
sample was pre-acidified by addition of TFA to pH2 and applied onto the column, and washed 
with 5 ml of 0,1%TFA in water (v/v). Bound peptides were eluted with 2-4ml 80% 
acetonitrile in water with 0,1%TFA (v/v). 
2.4.3.3 Electroporation 
DC2.4 cells (5x106) were grown in DMEM without phenol red, washed in PBS and 
resuspended in 0,8 ml PBS containing 5 mg ovalbumin. The cellular suspension was placed in 
an electroporation vial and incubated on ice for 10 min. Electroporation was performed by 
single pulse of 280 V / 960 µF for 30 sec with decay time constant 3-6 A, followed by 5 min 
incubation on ice. Electroporated cells were resuspended in 70 ml complete media, incubated 
for 24 h at 37°C and 5 % CO2, washed in PBS (3 x 5 ml) and acid eluted for 1 minute. The 
acid eluat was centrifuged, purified on C18 solid phase extraction as described 
(section 2.4.3.1.4) and analysed by MALDI/TOF/MS and by FindPep software. 
The efficiency of the method was checked by pulsing 1x107 DC2.4 cells with FITC-labelled 
ovalbumin epitope SIINFEKL. Cells were resuspended in 800µl of PBS with 100µg 
SIINFEKL-FITC, and electroporated as described. After the electro-pulse the presence of 
peptide in the cytosol was monitored by a fluorescent microscope.  
2.4.3.4 Formation of Peptide Loaded Poly-lactic Acid Vesicles: 
Poly-lactic acid based vesicles were generated mixing two solutions: 
Solution A: 200 nmol of P2 peptide (1 mg) resolved in 3 % cold water solution of poly-vinyl                       
alcohol 
Solution B: 5% poly-lactic acid in a mixture of ethanol and acetone (9:1, v/v)  
Solution B (30 ml) was slowly added to solution A (150 ml) under constant mixing and 
stirring overnight at room temperature. Next day the mixture was centrifuged at 10.000xg for 
10 min and washed three times with PBS (200 ml), followed by centrifugation steps as 
mentioned. The generated vesicles were resuspended in 330 µl of PBS and added to media of 
4x108 DC2.4 cells growing confluent in 9 cell culture flasks (300cm²). The cells were grown 
as described above (section 2.1.1), but with exosome-free FCS (section 2.4.3.3.1).  
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Cells were incubated with PLA-vesicles for 24 h at 37°C and 5% CO2. The cell culture 
supernatant was collected and exosomes were isolated as described (section 2.4.3.3.1). 
Isolated exosomes were resuspended in 100µl 0,1%TFA/H2O. Acidification of exosomes 
denatures tertiary MHC complex and releases bound peptide epitopes. The solution was 
shortly spinned and injected on an rpHPLC narrow-bore ODS column to chromatogram as 
described in section 2.2.2.1 for analytical chromatography. Fractions were collected manually, 
dried and analysed by MALDI/TOF/MS as described (section 2.2.4). Molecular masses of 
detected ions were analysed by FindPep software (section 2.2.5) and by nanospray MS/MS 
analyses (section 2.2.4).  
2.4.3.4.1 Isolation of exosomes 
Exosomes were isolated from FCS or cell culture supernatant by subsequent centrifugation 
steps: 10min/1200g; 30min/10000g; 30min/20.000g; 60min/100.000g. The exosomes were 
pelleted in the final centrifugation step. Exosomes were washed with PBS and used for further 
analyses. For the generation of exosome-free FCS, exosomal pellet was discarded and the 
supernatant sterile filtrated through 0,22 µm syringe filter.  
2.4.4 Isolation of MHC bound peptides from breast cancer tumor cells  
2.4.4.1 Testing the MHC Expression on breast cancer cell lines 
MCF7 and T47D breast cancer tumor cell lines were analysed for the expression of MHC 
alleles by fluorescence-activated cell sorting (FACS) and confocal laser microscopy.  
2.4.4.1.1 Confocal laser microscopy 
Glass coverslips were cleaned over night by incubation in 70% ethanol with 5% HCl solution. 
Coverslips were placed on a parafilm covered glass plate to dry, washed with PBS and 
covered with cell suspension. A 300 µl of cell suspension (1x106) was applied per coverslip 
and cells were allowed to attach for 30 minutes. Thereafter, cells were washed with PBS from 
the residual medium and fixed by incubation in PBS containing 3% formaldehyde for 15 min. 
The fixing solution was aspirated and the coverslip washed with PBS containing few drops of 
0.1M glycine/HCl, pH 8.0 (3x5 min).  Fixed cells were incubated with 1µg of primary mouse 
monoclonal W6/32 antibody (0.1µg/ml PBS) for 30 min, washed with PBS (3x5 min) and 
covered with 100 µl of secondary anti-mouse Alexa 488 antibody diluted 1:1000 in PBS. Cells 
were incubated in the dark for 30 min, washed with PBS (3x5 min) and mounted on glass slides. 
For the mounting on glass slides, the coverslip was swirled once in deionised water and the 
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excessive water was soaked off with soft tissue paper. A drop of DAKO mounting medium 
was placed on the glass slide and the coverslip with cells facing the glass slide mounted 
avoiding formation of air bubbles. Mounted glass-slides were allowed to dry during the night 
on 4°C before they were analysed on fluorescent microscopy.  
Visual analyses of stained cells were performed on a confocal laser scanning microscope.  A 
488 nm Argon laser for excitation of green flurophores of Alexa 488 antibody was used.   
2.4.4.2 Isolation of MHC-Ligands from tumor cell lines by acid elution 
Breast cancer cell lines T-47D and MCF7 were screened for MHC-bound MUC1 derived 
(glyco) peptides. The 8x107 cells were grown under standard conditions in phenol red free 
media, washed with PBS and acid-eluted as previously described (section 2.4.3.1.3). Acid 
eluent was centrifuged and purified by solid phase extraction on C18 as described in section 
2.4.3.1.4. The purified material was dried by vacuum centrifugation, resuspended in 50 µl of 
2.5 mM phosphoric acid and analysed by coupled cation exchange /reversed phase liquid 
chromatography/MS/MS in the central service facility of the Center for Molecular Medicine 
Cologne. Alternatively, MHC molecules or MHC molecules were affinity purified by HLA-A, 
B, C antibody W6/32. The eluted epitopes were analysed by ESI/MS/MS analyses.  
2.4.4.3 Isolation of MHC ligands from tumor cells by affinity chromatography 
T-47D cells (8x107) were washed with PBS and collected by cell scraping. After 
centrifugation at 180xg for 5 min the cell pellet was lysed for 1 h at 4°C in 1 ml of lysis buffer 
containing 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 1,5 % Nonidet-N40, 0.2 % Sodium azide 
and protease inhibitor Complete mini. The lysate was ultracentrifuged at 100.000xg for 30 
min and HLA molecules purified by affinity chromatography with the W6/32 antibody on a 
protein-A column. The protein A column (2 ml) was packed according to the manufacturers’ 
protocol, with PBS used as packing buffer and 0,05 M Tris-HCl, 3 M NaCl, pH 7,8 as start 
buffer. The column was washed with start buffer and cell lysate applied continuously during 
the night at 4°C with a flow rate of 0,3 ml/h using a peristaltic pump. Unbound material was 
washed successively by 10 ml of start buffer, 10 ml of lysis buffer, 10 ml of lysis buffer 
without detergent, 10 ml of lysis buffer without detergent and NaCl. The bound protein was 
eluted with 9,1 ml of 0,2 M acetic acid. The MHC molecules were denaturated by addition of 
0,9 ml of concentrated acetic acid and incubated for 30 min on ice. The released peptide 
epitopes were separated from the protein fraction by ultrafiltration on a 3000 Da cut-off 
membrane. The filtrated peptide fraction was purified on C18 SPE as described, dried and 
analysed by mass spectrometry.  
                                                                                                                                           Results                        
 
 43
 
 
 
 
 
 
 
 
 
 
 
3 RESULTS 
                                                                                                                                           Results                        
 
 44
3.1 Biochemical studies 
3.1.1 Influence of buffer composition on processing efficiency 
Peptides and glycopeptides were processed by immunoproteasomes in parallel using three 
different buffers, as described in section 2.2.3.2, and processing efficiency was analysed by 
rpHPLC (Fig. 13). The most effective degradation of glycopeptides, indicated by the amount 
of starting substrate remaining after 24h digestion time, was achieved with buffer C 
(containing DTT), whereas nonglycosylated peptides were most efficiently processed in 
Buffer B (DTT free) as shown on figure 13. The efficient use of buffer A in in vitro  
proteasomal assays reported by Groettrup M was not confirmed for MUC1 VNTR peptides 
and glycopeptides (Groettrup M et al., 1995).  
 
 
 
Figure 13. Influence of buffer composition on processing efficiency of MUC1 peptide and 
glycopeptide by immunoproteasomes.   Digestion of MUC1 P1 peptide (1) and GP11 glycopeptide 
(2) was performed in different buffer systems and analysed by rpHPLC. (1) rpHPLC of IP digests of 
non-glycosylated 100mer P1 in three tested buffers shows highest amount of unprocessed substrate 
in Buffer A, and lowest in buffer B (without DTT). This indicates that processing of non-glycosylated 
substrates is most effective in HEPES buffer without DTT (Buffer B). (2) The part 2 shows two overlaid 
rpHPLC chromatograms of IP digests of glycosylated GP11 substrate,. The amount of nonprocessed 
substrate is higher under buffer B conditions, while the addition of DTT improves digestion efficiency.  
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3.1.2 Control of proteasome purity 
To control the purity of purchased proteasome preparations, the P1 peptide as substrate was 
incubated with immunoproteasome in the presence of proteasome specific inhibitor. A parallel 
control assay without proteasome inhibitor was performed. Digests were fractionated by 
rpHPLC and fractions analysed by MALDI/MS/TOF/MS.  
Upon addition of proteasome inhibitor no processing activity was noticed (Fig. 14). This 
indicates purity of the proteasomal preparation and absence of contaminating proteases.  
 
Figure 14. The control of proteasome purity by rpHPLC of P1 proteasome digest.  The P1 100-
mer was processed by immunoproteasomes in buffer B in the presence of proteasome inhibitor (1). 
The result was compared with a control experiment without addition of inhibitor (2). The single peak 
present in the chromatogram 2 represents the non-processed P1 peptide (marked by asterisk) and 
proves the complete inhibition of proteasomal activity and the absence of contaminating proteases.  
1 
2 
Buffer B + inhibitor 
Ada(Ahx)3-(Leu)3-Vinyl 
sulphon 
Buffer B 
- residual unprocessed sample  
P1  -  (HGVTSAPDTRPAPGSTAPPA)x5 
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3.1.3 Influence of glycosylation on proteasomal processing efficiency  
To test the influence of glycosylation on proteasomal processing efficiency, the array of 29 
MUC1 peptides and glycopeptides was in vitro processed by immunoproteasomes (Table 2, 
section 2.2.1). We  used a labelling system by sorting of glycopeptides based on their glycan 
chain length. Unglycosylated peptides are named systematically starting with P followed by 
the number, glycopeptides with GP when glycosylated with the monosaccharide GalNAc, 
with GGP when glycosylated with the disaccharide Gal-GalNAc and as SGGP when carrying 
sialylated disaccharide. Previously used, unsystematic, names are mentioned in brackets.  
The substrates represented sections of the MUC1 tandem repeat domain starting with different 
motifs of the repeat (AHG or SAP). Twenty five of them were O-glycosylated with single or 
multiple GalNAc, Gal1-3GalNAc or NeuAc2-3Gal1-3GalNAc moieties at Ser/Thr positions. 
In vitro proteolysis with immunoproteasomes was performed until the reference substrate, a 
non-glycosylated 100-meric repeat peptide (P1), was completely processed and no starting 
peptide detectable. Generated fragments were chromatographed by rpHPLC for identification 
and quantification. The amino acid sequences of fragments were identified either by 
MALDI/MS-TOF mass spectrometry via their molecular mass ions or by ESI-Q TOF-MS/MS 
via their bi or yi fragment ions (Figure 15). Two independent assays were performed with 
most of the substrates and showed close similarity with respect to proteolytic fragmentation 
patterns and relative amounts of fragments, thereby proving the reproducibility of the assay. 
The relative amounts of all generated fragments were calculated based on relative HPLC peak 
areas and MALDI/MS ion intensities, (section 2.3.1). The rpHPLC chromatograms and tables 
listing digestion rates for all analysed peptides and glycopeptides are attached in appendix. 
3.1.3.1 Processing of nonglycosylated peptide 
Digestion of all non-glycosylated peptides occurred at high rates, resulting in quantitative 
degradation of substrates during 48h, independent of their sizes (21-mer to 100-mer) and 
irrespective of sequence variations at the immunodominant motif (DT > ES). During the same 
time period digestion of all glycopeptide substrates resulted in more or less reduced 
degradation rates that varied from <1 to 90% (Table 4).  
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 A P D T R P A P G S  
 
                                                                            b3    b5 b6 b7 
 
 
Figure 15. Analysis of digestion mixture of GP3 glycopeptide by rpHPLC, MALDI/TOF/MS and 
ESI/MS/MS. The HPLC fraction labelled with red arrow was measured by MALDI/TOF/MS. Ion of MW 
1171 was sequenced by ESI/MS/MS and APDTRPAPGS-GalNAc glycopeptide identified according its 
bi  and yi fragment ions 
 
 
rpHPLC 
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TOF/MS 
ESI/MS/MS 
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3.1.3.2 Processing of glycosylated peptides 
Two series of glycopeptides with different starting motif: SAP or AHG were used in our 
experiments. The 20-meric glycopeptides (GP9-GP14) starting with SAP amino acid motif 
were degraded at 50-70% rate of the nonglycosylated peptide rate even when carrying three, 
two or one glycan moieties. In this series of glycopeptides no direct correlation between 
number of glycan chains per repeat and proteolysis efficiency was revealed, since these 20-
mers were degraded at comparable rates (see section 3.1.4.2.2). 
On the other hand, glycosylation of AHG series glycopeptides provoked a strong specific 
impact on the degradation rate. The heavily O-glycosylated 20-meric glycopeptide GP16 
resembling one tandem repeat of the fully glycosylated, naturally occurring MUC1 glycoforms 
in tumor patients was revealed as the poorest substrate with a degradation rate of <1% (Fig. 16).  
Reduction of glycosylation to three GalNAc moieties per repeat on 100-meric GP1 
glycopeptide did not improve the processing efficiency. The length of the densely 
glycosylated substrate had no influence on the degradation rate.  
Strikingly, the 20-meric glycopeptide GP15 with only two GalNAc residues was also fully 
resistant to IP proteolysis pointing to site-specific effects of O-glycosylation (Fig. 16). 
Noticeably, the digestion of monoglycosylated peptides GP2-GP7 occurred at 60-70% rate of 
the nonglycosylated peptide, irrespective of sequence variation (DT>ES). No clear-cut 
evidence could be obtained that variation of single glycosylation sites did strongly influence 
the overall processing efficiency (Table 4). 
 
Figure 16. Influence of glycan presence on processing efficiency. Glycosylated MUC1 VNTR 
peptides GP15, GP16 and GP3 were processed by IPs and analysed by rpHPLC. The residual 
unprocessed peptide is marked by an asterisk and positions of glycosylation within amino acid 
sequences by bold underlined letters.  
 
 
AHGVTSAPDTRPAPGSTAPPA 
 
GP15 GP16 GP3 
AHGVTSAPDTRPAPGSTAPPA AHGVTSAPDTRPAPGSTAPPA 
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3.1.3.2.1 Influence of glycan length on processing efficiency 
We addressed the question whether more elongated glycans, like the disaccharide Gal1-
3GalNAc or NeuAc2-3Gal1-3GalNAc, could have negative effects on processing rates 
compared to substrates glycosylated with the core sugar GalNAc. Sequence identical peptides 
with the AHG starting motif (GP2-GP4; GGP1-GGP3; SGGP1-SGGP5) mono-substituted 
with any of the three glycans were assayed. Strikingly, rpHPLC analyses revealed higher 
degradation rates for the disaccharide substituted peptides than for complementary 
monosaccharide substituted peptides (Table 4). The replacement of GalNAc by 
Gal(1-3)GalNAc at the same peptide position increased the degradation rate by 30% (compare 
GGP1 vs. GP2; GGP3 vs. GP4). 
On the other hand, sialylated glycopeptides were processed at very low rate, comparable to 
the densely glycosylated GP1 and GP16 glycopeptides.  
Together these data indicate that glycopeptide antigens can be processed by 
immunoproteasomes, but the process is influenced by localisation and type of glycan chains. 
Furthermore, naturally occurring densely glycosylated MUC1 is a poor substrate for 
immunoproteasomes due to its abundant glycosylation.  The reduction of glycosylation 
density or change of the peptide starting motif plays important roles in in vitro processing of 
MUC1 VNTR peptides. The influence of the peptide starting motif on processing rates could 
be explained by the specificity of proteasomal digestion, which together with glycan 
substitution influence digestion outcome. To analyse the specificity of proteasome for MUC1 
repeat sequence, further studies were performed. 
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Peptides table 
 NAME SEQUENCE % 
PROCESSED 
P  
E  
P  
T   
I   
D 
E  
S 
P1(DTR100) (HGVTSAPDTRPAPGSTAPPA)x5 100 
P2(ESR61) A(HGVTSAPESRPAPGSTAPPA)x3 100 
P3(AHG21DTR) AHGVTSAPDTRPAPGSTAPPA 100 
P4(AHG21ESR) AHGVTSAPESRPAPGSTAPPA 100 
 
 
 
 
G
L
Y
C
O
P
E
P
T 
I
D
E
S 
 
 
 
M 
O 
N 
O  
S  
A 
C  
C 
H 
A 
R   
I   
D  
E  
 
 
 
      
GP1(Tn100) (HGVTSAPDTRPAPGSTAPPA)x5 <1 
GP2 (H11) AHGVTSAPDTRPAPGSTAPPA 57 
GP3(H12) AHGVTSAPDTRPAPGSTAPPA 94 
GP4(H13) AHGVTSAPDTRPAPGSTAPPA 63 
GP5(H14) AHGVTSAPESRPAPGSTAPPA 65 
GP6(H15) AHGVTSAPESRPAPGSTAPPA 74 
GP7(H16) AHGVTSAPESRPAPGSTAPPA 64 
GP8(A4GALNAC) AHGVTSAPESRPAPGSTAPPA 70 
GP9(SAP20-1) SAPDTRPAPGSTAPPAHGVT 54 
GP10(SAP20-2) SAPDTRPAPGSTAPPAHGVT 54 
GP11(SAP20-3) SAPDTRPAPGSTAPPAHGVT 65 
GP12(SAP20-4) SAPDTRPAPGSTAPPAHGVT 56 
GP13(SAP20-5) SAPDTRPAPGSTAPPAHGVT 74 
GP14(SAP20-6) SAPDTRPAPGSTAPPAHGVT 68 
GP15(A11) HGVTSAPDTRPAPGSTAPPA <1 
GP16(A12) HGVTSAPDTRPAPGSTAPPA <1 
D        
I        
S       
A       
C      
C      
H.  
GGP1(A1) AHGVTSAPDTRPAPGSTAPPA 91 
GGP2(A2) AHGVTSAPDTRPAPGSTAPPA 89 
GGP3(A3) AHGVTSAPDTRPAPGSTAPPA 88 
GGP4(A4) AHGVTSAPDTRPAPGSTAPPA 86 
S     
I    
A   
L   
Y   
L. 
 
SGGP1 (A4ST) AHGVTSAPDTRPAPGSTAPPA  <1 
SGGP2 (A13ST) AHGVTSAPDTRPAPGSTAPPA <1 
SGGP3 (A14ST) AHGVTSAPDTRPAPGSTAPPA <1 
SGGP5 (A8ST) AHGVTSAPDTRPAPGSTAPPA <1 
 
Table 4. List of synthetic peptides and glycopeptides used in experimental studies. Synthetic 
peptides and glycopeptides were incubated with 20S IPs and the products were chromatographed by 
rpHPLC to quantify the residual amount of non-processed peptide. Peptides and glycopeptides, 
named according to a systematic labelling system are grouped based on their glycosylation type.  The 
glycosylated amino acids in the peptide sequences are labeled with bold underlined letter. 
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3.1.4 Influence of glycosylation on processing pattern of MUC1 VNTR 
sequence 
3.1.4.1 Processing pattern of nonglycosylated peptide  
The processing pattern of MUC1 VNTR peptides was elucidated from the frequencies of 
cleavage at each peptide bond within the analysed substrates. The influence of glycosylation 
on processing patterns was evaluated from comparative analyses of preferred cleavage sites 
for different glycopeptides and for peptides. Between two independent digests of the same 
peptide no difference in cleavage patterns was observed. 
The most frequent cleavages of nonglycosylated 100meric P1 peptide occurred within the 
S-A-P motif contributing to 50% of all proteolytic products (Fig. 17). The high specificity of 
IPs for this motif is emphasized by the fact that other peptide bonds are cleaved at less than 
1% rates.  This confirms previous reports claiming that the relative usage of processing sites 
can differ substantially. (Niedermann G et al., 1996; Toes RE et al., 2001).  
The second frequently used cleavage region is G-S-T releasing about 9% of generated 
fragments.  
 
Figure 17. The digestion frequencies of peptide bonds of nonglycosylated P1 (100mer). The P1 
peptide was digested by IPs and the cleavage frequencies between its amino acids calculated. The 
histogram bars show cleavage frequency between amino acids. The amino acid sequence is given on 
the x-coordinate. The numerical values of cleavage frequencies are shown by the numbers above 
the bars. The processing of long nonglycosylated P1 peptide occurs most frequently within the SAP 
motif as well as within the GST motif. 
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The processing pattern depicted by the digestion frequencies is reflected by the pool of major 
peptide fragments. Fragments generated during proteolysis of P1 peptide originate from the  
digestions in the S-A-P and/or G-S-T region, as shown in figure 18.   
 
Figure 18. The most prominent peptide fragments generated by immunoproteasomal cleavage  
from P1 peptide. Fragments are presented as the horizontal bars and most frequent terminating 
positions squared by the box. The majority of generated fragments terminate in the SAP or GST 
regions.  
3.1.4.1.1 Influence of variant amino acid sequence of VNTR region on processing 
patterns 
The introduction of variant amino acid sequence (DT>ES) into the 61meric P2 peptide did not 
substantially change the processing pattern of immunoproteasomes, as presented on figure 19. 
 
 
Figure 19. The digestion frequencies of peptide bonds of nonglycosylted P2 61-mer. The 61-
meric P2 peptide was digested by IPs and the processing frequencies between its amino acids 
calculated. The histogram bars show cleavage frequencies between two amino acids. The amino acid 
sequence is given on the x-coordinate. The numerical value of cleavage frequencies are shown by the 
numbers above the bars. The processing of long nonglycosylated sequence-variant P2 peptide occurs 
most frequently within the SAP motif as well as within the GST motif. 
Moreover, the shorter nonglycosylated substrates, like the 21-meric peptides P3 and P4, are 
also processed in identical manner as longer substrates. The S-A-P and G-S-T motifs are for 
both peptides the major cleavage regions. These data confirm that naturally existing variation 
of the amino acid sequence does not considerably influence processing of the nonglycosylated 
MUC1 VNTR core protein (Fig. 20).  
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Figure 20. The cleavage frequencies of peptide bonds of nonglycosylted P3 and P4 20-mers. 
The 20-meric P3 and P4 peptide were digested by IPs and the cleavage frequencies between their 
amino acids calculated. The histogram bars show cleavage frequencies between two amino acids. 
The amino acid sequence is shown on the X-coordinate. The numerical value of cleavage frequencies 
are shown by the numbers above the bars. The processing of short nonglycosylated peptides occurs 
most frequently within the SAP motif as well as within the GST motif. Digestion frequencies of 
sequence variant peptide P4 (DT>ES) is comparable to frequencies of P3 peptide.  
From these data we conclude that immunoproteasomes can digest all peptide bonds of the 
MUC1 VNTR sequence, but show strong preference for peptide bonds within SAP and GST 
motifs. This processing pattern is irrespective of the peptide length or naturally existing 
sequence variance (DT>ES).  
3.1.4.2  Processing pattern of glycosylated peptide 
Abundant O-glycosylation of MUC1 is regarded as the reason for its weak immunogenicity 
by sterically blocking endosomal processing. We assessed whether and how the presence and 
position of  O-glycans within MUC1 VNTR peptides influence the proteasomal processing 
specificity and efficiency. Previosly we identified SAP and GST motifs as the major 
processing regions in MUC1 VNTR peptide. Interestingly, the immunodominant peptide 
epitopres of  MUC1 are located within the VNTR domain, which is generally heavily O-
glycosyltated at 5 positions, and four of which overlap with the defined major processing 
sites.  
As expected, the presence of glycans at these major processing regions significantly reduced 
the cleavage rates by IPs, as shown in figure 21. Glycosylation of Thr adjacent to the SAP 
motif significantly reduced the relative frequencies of cleavage within the motif to about 8% 
compared to app 50% observed in nonglycosylated P4 peptide (refer to glycopeptide GP5 and 
the nonglycosylated reference peptide P4 in figure 21. Glycosylation at this position did not 
significantly change cleavage frequencies at the distant GST region.  
 
 E S
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Vice versa, glycosylation of Thr within the GST motif reduced cleavage rates at this region 
from 8% to 3%, while the cleavage frequency within the SAP region remained largely 
unaffected compared to the reference peptide (refer to glycopeptide GP7 and P4 peptide). The 
negative influence of glycosylation is in this case less striking than the one noticed for the 
SAP region.  
Glycosylation of the Thr within the DTR motif located proximal to both preferred cleavage 
sites did not change the proteasomal cleavage pattern (refer to glycopeptide GP6 versus 
peptide P4in figure 3). 
Figure 21 further depicts major processing products of GP5, GP6 and GP7 mono-glycosylated 
peptides in comparison to nonglycosylated P4 peptide. It is noticeable that glycosylation of 
threonine adjacent to the SAP motif reduces the amount of fragments generated by digestion 
within the SAP region (light blue bars), whereas glycosylation of threonine within GST region 
reduces the amount of fragments terminating within the GST region (dark red bars). As the 
SAP region contributes to 50% of generated fragments, compared to maximally 8% reported 
for GST motif, its glycosylation has much stronger effect on processing efficiency. The 
glycosylation of central threonine within the DTR motif does not change proteasomal 
processing patterns and generates major fragments comparable to nonglycosylated reference 
peptide P4 (grey bars). 
From these data it can be concluded that the cleavage frequencies at the major processing 
regions are affected by the positions of O-glycans. Precisely, presence of O-glycosylation 
reduces cleavage frequency at the peptide bonds in its close proximity, without affecting more 
distant positions. Simultaneous presence of glycans at both preferred regions of cleavage 
therefore prevents IP proteolysis almost completely. This result explains low digestion 
efficiency of glycopeptides GP15, GP16 and GP1 that are glycosylated at both (T)SAP and 
GST motifs as well as low cellular immunogenicity of naturally occurring cancer associated 
form of MUC1.  
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Figure 21. Frequency of digestion between each two amino acids of three differently 
glycosylated peptides and major generated fragments.  The GP5, GP6 and GP7 glycopeptides 
were digested by IPs in parallel to nonglycosyalted P4 peptide and the processing frequencies 
between their amino acids were calculated. The histogram bars show cleavage frequencies between 
two amino acids. The amino acid sequence is shown on the x-coordinate. The numerical value of 
cleavage frequencies are shown by the numbers above the bars. Cleavage frequencies of 
glycopeptides were compared to values calculated for non-glycosylated P4 substrate. The frequencies 
of GP5 glycopeptide with GalNAc on Thr5 show significant reduction of cleavage within the SAP 
region (light blue bars).  The glycosylation at the central ESR region does not change the pattern of 
immunoproteasomal activity (dark blue bars). Presence of GalNAc at Thr17 within the GST region of 
GP7 slightly reduces the cleavage within this region. Major processing fragments are presented as the 
horizontal bars in the corresponding colours and most frequent terminating positions squared by the 
orange box. The majority of generated fragments terminate in the SAP or GST regions.  
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3.1.4.2.1 Influence of glycan length on processing pattern 
As notices previously, peptides glycosylated with disaccharide chains were processed at even 
increasing processing rate compared to GalNAc substituted peptides. To study weather the 
replacement of a monosaccharide (GalNAc) by a disaccharide (Gal1-3GalNAc) introduces 
changes in proteasomal site specificity, we performed parallel assays with peptides 
glycosylated at identical positions with either of these sugars. We noticed no change of 
cleavage specificity upon introduction of more elongated glycans. Major fractions generated 
from sequence identical peptides GGP2/GP3 and GP8/GGP4 mono-substituted at identical 
positions were terminated within SAP and /or GST regions (Fig. 22). 
3.1.4.2.2 Influence of starting motif on processing pattern 
The elucidation of MUC1 VNTR processing patterns presents the base for understanding the 
difference in processing efficiency of glycopeptides with different starting motifs, reported in 
section 3.1.3.2. Glycopeptides starting with the SAP motif were efficiently digested by IPs 
irrespective of the number of glycan chains per repeat. As the major processing region SAP is, 
in this case, located at the N terminus of the peptide, that major processing region was not 
used by IPs and therefore no block by O-glycosylation was noticed. 
In this series of experiments we addressed the question wether short peptides starting with 
another repeat motif generate a principally different pool of fragments and if the starting motif 
influences proteasomal site specificity. Glycopeptides with AHG or SAP starting motifs were 
assayed in parallel and the released peptide products identified. As shown in figure 22 major 
processing products in both cases are mainly terminated in SAP or GST region indicating that 
proteasome cleavage site specificity is not influenced by substrate starting motif.(Fig. 22). 
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Figure 22. The most prominent peptide fragments generated by IP digestion from 
glycopeptides with different starting motif and glycosylation type (GGP2, GP3 and GP11). 
Fragments are presented as horizontal bars and most frequent terminating positions squared by the 
grey-shaded box. The majority of generated fragments terminate within the SAP or GST region. The 
type of glycan or the shifted starting motif did not cause changes in proteasome specificity. 
Glycosylated amino acids are marked with bold letters and underlined in the case of disaccharide 
substitution. 
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3.1.5.1 Average peptide length and number of different fragments 
After defining major processing regions within the MUC1 VNTR sequence, explaining the 
influence of glycosylation on proteasome specificity and digestion outcome and identifying 
tolerated glycan positions and type, we approached the problem of best suited glycopeptides 
for eventual breast cancer vaccination strategies. These glycopeptides should resemble cancer 
related MUC1, should be processable by immunoproteasomes and be the source of MHC 
fitting glycosylated fragments/epitopes.  
To determine which glycopeptides could be possible sources of MHC fitting glycosylated 
fragments, we analysed the total number of generated fragments as well as the average 
fragment length generated by IPs digestion (Table 5).  
In the digest of a nonglycosylated MUC1-100mer by immunoproteasome 105 different 
peptides with a mean fragment length of 25,2 amino acids were identified. The digest of 
shorter MUC1 derived peptide AHG21 contained 30 different peptides with a mean fragment 
length of approx. 11 amino acids. The digestion of AHG series glycopeptides substituted with 
GalNAc released between 45 and 63 different peptides. The general mean fragment length in 
the digest of shorter substrates was 11 amino acids.  
NAME SEQUENCE 
Nr of 
fragments 
Average 
fragment length 
P  
E  
P  
T   
I   
D
E   
P1(DTR100) (HGVTSAPDTRPAPGSTAPPA)x5 105 25,2 
P2(ESR61) A(HGVTSAPESRPAPGSTAPPA)x3 105 17,5 
P3(AHG21DTR) AHGVTSAPDTRPAPGSTAPPA 29 10,8 
P4(AHG21ESR) AHGVTSAPESRPAPGSTAPPA 31 11,6 
G
L
Y
C
O
P
E
P
T
I
D
E 
GP2 (H11) AHGVTSAPDTRPAPGSTAPPA 63 11,7 
GP3(H12) AHGVTSAPDTRPAPGSTAPPA 33 10,9 
GP4(H13) AHGVTSAPDTRPAPGSTAPPA 47 12,9 
GP5(H14) AHGVTSAPESRPAPGSTAPPA 46 11,6 
GP6(H15) AHGVTSAPESRPAPGSTAPPA 46 10,6 
GP7(H16) AHGVTSAPESRPAPGSTAPPA 61 11,7 
GP8(A4GALNAC) AHGVTSAPESRPAPGSTAPPA 46 10,5 
Table 5. Number of fragments generated by IPs and average fragment length in the digest of 
MUC1 VNTR peptides and glycopeptides. Nonglycosylated and glycosylated peptides with AHG 
starting motif were processed by IPs, and analysed by rpHPLC and MALDI/MS mass spectrometry 
followed by identification and quantification of fragments. We found that shortening of substrate results 
in shorter average fragment length. 20-meric peptides are releasing 11 amino acids long fragments in 
average, thereby enriching the amount of short MHC fitting epitopes. 
From these results it can be concluded that average length of fragments is proportional to the 
substrate length. Processing of short 21-meric peptides resulted in shorter average fragment 
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lengths. The shorter mean fragment length increases the probability that a higher number of 
MHC fitting glycosylated epitopes is generated. 
3.1.5.2 Amount of generated 8 to 11-meric fragments  
To determine a percent of MHC fitting fragments within all generated fragments, the amounts 
of 8 to11-meric peptides were calculated. In the case of long nonglycosylated P1 and P2 
peptides 8 to11-mers represented only 20% of all generated fragments, whereas their amount 
showed a tendency to increase up to 50% with shortening of the substrate (refer to line A, 
Table 6). 
The design of breast cancer vaccines should involve glycosylated MHC epitopes, resembling 
the structure of cancer-associated MUC1 protein. Therefore, we analysed the amount of 
glycosylated 8 to11-mers within the pool of all generated fragments of the substrate. As 
nonglycosylated peptides can not be the source of peptides that resemble fragments of cancer 
MUC1, they should be considered inapplicable. The GP2 and GP5 glycopeptides glycosylated 
at threonine adjacent to the SAP motif released high amounts of 8 to11-mers, but only 20% of 
them were glycosylated. The glycosylation of Thr within the GST region resulted in 
generation of high amounts of 8 to11-mers (app 40% of all generated fragments), of which 
app 40% were glycosylated. 
GP3 and GP6 glycopeptides, although releasing lower amounts of 8 to11-mers (app 25%) 
compared to other glycopeptides, generated almost exclusively glycosylated fragments. 
Therefore peptides with glycosylation at the central DTR/ESR motif can be considered as the 
best source of short, glycosylated MHC fitting fragments. 
Table 6. Amount of 8 to 11-meric fragments (A) compared to the amount of glycosylated  8 to 
11-meric fragments (B). Amount of MHC fitting fragments, 8 to 11 amino acids long was calculated 
and expressed as the percent of the total amount of all digestion products of one substrate. From the 
amount of  8 to 11-mers, the percent of glycosylated fragments was calculated.   
peptide P1 P2 P3 P4 GP2 GP3 GP4 GP5 GP6 GP7 GP8 
8-11 mers (%) 13 26 52 50 55 15 48 79 35 29 35 
% of 
glycopeptide 0 0 0 0 18 98 45 26 96 39 21 
A 
B 
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3.1.5.3 Region of origin of 8 to 11-meric peptides 
To explain the difference in amount of glycosylated 8 to11-mers we analysed, from which 
region of peptide they were generated. The 8 to11-meric fragments from the digest of MUC1 
VNTR glycopeptides were grouped based on their N-terminal amino acid in three groups and 
the relative amounts of fragments in each group were calculated (expressed as % of the total 
amount of 8 to11-mers).  
The majority of 8 to 11-mers was produced by successive digestion at the SAP and GST 
motifs of analysed peptides. (Table 7, middle section). As GP3 and GP6 carry sugar at the 
central DTR/ESR localised between two major cleavage regions, most of the 8 to11-mers 
released are glycosylated.  
 
 
 
 
 
 
 
 
Table 7.Relative frequencies of 8 to 11-meric peptide fragments grouped according to their N-
terminus. The 8 to11-meric fragments from the digest of MUC1 VNTR glycopeptides were grouped 
based on their N-terminal amino acid into three groups and the relative amount in each group was 
calculated (expressed as % of the total amount of 8 to 11mers). Bold grey squares mark the third of 
the peptide that carries glycan.  
 
One more confirmation that DTR/ESR glycosylated peptides represent the best substrates for 
generation of potential MHC epitopes was found in the rpHPLC chromatograms of three 
different mono-glycosylated peptides: GP2, GP3 and GP4. DTR glycosylated GP3 releases 
the largest amount of short peptides (section 3 on Fig. 23), when compared to GP2 and GP4. 
GP4 releases large amounts of longer fractions, generated mainly by digestion within the SAP 
motif (section 2 Fig. 23). These peaks are present in low amount in the digest of GP2 
glycopeptide glycosylated on Thr proximal to SAP, and the majority of substrate remains 
unprocessed (section 1, Fig. 23)  
 
 
 A H G V T  S A P D T R P A P G S T A P P A 
GP2 18% 42% 40% 
GP3 20% 78% 2% 
GP4 3% 60% 37% 
GP5 26% 27% 47% 
GP6 55% 42% 3% 
GP7 8% 61% 31% 
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Figure 23. Influence of glycan position on the generation of 8 to11-meric peptides and 
processing specificity. The digests of three peptides mono-glycosylated at three different regions 
were analysed by reversed phase HPLC. On the chromatograms, area 1 marks time frame when non-
processed peptide elutes from the column while area 2 - when peptides generated by single 
processing in VTSA region and with unprocessed C terminus elute. Area 3 marks the time period 
during which short 8 to 11-mers starting at VTSA and finishing within the GST region are eluted. The 
GP2 glycopeptide was weakly processed due to blocked digestion in the VTSA region. Glycosylation 
of the DTR motif in GP3 did not prevent the cleavage at VTSA and GST regions, but reduced 
processing efficiency. Glycosylation of GP4 at the GST region reduced digestion within the motif as 
well as overall processing efficiency.  
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3.1.5.4 Prediction of MHC binding activity of 8 to11-meric fragments 
In the digests of all analysed 21-meric glycopeptides, 117 fragments in the size range of 8 to 
11 amino acid long peptides and glycopeptides were generated (Table 8).  
AHGVTSAP GVTSAPDT  PDTRPAPGSTA  SRPAPGSTAP 
AHGVTSAPDTR  GVTSAPDT  PESRPAPG SRPAPGSTAPP 
AHGVTSAPE GVTSAPDTR PESRPAPG TRPAPGST 
AHGVTSAPE GVTSAPDTR PESRPAPGS TRPAPGSTA 
AHGVTSAPES GVTSAPDTRP PESRPAPGST TRPAPGSTA 
AHGVTSAPESR  GVTSAPES  PESRPAPGSTA TRPAPGSTAP 
AHGVTSAPESR  GVTSAPES  PGSTAPPA TRPAPGSTAP 
APDTRPAP GVTSAPESR RPAPAGSTAP TRPAPGSTAPP 
APDTRPAPG GVTSAPESRP RPAPGSTA TSAPDTR 
APDTRPAPG HGVTSAPD RPAPGSTA TSAPDTR 
APDTRPAPGS HGVTSAPD RPAPGSTAP TSAPDTRP 
APDTRPAPGS HGVTSAPDTR RPAPGSTAPP TSAPDTRPA 
APDTRPAPGST HGVTSAPES RPAPGSTAPPA TSAPDTRPA 
APDTRPAPGST  HGVTSAPES RPAPGSTAPPA TSAPDTRPAPG 
APESRPAP HGVTSAPES SAPDTRPA TSAPDTRPAPG 
APESRPAPG HGVTSAPESR SAPDTRPAP TSAPDTRPAPG  
APESRPAPG HGVTSAPESR SAPDTRPAPG  TSAPESRP 
APESRPAPGS HGVTSAPESRP SAPDTRPAPG  TSAPESRPA 
APESRPAPGS PAPGSTAP  SAPDTRPAPGS TSAPESRPAPG 
APESRPAPGST  PAPGSTAPP SAPESPAPG  TSAPESRPAPG  
APGSTAPP PAPGSTAPPA SAPESRPA VTSAPDTR 
APGSTAPPA PAPGSTAPPA SAPESRPA VTSAPDTR 
DTRPAPGS PDTRPAPG SAPESRPAP VTSAPDTRPAP 
DTRPAPGST PDTRPAPG SAPESRPAPG  VTSAPESR 
DTRPAPGSTAP PDTRPAPGS SAPESRPAPG   VTSAPESRPA 
ESRPAPGS PDTRPAPGS SAPESRPAPGS VTSAPESRPAP 
ESRPAPGST PDTRPAPGST SAPESRPAPGS VTSAPESRPAP 
ESRPAPGST  PDTRPAPGST SRPAPGST  
ESRPAPGSTA PDTRPAPGST SRPAPGSTA  
ESRPAPGSTAP PDTRPAPGSTA SRPAPGSTAP  
Table 8. The list of all found 8 to 11meric peptides with marked glycosylation position. Fractions 
found in digests of AHG series (glyco)peptides were analysed and 8 to 11 amino acids long fractions 
selected fro further analyses.  
 
To identify MHC binding glycopeptides, we performed a pre-selection based on predicted 
ligation strength of the peptide. The ligation strength of found 8 to 11-meric fragments to 
MHC class I was analysed by the SYFPEITHI MHC-epitopes analysing software and 
experimentally tested by MHC stabilization assay (Table 9). The tested peptides and 
glycopeptides were different in their amino acid sequence and glycosylation position. The 
prediction software could not incorporate the glycosylation parameter, since its influence on 
MHC binding is not known. Furthermore, the software is not able to include 11 amino acids 
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long fragments.  Therefore the information on glycosylation position was not included and 
just amino acid sequence of glycopeptides was analysed. Due to these restrictions,  the 
number of software-analysed peptides was reduced to 52 8 to 10-meric peptides. Analyses 
concentrated on the HLA-A0201, as the most frequent MHC class I allele.  
Fragment  
Ligation 
strength Fragment  
Ligation 
strength Fragment  
Ligation 
strength 
SAPESRPAP 10 GVTSAPDTRP 4 AHGVTSAPDTR 0? 
SAPESRPAPG 10 GVTSAPESRP 4 AHGVTSAPESR 0? 
TSAPDTRPA 10 APESRPAPG 3 APDTRPAP 0? 
PGSTAPPA 9 APESRPAPGS 3 APDTRPAPGST 0? 
RPAPGSTA 9 HGVTSAPES 3 APESRPAP 0? 
SAPDTRPA 9 PESRPAPGST 3 APESRPAPGST 0? 
SAPDTRPAP 9 SRPAPGSTAP 3 DTRPAPGS 0? 
SAPDTRPAPG 9 HGVTSAPDTR 2 DTRPAPGSTAP 0? 
SAPESRPA 9 HGVTSAPESR 2 ESRPAPGS 0? 
SRPAPGSTA 9 PDTRPAPGST 2 ESRPAPGSTAP 0? 
VTSAPESRPA 9 TRPAPGSTAP 1 HGVTSAPESRP 0? 
PAPGSTAPPA 8 GVTSAPDT  0 PDTRPAPGSTA 0? 
TSAPESRPA 8 GVTSAPES  0 PESRPAPGSTA 0? 
APGSTAPPA 7 HGVTSAPD 0 RPAPGSTAPPA 0? 
PAPGSTAPP 7 PAPGSTAP  0 SAPDTRPAPGS 0? 
RPAPGSTAP 7 PDTRPAPG 0 SAPESRPAPGS 0? 
TRPAPGSTA 7 PDTRPAPGS 0 SRPAPGSTAPP 0? 
GVTSAPDTR 6 PESRPAPG 0 TRPAPGSTAPP 0? 
GVTSAPESR 6 PESRPAPGS 0 TSAPDTRPAPG 0? 
RPAPGSTAPP 6 SRPAPGST 0 TSAPESRPAPG 0? 
AHGVTSAPES 5 TRPAPGST 0 VTSAPDTRPAP 0? 
ESRPAPGST  5 TSAPDTRP 0 VTSAPESRPAP 0? 
ESRPAPGSTA 5 TSAPESRP 0 VTSAPESR 0 
AHGVTSAPE 4 VTSAPDTR 0   
APDTRPAPG 4 APGSTAPP 0   
 
Table 9. Binding prediction of proteasome generated fragments to the HLA-A0201 allele. 52 
experimentally found 8 to 10-meric fragments were analysed by the SYFPEITHY software tool for 
ligation strength to the human HLA-A0201 allele. The information about glycosylation position was not 
included in analyses due to software restrictions.  
 
From the list of analysed fragments, the following peptides were synthesized: GVTSAPDTR, 
GVTSAPESR, SAPDTRPAPG, SAPESRPAPG (Table 10). Peptides with DTR/ESR sequence 
in the central region were not synthesised regardless of the good binding prediction because 
they could not be glycosylated in vitro (Table 10).  
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The fragments of the MUC1 VNTR sequence that were not found in the digests, but predicted 
by SYFPEITHY to have high ligation strength were synthesized if they had possible in vitro 
glycosylation sites.    
 
found in digests 
 
not found in 
digests   
found in digests,   
not synthesised 
 
 
GVTSAPDTR 
GVTSAPESR 
SAPDTRPAPG 
SAPESRPAPG 
 
 
 
 
STAPPAHGVT 
STAPPAHGV 
APPAHGVTSA 
 
 
 
 
VTSAPESRPA 
SAPESRPA 
SAPDTRPA 
TSAPDTRPA 
TSAPESRPA 
SAPESRPAP 
APDTRPAPGS 
APESRPAPG 
APDTRPAPG 
DTRPAPGST
 
Table 10. List of peptides that bind to HLA-A0201 with strong ligation strength, as predicted by 
SYFPEITHI software. Peptides found in the digests of analysed MUC1 VNTR substrates and 
theoretical fragments of MUC1 VNTR sequence, not found in the digests, were selected for further 
analyses. Peptides that were found in digests of analysed substrates and predicted as good binders in 
non glycosylated form, but could not be glycosylated in vitro were not analysed further.  
3.1.5.5 Binding efficiency of MUC1 peptides and glycopeptides to cellular 
HLA-A0201 molecules 
The selected peptides were synthesised, glycosylated in vitro and tested for binding to empty 
HLA-A0201 molecules on T2 cells by MHC stabilisation assay. Tested peptides were 
analysed in parallel with the positive control: FLPSDCFPSV peptide. T2 cells incubated 
without addition of peptide were used as negative control.  The binding affinities were 
measured by FACS and results for glycosylated peptides were compared with affinities of 
their non-glycosylated forms. Figure 24 presents the ligation strengths of tested peptides 
compared with negative control considered as 0 and positive control considered as 100%. 
The strong reduction of ligation strength is noticed upon introduction of GalNAc, reducing it 
to the level of negative control. The exception presents the glycopeptide 
SAPDTRPAPG-GalNAc (SAP10-GalNAc) which is the only MUC1 VNTR glycopeptide 
binding with the same affinity in the glycosylated and the nonglycosylated form. All other 
peptides lost their binding abilities after glycosylation.  
 
                                                                                                                                           Results                        
 
 65
 
0 20 40 60 80 100 120
GVTSAPDTR-GalNAc
GVTSAPDTR
GVTSAPESR-GalNAc
GVTSAPESR
APPAHGVTSA-GalNAc
APPAHGVTSA
SAPDTRPAPG-GalGalNAc
SAPDTRPAPG-GalNAc
SAPDTRPAPG-GalGalNAc
SAPDTRPAPG-GalNAc
SAPDTRPAPG
STAPPAHGV-GalNAc
STAPPAHGV
STAPPAHGVT-GalNAc
STAPPAHGVT
FLPSDCFPSV
 
Figure 24. Ligation strength of MUC1 VNTR peptides and glycopeptides to HLA-A0201. Binding 
affinities of tested peptide and glycopeptides were measured by MHC stabilisation assay and 
expressed as % of the positive control. The negative control was considered as 0. Glycosylation  
position is labelled with asterisk above the amino acid (Thr or Ser); two asterisks represent 
disaccharide.  
3.2 Cellular assays 
3.2.1 Cross presentation 
In another series of experiments we analysed the processing of MUC1 VNTR sequence on the 
cellular level. We performed cross-presentation of MUC1 peptide in the mouse dendritic cell 
line DC2.4 or in human monocyte derived dendritic cells. MUC1 peptides P1 or P2 were 
introduced into the cytosol of DCs by electroporation, loaded liposomes or poly-lactic acid 
vesicles. The liposomal approach as well as electroporation did not generate enough amount 
of MUC1 derived MHC-ligands to enable a mass spectrometric detection. The control 
experiment showed that electroporation results in the introduction of fluorescently labelled 
peptides into the cytosol of 5-10% of treated cells. The liposomal approach was confirmed 
successful with ELISPOT assay performed by Dr. Kondo Eisei at Molecular tumor biology 
and tumor immunology group, University of Cologne, but generated epitopes could not be 
identified by mass spectrometry.  
*
*
*
*
**
**
*
*
*
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The loading of poly-lactic vesicles with antigen resulted in the generation of high amounts of 
MUC1-derived MHC epitopes that could be identified for the first time on the peptidomic 
level by mass spectrometry. After incubation of mouse dendritic cells DC2.4 with poly-lactic 
acid vesicles (PLA) carrying P2 peptide, exosomes produces by the cells were collected by 
ultracentrifugation, acidified and fractionated by rpHPLC. Collected fractions were dried by 
vacuum centrifugation and analysed by MALDI/MS/MS. The molecular masses of detected 
ions were analysed by FindPep software application, as described in section 2.2.5. 
The following MUC1-generated fragments were detected after the pulse of DC2.4 with PLA-
encapsulated P2 peptide (Table 11):  
(DA) SEQUENCE MW(DA) SEQUENCE 
823 APESRPAP        1264 PESRPAPGSTAPP 
844 TSAPESRP 1523 TSAPESRPAPGSTAPP 
881 APESRPAPG 1549 HGVTSAPESRPAPGST 
896 PESRPAPGS 1629 SAPESRPAPGSTAPPAH 
937 
STAPPAHGVT            
TAPPAHGVTS 1692 
AHGVTSAPESRPAPGSTA 
      VTSAPESRPAGSTAPPA 
968 
SAPESRPAPG                
APESRPAPGS 
1786 
SAPESRPAPGSTAPPAHGV 
999 PESRPAPGST 1986 VTSAPDTRPAPGSTAPPAHGV 
1056 SAPESRPAPGS 2323 TAPPAHGVTSAPESRPAPGSTAPPA 
1169 
GVTSAPESRPAP                 
VTSAPESRPAPG 
2459 
TSAPESRPAPGSTAPPAHGTSAPES 
 
Table 11. Peptides generated during cross-presentation of P2 peptide in DC2.4 mouse dendritic 
cells. To masses measured on MALDI/MS the corresponding sequence of P2 was assigned.    
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3.2.2 Analyses of MHC bound MUC1 glycopeptides on breast cancer cell 
lines  
Presence of MHC molecules on the breast cancer cell line T-47D was confirmed by confocal 
microscopy (Figure 25) and flow cytometry. We attempted to detect MUC1 derived 
(glyco)peptides bound to MHC class I molecules of T-47D cells. Cells were acid-eluted or 
MHC molecules were affinity purified by HLA-A,B,C antibody W6/32. The eluted epitopes 
were analysed by ESI/MS/MS analyses. To the ionisation spectra the corresponding amino 
acid sequences of human proteins were assigned and the reliability of the result presented as 
homology score. The majority of fragments corresponded to house-keeping proteins of the 
cell. Table 12 presents the selection of 8-11meric peptides connected to cancer phenotype and 
the normal house keeping cellular proteins.  
We did not succeed in the identification of MHC-bound MUC1-derived peptides. The eluted 
mixture contained a group of 14 different peptides corresponding to the CA125 protein from 
mucin gene family (MUC16). In table 12 only a nonameric fragment is listed. Beside 
MUC16, a tumor necrosis factor derived peptide, a cervical cancer suppressor derived peptide 
and the macrophage migration inhibitory factor were identified.  
 
 
 
 
 
Figure 25. Fluorescent 
microscopy of T-47D cells stained 
with MHC class I specific antibody 
and FITC labelled secondary 
antibody.  
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Suggested sequence 
Homology 
score 
MW Name 
DQGITSLTN  9 947,5 gi|24419041 CA125  ovarian cancer related tumor marker 
KPGMVVTFA 
FSDYPPLGRF 
13 
24 
948,56 
1197,61 
gi|24210508 
Cervical cancer suppressor 3 
LFIMLENSQMR  19 1380.72 gi|339992,  
Tumor Necrosis Factor  
LTIGSKLQDA 
ALIYNEALKG 
LDRNKDQEVNF 
32 
32 
30 
1044,58 
1090,61 
1376,65 
gi|30582769  
Calcyclin 
FVQMMTAK 54 954,56 gi|16974826   
Calcium calmodulin 
QPGMVVTFA 13 948,56 gi|12006049  
EF1a-like protein 
FADKVPKTAEN 
ILKHTGPGILS 
35 
23 
1218.65 
1134.68 
gi|3659980  
Cyclophilin A  
RISPDRVY 
RLRISPDRVY 
27 
23 
1004,54 
1273,73 
gi|188556  
(Macrophage) migration inhibitory 
factor 
PVGAANFREA 
FRSGKYDLD 
41 
15 
1030,50 
1099,54 
gi|2661039   
Alpha enolase 
QLALETIDINK 27 1256.84 
gi|409219,  
Spliceosomal protein 
 
EDQDLLKLVK 14 1199,54 
gi|14488774, Human Mica In 
Complex With Natural Killer Cell 
Receptor Nkg2d 
FYYLGPFK 12 1033.55 gi|5514625, 
cadherin-10 
VIQKKSGK 12 1263.67 gi|2257764,  
polymerase 
MAMDSSLQAR 19 1108.58 gi|14250610,  
Kinesin family member 2C 
YTFEIFDGK 11 1118.67 gi|31418212,  
Myomesin 2 
FTMTIDAHTN 24 1149.72 gi|28780,  
apo-B100 precursor 
PPGTFGQN 19 816.46 gi|14017779,  
MEGF11 protein 
LLKDVQCS 17 904.68 gi|15826732, Chain B, Human S-
Adenosylmethionine Decarboxylase 
MRYVASYLL 38 1114.66 gi|4506671,  
ribosomal protein P2 
Table 12. The list of ESI/MS/MS sequenced peptides from acid eluent of T-47D breast cancer 
cell line.  
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4.1 Tumor antigen MUC1 and the immune system 
MUC1 is a human tumor antigen used in tumor diagnostics serum tests (CA15-3) and 
involved in numerous attempts to develop tumor specific vaccines for both preventive and 
therapeutic purposes. Unlike the majority of mucins that are secreted from cells, MUC1 is 
expressed in a transmembrane and secreted form. Though encoded as a single protein, it is 
expressed as a type I transmembrane heterodimer. The major part of the MUC1 ectodomain is 
composed of tandemly repeated 20 amino acid sequences, GVTSAPDTRPAPGSTAPPAH, 
referred to as VNTR domain. The 20-mer can be repeated up to 120 times in a single MUC1 
molecule and is densely O-glycosylated on its five serine and threonine residues. During the 
lactation phase in women and breast cancer development secreted and shed forms of MUC1 
can be detected in serum and bod fluids. Lactation-associated protein is less densely O-
glycosylated by long polylactosamine-type chains on its VNTR domain. The extensive 
shortening of the carbohydrates together with their increased density and a higher substitution 
with sialic acid are the hallmarks of cancer-associated MUC1 glycoforms. This shortening of 
carbohydrates exposes the peptide core residue to antibodies, protein receptors and digestive 
enzymes (Liu X et al., 1995; Grinstead JS et al., 2002; Vlad AM et al., 2004). 
The secreted or shed MUC1 in sera of cancer patients reaches lymph nodes and other 
immunogenic hot-spots. Antigen-presenting cells residing there can take up the circulating 
MUC1 and possibly present its peptides on MHC class I and class II molecules stimulating 
thereby the cellular immune response. 
Vlad et al (Vlad AM et al., 2002), and Apostolopoulos et al (Apostolopoulos V et al., 2003) 
showed that MUC1 glycoprotein can be presented to T cells without prior removal of sugar 
chains at MHC class II or class I complexes of antigen presenting cells. In a previous study 
published by Hanisch et al (Hanisch FG et al., 2003), we showed that cathepsin L, the major 
enzyme involved in generation of MHC class II epitopes, can process glycosylated MUC1 
peptides, with restrictions introduced by glycosylation positions and type. The study identified 
T-S-A-P, G-ST and H-GV peptide bonds as main processing regions within the MUC1 VNTR 
sequence. Moreover, it showed that glycans located in the proximity of the cleavage sites 
caused inhibitory effects on enzyme activity, whereas their localisation on amino acids distant 
from the digestion site did not have effects on processing efficiency. The MHC class II bound 
MUC1 glycopeptides can stimulate T helper cells as shown by Vlad et al (Vlad A et al., 2002). 
Although the stimulation of T helper cells is of importance for long-lasting anti-cancer 
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immune responses and the induction of B-cell responses, the activation of cytotoxic T-cells is 
necessary for tumor eradication.   
4.2 Processing of nonglycosylated MUC1 sequence by 
immunoproteasomes 
The stimulation of cytotoxic T-cells requires the presentation of MUC1 derived glycopeptides 
on MHC class I molecules of antigen presenting cells. The generation of MHC class I bound 
peptides is performed by a special type of proteasomes, although the involvement of 
cytoplasmic endopeptidases or even cathepsins have been reported (Seifert U et al., 2003; 
Shen L et al., 2004). 
According to results described in this work, isolated proteasomes process the MUC1 VNTR 
sequence most frequently within two major digestion regions of the tandem repeat peptide- 
S-A-P and G-S-T, in contrast to some peptide bonds that are rarely used and that release only 
1% of fragments. Some processing is also noticed at RP and AP(PA) regions.  
Processing and presentation of peptides in cellular assays showed a more specific cleavage 
pattern restricted almost exclusively to S-A-P and G-S-T motifs. No peptides that were eluted 
from mouse H2Kb MHC class I allele started within minor processing regions. The high 
similarity of results we achieved by in vitro proteasome digestion and in cellular assays 
supports the use of in vitro system for the analysis of antigen processing and presentation 
pathways.  
The frequent proteasomal cleavage within S-A-P and G-S-T motifs correlates with the 
prediction assay at NetChop 3.0 server and with known proteasomal processing patterns (Fig. 
26) (Nielsen M et al., 2005).   
According to the proteasomal cleavage site prediction tool, the main digestion region within 
MUC1 VNTR peptides is the VTSAP motif, but processing can occur also at RP, GS and AP 
regions (Fig. 26). The results of in vitro experiments indeed revealed that proteasomes 
preferentially process MUC1 VNTR nonglycosylated peptides within S-A-P and G-S-T 
regions with some digestion of lower frequency at RP or AP motifs (Fig. 26B). Cleavage 
frequencies at low level could be noticed at all peptide bonds of the sequence. The variation 
of amino acid sequence from DTR to ESR did not influence the processing specificity of 
proteasomes. All non-glycosylated MUC1 VNTR peptide sequences were processed by 
immunoproteasome at high rate (100%) with no residual substrate detected. This shows that 
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the MUC1 VNTR amino acid sequence is processed in a highly specific manner and contains 
no peptide bonds resistant to proteasomal processing. 
 
Figure 26. The processing pattern of MUC1 VNTR sequence predicted by NetChop 3.0 (A) and 
experimentally shown. (B). According to prediction of cleavage sites performed by NetChop 3.0, 
major cleavage regions of non-glycosylated MUC1 VNTR are located within S-A-P and G-S-T motif. 
Digestion of non-glycosylated and glycosylated MUC1 VNTR peptides by immunoproteasomes 
revealed S-A-P and G-S-T as the main digestion regions which are blocked by glycosylation in their 
close proximity 
Our experimental result of processing specificities correlates with known proteasomal 
preferences (Fig. 27) (Emmerich NP et al., 2000; Toes RE et al., 2001). The proteasome is a 
multi-catalytic protease complex containing three different active sites with chymotrypsin-, 
trypsin and caspase like activity. But the proteasome cannot be considered a simple collection 
of such enzymes. In fact it is the structural architecture of the proteolytic chamber that 
determines specificity. The local structure around the enzyme active site structurally selects 
the peptide substrates fitting to the substrate binding clefts to be lysed. Due to its substrate 
specificity, the proteasome digests preferentially between specific amino acids (labelled P1 
and P1’), but more distant acids also influence the process.  
The major cleavage sites of MUC1 VNTR, the S-A-P and G-S-T regions, correspond to the 
frequent Ser and Gly, as well as Thr and Ala occurrence at P1 position (N terminaly of the 
cleaved peptide bond) (Fig. 27). Digestion at RP region corresponds to tryptic like activity of 
proteasome with preference for Arg at P1 position. Digestions occurring within DTR/ESR 
motifs can be attributed to caspase like activity with preference for Glu or Asp at P1 position.  
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Figure 27. Sequence logo generated using in vitro data on digestion of enolase and ß-casein by 
human 20S constitutive proteasome. Prefered amino acids for proteasomal digestion on the place 
of processing (P1 and P1’) and distant from it. Amino acids are colour coded according to their 
physicochemical characteristics. Neutral and polar, green; basic, blue; acidic, red; neutral and 
hydrophobic, black. Upside-down letters show the amino acids that are under-represented compared 
to the background distribution. Proteins digestion statistic generated on enolase (Toes et al., 2001) and 
ß-casein (Emmerich et al., 2000). Picture from Kesmir C et al.,2002.  
 
4.3 Processing of glycosylated MUC1 by immunoproteasomes 
Up to now, no proteasomal processing of glycosylated peptides was described. Although it 
was shown that MHC molecules can bind glycopeptides and that glycopeptide specific T-cells 
exist, it is not known how the glycosylation of a substrate influences the proteasome 
specificity. The glycosylation was reported to prevent proteasomal degradation of Sp1 
transcription factor (Han I et al., 1997). The question whether glycan position and type could 
control processing was up to now not addressed.   
We performed for the first time the in vitro digestion of glycosylated MUC1 VNTR peptides 
and analysed the influences of glycan position and type on the processing outcome.  The 
digested MUC1 glycopeptides were fractionated by rpHPLC and analysed by MALDI-
TOF/MS or ESI/MS/MS. Based on relative peak areas in the chromatograms and MALDI/MS 
ion intensities we quantified the relative amounts of generated fragments, the percent of 
degraded substrate and the frequencies of cleavages at single peptide bonds. This 
quantification of processing efficiencies in a relative manner (%) allowed us to compare data 
obtained for different glycopeptides as well as to correct for eventual variations in absolute 
amounts of starting substrate. 
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We observed a general reduction in digestion rates of glycosylated peptides compared to 
nonglycosylated substrates, resulting in digestion efficiencies below 100%. We determined 
that activity and specificity of proteasomes is influenced by glycan structure and its position 
within the peptide sequence.  
• Monosaccharide glycopeptides  
Glycosylation of AHG series of peptides, even by GalNAc monosaccharide, modulated 
proteasomal efficiency. The proteasomes retain their site specificities of cleavage in case 
of glycopeptides, but the actual proteolysis is directed by glycan presence and thereby the 
digestion outcome is modulated. Glycosylation of major processing motifs significantly 
reduces processing within the motif. This reduction causes overall reduction of processing 
rate of the glycosylated substrate (Fig. 26B).  
The effect of glycosylation is stronger in the case of glycosylation of Thr adjacent to the 
SAP motif, than within the GST motif, agreeing with the observation that digestion within 
the GST motif contributes less to substrate degradation than within SAP. The 
glycosylation of DTR reduces the overall digestion rate in comparison to nonglycosylated 
peptides, but does not specifically influence the digestion outcome. Substrates 
glycosylated on both (T)SAP and GST positions are not processed due to the cumulative 
effect of glycosylation-induced blocking on both major processing motifs (Fig. 26B). In 
such cases poor substrate positions are used at low frequencies. As the immunoproteasome 
generates MHC binding peptides, the outcome of antigen processing and presentation will 
therefore be dependent on its glycosylation. We could not point out any universal pattern 
describing this low-specificity proteolysis.  
• Disaccharide-glycopeptides 
The cancer-associated MUC1 is often glycosylated by T antigen (Gal-GalNAc). 
Surprisingly, in vitro processing of disaccharide-glycosylated peptides resulted in higher 
digestion rate than that of monosaccharide-glycosylated peptides, although a decrease 
should be expected due to sterical hindrance. The analyses of processing products 
revealed that introduction of disaccharide increased the digestion at the AP(PA) motif 
proximate to the carboxy terminus and thereby resulted in a considerable amount of long, 
almost full-length fragments. This phenomenon was not observed in monosaccharide 
glycosylated substrates. The disaccharide substituent possibly introduces a shift in 
substrate conformation and alters its interaction with the proteasomal active site. 
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However, the digestion in S-A-P and G-S-T was reduced by adjacent glycosylation as 
much as in the case of monosaccharide glycosylated peptides.  
• Sialylated-glycopeptides 
The most common form of glycan chains of tumor-associated MUC1 is sialylated T 
antigen (NeuAc-Gal-GalNAc). The secretory MUC1 found in sera of cancer patients is 
densely sialylated and proteasomes of antigen presenting cells in cancer patients possibly 
come into contact with this form of antigen. Sialyl-Gal-GalNAc modifications of peptides 
completely prevented substrate degradation by immunoproteasomes. Substrates with one 
sialylated disaccharide even outside of the main processing region were not processed.  
The possible explanation for this could be found in the size of the glycan chain, 
preventing introduction of the glycopeptide into the 1,3 nm wide entrance of 20S 
proteasome. As the average size of monosaccharide unit is 0,5nm, the trisaccharide can be 
bigger than hollow diameter of the proteasomal entrance. The 20S proteasome used in 
these in vitro studies lack the regulatory and activator subunits. The studies have shown 
that hydrophilic substrates (and MUC1 VNTR sequence belongs to these) can enter the 
20S proteasome without opening of the entrance by proteasomal 19S regulatory subunit or 
proteasomal activator PA28 (Kohler A, Finley D, Mol Cell 2001).  
The other reason for unsuccessful processing of NeuAc-Gal-GalNAc glycosylated 
peptides can be the strong charge of sialic acids. Their negative charge could interfere 
with polar amino acids of the proteasomal active centre and disturb the proteolytic 
mechanism. The activation of proteasomal proteolyses depends on fine interaction of 
electro-negativities and charges of amino acids within the active site of the proteasome. 
The presence of a strong negative charge of sialic acid could probably interact with 
positively charged Lys and therefore block the stabilisation of Thr–O- and shift of its H to 
NH2, and with that the complete proteolytic process.  
4.4 Influence of peptide starting motif 
In contrast to these results, which are acquired by processing of peptides with the AHG 
starting motif, glycosylation of peptides with the SAP starting motif revealed less clear 
interference with proteasome specificities. In this case the main cleavage site (SAP) is 
localised N terminally and therefore no processing at that position takes place. Therefore, the 
glycosylation of Ser within SAP did not considerably change proteasomal specificity although 
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it reduced the processing rate. The GalNAc located on Thr of DTR and on Thr of G-S-T 
reduced the processing efficiency in a similar way as reported in case of AHG starting 
peptides.  
4.5 The buffer influence 
MUC1 VNTR peptides and glycopeptides were processed in three different buffer systems 
and optimal degradation was achieved with HEPES buffer containing DTT. The digestion of 
glycopeptides was remarkably increased under these reducing conditions. The effect was not 
visible with nonglycosylated substrate. The function of DTT could be correlated with 
reduction of the S-S bridges within proteasomes that can form by oxidation processes under in 
vitro conditions. The proteasomes are reported to be oxidised with aging as do most other 
proteins, and this oxidation is reducing their proteolytic functions (Ferrington DA et al., 
2005). A similar process could take place in vitro and addition of DTT could explain reversion 
of oxidative deactivation. Why the same phenomenon is not observed in the case of non-
glycosylated peptides is not clear. The processing of nonglycosylated peptides occurs at 
higher rates and can be completed before proteasomal deactivation. In cellular system 
reducing metabolites could take over the role of DTT, keeping the proteasome active for 
longer periods of time. Another possible role of DTT could be its interaction with OH groups 
of glycans, thereby preventing them to displace the Thr OH group in interaction with Lys 
from the active site of the proteasome.  
4.6 Low immunity of cancer related MUC1 glycoforms 
The VNTR domain of MUC1 is O-glycosylated at Thr and Ser and primarily at the TSAP and 
GST motifs. From the processing results the overlapping of major digestion and glycosylation 
regions: S-A-P/G-S-T is obvious. This location of glycans on major processing regions 
protects native, cancer related MUC1 from digestion by proteasomes and thereby prevents the 
formation of MHC class I ligands. This can explain the low immunogenicity of the protein. 
Design of a peptide vaccine with glycans located at tolerated positions could stimulate 
glycopeptide specific immune responses. An additional physiological role of glycosylation 
could be the protection of the core peptide from proteolytic attack by enzymes of the host and 
pathogen. Therefore, the function and immunogenicity of MUC1 could be dependent on this 
overlapping of regions.  
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Independent of the glycan influence on processing efficiency, we can conclude that the 
digestion of O-glycosylated MUC1 peptides can take place without prior removal of 
glycans and the glycopeptides can be suitable substrates for proteasomal digestion. Previously 
it was reported that glycosylated proteins of the ER are retrotranslocated into the cytoplasm in 
a glycosylated state (Hiller et al., 1996; Wiertz et al., 1996). The N-glycosylated proteins are 
than de-glycosylated prior to proteasomal degradation by cytoplasmic N-glycanase and the 
de-N-glycosylated intermediates were discovered in the cytosol upon inhibition of the 
proteasome. Recently, a highly conserved cytoplasmic N-glycanase (Png1p), which forms a 
complex with proteasome over RAD23 proteins, has been identified in yeast. It efficiently 
deglycosylates the substrate prior to degradation (Suzuki et al., 2001). Besides this, a 
proteasomal role in de-N-glycosylation was reported and suggested that they have a direct 
contact with the cytosolic side of the ER (Kraivanova RK et al., 2000)  
In difference to N-glycosylated proteins, the O-glycoproteins were shown to be presented in 
MHC class I and II pathway without prior removal of glycan residues (Vlad AM et al., 2002).  
The question whether O-glycosylated proteins are really processed by proteasomes could be 
raised, since other ways of generation of MHC bound peptides were reported (Jondal M et al., 
1996; Rock KL et al., 1996). Moreover, it was shown that Sp1 transcription factor cannot be 
processed by proteasomes when glycosylated by single O-GlcNAc and this process is 
correlated with optimal nutritive conditions (Han I et al., 1997). Our results presented in this 
work showed that O-glycosylated MUC1 peptides are suitable substrates for 
immunoproteasomes and glycan location on major processing regions exerted specific 
inhibitory effects on digestion efficiency. 
4.6.1 Sterical influence of glycans on processing outcome 
The inhibitory influence of carbohydrates can have a sterical background. The likelihood of 
substrate cleavage depends on the mean residence time at the proteolysis sites, which is 
maximal if all binding sites are occupied (Dick TP et al., 1998; Nussbaum AK et al., 1998) The 
distance between proteolytic active sites is 2.8 nm, which corresponds to an extended structure 
of hepta or octapeptides (Baumeister W et al., 1998). The introduction of the glycan chain can 
introduce a sterical hindrance for interaction of peptide with proteasomal active sites and the 
incomplete occupancy of all binding sites can occur. This would result in reduced processing 
(Kinarsky L et al., 2003).  
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Although glycan presence in vitro had potential to completely prevent processing, the situation 
in cellular assays could have different outcome. The cellular proteasomes contain 19S 
regulatory and PA28 activator subunits, besides a catalytic 20S core, which was used in our 
study.  The 19S particle has several functions. It opens gates of the 20S proteasome (13Å wide 
in isolated 20S proteasome, Lowe J et al., 1995), binds ubiquitinated substrates, de-ubiqutinates 
them and destabilizes their tertiary and/or quaternary structure and translocates the unfolded 
protein chain through the proteasomal open ends to the central chamber where catalytic sites for 
peptide-bond hydrolysis are located. The binding of the 19S subunit to the proteasome strongly 
activates the hydrolysis of short peptide substrates, probably by increasing the access of these 
substrates to the catalytic sites (Ma CP et al., 1993). In the processing of MUC1 by dendritic 
cells in in vivo, the 19S subunit could open the alpha rings of the proteasome and increase the 
annulus diameter, allowing peptides with longer glycan chains, such as the sialylated 
disaccharide, to enter the proteolytic chamber. Therefore the MUC1 glycopeptides that were not 
be processed under in vitro conditions could be the substrates of cellular proteasomes. The 
detailed molecular explanation for 19S induced proteasome activation is lacking due to the 
absence of a crystal structure of the 26S proteasome. Additionally, the presence of proteasome 
activator, PA28 could increase the processing of glycosylated peptides, as it is reported to 
activate the proteasomal hydrolysis of short peptides. The interaction between PA28 and 
proteasome entrance rearranges the annulus occluding amino acids thereby opening a pore 
through which substrate may pass (Whitby FG et al., 2000).  
4.7 Identification of the best glycopeptide for MHC class I 
ligands generation 
To identify the glycopeptide that could serve as the best proteasomal substrate and source of 
high-affinity MHC ligands, we analysed the diversity of derived fragments (number, length, 
glycosylation state). 
Generally, the cleavage products of the proteasome vary in length between 3 and 25 amino 
acids with an average length of 7-8 amino acids. Several models have been suggested for the 
“molecular ruler” that determines the fragment length. Groll M and Huber R (Groll M et al., 
1999) suggest that this is determined by the substrate binding clefts designed for peptides 7-9 
amino acids long.  
We have identified that digestion of longer substrates resulted in a higher number of diverse 
fragments and digestion of shorter substrates in a lower number of fragments. The reduction 
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in fragment diversity observed in the digest of shorter substrates could be based on missing 
generation of longer fragments from G-S-T or AP digestion regions which are found in digest 
of P1.  
Although none of the glycosylated 21-meric peptides was processed completely, their 
digestion yielded a higher number of diverse fragments than the corresponding 
nonglycosylated peptides. This could be due to reduced specificity of proteasomes caused by 
glycosylation of the substrate, preventing specific processing and increasing cleavage rates at 
less favourable positions. 
To study how efficient the generation of glycopeptide derived MHC class I epitopes is, we 
calculated the relative amount of 8- to 11-meric peptides (size fitting to MHC class I groove). 
The average length of generated peptides varied dependent on the substrate length and 
glycosylation state.  
Longer substrates released in average longer fragments, whereas shorter substrates released in 
average shorter fragments. Therefore, 21-meric substrates generated substantially higher 
amounts of potential MHC class I ligands (50%) and because of that could be better 
applicable for the peptide vaccine design. It was reported that about 15% of the proteasomal 
products fall within the size range (8-9 residues) of typical MHC-I ligands (reviewed in 
Baumeister W et al., 1998) which correlates with our result in case of long peptide substrates, 
but is in discrepancy with amounts detected in digests of 20-meric peptides (50% of 8-
11meric fragments). This result points out that shorter substrates, although decreasing the 
diversity of generated fragments actually generate higher amounts of MHC fitting peptides, 
what is of highest importance for vaccine design.  
Additionally, we found out that glycosylation influences the efficient generation of MHC 
ligands. Glycosylated substrates varied in their generation of 8- to 11-meric fragments. 
Although in average 11 amino acids long peptides are generated by proteasomal digestion, 
glycosylation of the central DTR noticeably reduces the percent of generated 8- to 11-mers 
and slightly the average fragment length. This feature would disfavour DTR/ESR 
glycosylated peptides for the vaccine design, however almost all released 8- to 11-mers are 
glycosylated (98%) and actually derived from the central region of the substrate.  In case of 
other glycopeptides with (T)S-A-P or G-S-T glycosylation the amount of glycosylated 8- to 
11-mers is significantly lower (about 20-40%), and it is higher for G-S-T than for (T)SAP 
glycosylated peptides. The reason for this could be the use of main processing sites. As the 
main processing site is located within the S-A-P region, glycosylation of Thr in the proximity 
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of (T)S-A-P is near the cleavage site. At the same time processing is reduced by glycosylation 
and consequently low amounts of glycosylated 8- to 11-mers will be released. The G-S-T 
glycosylation is located downstream of the major processing sites S-A-P and the relatively 
often used RP motif, so the glycosylated Thr can be included in 8- to 11-meric peptides.  The 
glycosylation of DTR does not block processing in major digestion motifs and allows the 
generation of DTR containing glycosylated 8- to 11-meric peptides by simultaneous digestion 
at these two sites. 
Therefore, the glycopeptides with Thr glycosylation within DTR would represent the optimal 
antigen for a vaccine formulation: although they do reduce the processing efficiency, they do  
not disturb proteasomal specificity, they release almost only glycosylated 8- to 11-mers which 
is important for glycopeptide-based vaccine approaches, and the released glycopeptides are 
generated by simultaneous cleavages in proximity or within the S-A-P and G-S-T regions. 
The (T)S-A-P glycosylated substrates could be considered as the least appropriate vaccine-
model, as the glycosylation of major cleavage sites dramatically reduces processing efficiency 
and proteasomal specificity, and the level of released glycopeptides is low. The G-S-T 
glycosylated peptides could represent a second, less favourable basis for glycopeptide- 
vaccines, as they do not exert so strong negative effects on proteasomal specificity as (T)SAP 
glycosylated peptides and are found to release relatively high amounts of glycosylated 8- to 
11-mers.   
4.7.1 Identification of MHC class I binding MUC1 glyco-epitope 
The generated fragments were tested for binding to human MHC class I allele HLA-A0201. 
We identified the SAPDTRPAPG-GalNAc glycopeptide as a strong ligand for this allele. The 
binding of glycosylated peptide was comparable, but slightly lower than that of the 
nonglycosylated SAP10, indicating the influence of sugar on binding affinity of peptide. The 
disaccharide glycosylated SAP10 was not binding active on HLA-A0201.  
The SAP10 glycopeptide can be derived from DTR glycosylated MUC1 VNTR peptides with 
either AHG or SAP starting motif. The mass signals corresponding to SAP10 and APD10 
glycopeptides was found in the digests of AHG glycopeptide GP3 (AHGVTS-A-PDTRPAPG-
S-TAPPA) as well as in the SAP glycopeptide GP13 (S-A-PDTRPAPG-S-TAPPAHGVT). 
The amount of fragment peptides found in AHG starting GP3 digest was lower (3 % of all 
substrate converted into SAP/APD10) than one found in SAP starting GP13 digest (8 % of all 
substrate converted into SAP/APD10). Although from this perspective SAP glycopeptides 
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could appear as the better choice for vaccine development, they yielded a restricted panel of 
fragments (20 different peptides compared to 33 from GP3) due to the absence of processing 
within major processing sites and long stretches of amino acids C terminally of the GST motif 
that are weakly processed. This could prevent the generation of other glycosylated MHC class 
I ligands that were not identified in our study. 
The ESI/MS/MS analysis of the putative SAP10 or APD10 glycopeptides derived by 
proteasomal cleavage from GP3 glycopeptide, confirmed the presence of APD10 sequence.  
Previously it was reported by Apostolopoulos et al (2003) that SAP8 glycopeptide 
(SAPDTRPA-GalNAc) was binding the MHC peptide groove of mouse H2Kb allele stronger 
than its nonglycosylated form, but was recognized by same CD8 T-cell clone. They suggested 
that the sugar of the glycopeptide was directed toward the MHC peptide groove (F pocket) 
and used as an anchor residue. The glycosylation of SAP8 by a disaccharide failed to 
stimulate development of T-cell clones, possibly because it prevented binding to the MHC 
molecule.  
The MHC mediated presentation of glycopeptides was shown for diverse glycosylated 
molecules. O-GlcNAc glycosylated epitopes were detected after elution from MHC class I 
molecules (Haurum JS et al., 1994). It was described by Haurum et al. that binding of O-
GalNAc glycopeptides to MHC class I is possible if the glycan is not attached to the amino 
acid that serves as an anchor residue for binding to the MHC groove (Haurum JS et al., 1995).  
When crystal structures of H2Kb in complex with non-MUC1 RGY8-6H-Gal2 glycopeptide 
and of H2Db in complex with two synthetic O-GlcNAc glycopeptides were analysed, it 
became clear that the sugar chain, usually not longer that two saccharide units, is solvent 
exposed and that it is protruding from the MHC groove toward outside.  
4.8 Cross presentation 
On analysis of potential MHC class I ligands from non-glycosylated MUC1 VNTR peptides 
Apostolopoulos et al (1997, Eur J Immunol) identified two groups of peptides: SAP9, APD9, 
TSA9 (containing the DTR motif) and APG9, PAP9 and RPA9 (containing the GST motif) 
with binding activity to the mouse H2Kb allele. These peptides are in agreement with 
processing products of nonglycosylated MUC1 VNTR peptide reported in this work and are 
possibly generated by digestions within the SAP, GST and RP regions. The presentation of 
endocytosed antigen by dendritic cells in the MHC class I pathway proceeds by cross-
presentation pathways, that include the processing of extracellular antigen by proteasomes or 
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other peptidases and loading of epitopes onto MHC class I molecules. In the cellular cross 
presentation experiment we confirmed the presence of APD9 and TSA9 peptides presented by 
MHC molecule of a mouse dendritic cells line (H2Kb positive). Due to the lower sensitivity of 
mass spectrometry-based experimental set-up compared to immunological assays, we cannot 
exclude that other nonameric peptides reported by Apostolopoulos were generated and eluted 
from exosomal MHC molecules (Apostolopoulos V et al., 1997). No peptides containing the 
GST motif (i.e. APG9, PAP9 and RPA9 reported by Apostoloulos) were found. Among the 8- 
to 11-meric peptides possibly derived by cross-presentation only peptides starting within the 
(T)SAP region were detected after elution from the mouse H2Kb allele.  The MHC bound 
material eluted from exosomes contained also a fraction of longer MUC1 VNTR fragments 
(15-25 amino acids) possibly possibly eluted from MHC class II molecules.  
The cellular processing products were in full agreement with those generated by 
immunoproteasomal in vitro digestion. Therefore, MUC1 MHC class I binding peptides can 
be generated by proteasomal digestion without the help of additional proteases in the cytosol. 
In the past years several studies reported the involvement of non-proteasomal enzymes 
involved in generation of MHC class I peptides (Del Val M et al., 2002; reviewed in Rock KL 
et al., 2004).  Various cytosolic amino- and endopeptidases have been identified with the 
capacity to either degrade proteasome products into shorter fragments or to exert limited 
trimming at the amino-terminal end of the peptide. It was reported that many proteasomal 
products are intermediate products with optimally fitting C terminus of the definitive MHC I 
ligand, but an extended N terminal part of varying length (Niedermann G et al., 1996). Other 
groups confirmed that proteasomes can generate subsets of peptides in vitro that do not need 
any additional processing for MHC I binding (Dick TP et al., 1998; Lucchiari-Hartz M 2000). 
It was noted that about 15% of proteasomal products fall within the size range (8-9 residues) 
of typical MHC-I ligands, another 15-20% are larger and thus require additional trimming, 
and the remaining two thirds are too short and present the degradation products of the 
substrate. Our cross-presentation assay showed that MHC class I binding peptides reported by 
Apostolopoulos can be generated solely by proteasomal degradation of the antigen and that 
the outcome of in vitro digestion reflects the situation in vivo.  
The MUC1 VNTR peptide sequence does not contain any Lys residues and therefore can not be 
ubiquitinated and targeted to proteasomal degradation. But the processing of non-ubiquitinated 
substrates is a naturally existing phenomenon (Murakami Y et al.,1992; Benaroudj N et al., 
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2001). Thereby, we can assume that MUC1 fragments found in the cellular processing assay 
could be derived by proteasomal degradation.  
But the possibility that other enzymes are involved in our cross-presentation assay cannot be 
excluded.  A striking similarity is observed between MUC1 cleavage patterns of proteasomal 
and cathepsin L catalyzed proteolysis (Hanisch FG et al., 2003).  Cathepsin L is the main 
enzyme involved in generation of MHC-II binding peptides in late endosomes. The 
processing pattern of MUC1 VNTR peptides in the endosomal pathway overlaps largely with 
the proteasomal pattern described in this work. The loading of MHC molecules normally 
occurs via the ER/TAP/proteasome pathway, where peptides generated by proteasomes bind 
to empty MHC molecules. But also  re-endocytosed  MHC class I molecules from the 
plasmamembrane can loose their peptides under the low pH conditions in late endosomes and 
can bind new fragments generated by cathepsin L cleavage of exogenous antigens, like 
MUC1. The similar cleavage specificities of cathepsin L and proteasomes provide the basis 
for generation of similar peptide pools. The biochemical cause for this overlap could be in the 
caspase like activity of both cathepsin and proteasome, but this can not explain the processing 
pattern in complete. Also, the restrictions included by glycosylation of MUC1 sequence are 
comparable for proteasome and cathepsin L. The glycosylation of Thr within the TSA motif 
prevented the digestion by cathepsin L completely at the major cleavage site T-S, and 
drastically reduced it by proteasomes. The other main processing site H-GV reported for 
cathepsin L digestion of MUC1 VNTR was not strongly used by proteasome, but the 
molecular mass corresponding to GVT12 or VTS12 was detectable in the cross-presentation 
assay.   
4.9 MHC class I bound peptides of a breast cancer cell line 
The stimulation of MHC–restricted MUC1 glycopeptide-specific T-cell responses can be 
achieved only if both, tumor cells and antigen presenting cells, would be able to process 
glycosylated forms of MUC1. Our analyses of epitopes bound to breast cancer cell MHC class 
I did not reveal any MUC1-derived glycopeptides. This could be due to the sensitivity 
restrictions of the used mass spectrometry-based methods.  
A number of other MHC-presented peptides involved in tumorigenesis was identified, 
including a fragment derived from another mucin protein (MUC16), from macrophage 
migration inhibitory factor, and from tumor necrosis factor. The possible therapeutic use of 
these epitopes has to be evaluated.  
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The presentation of glycosylated MUC1 by tumor cells theoretically could be performed via 
the endocytotic pathway similar to the cross-presentation over endosomal compartments or by 
retrograde transport of glycosylated MUC1 from the Golgi to the ER (reviewed in Lee MC et 
al., 2004). MUC1 is known to be initially expressed in a non-mature glycoform on the 
plasmamembrane and to recycle for further glycosylation, probably via the trans-Golgi 
network or the trans-Golgi, but the re-entry into the secretory pathway via other 
compartments, like the ER or ERGIC, is not excluded. The proteins can be translocated from 
the ER to the cytosol (Fiebiger E et al., 2002; Ye Y et al., 2004) and targeted for degradation 
by the ERAD pathway. Also, glycoprotein specific ubiquitin ligases were reported recently 
(Yoshida Y 2005). The transport of N-glycosylated proteins from the ER to cytosolic 
proteasomes involves specific proteins that interact with glycoproteins by targeting them to 
ERAD (Kim W et al., 2005). The presence of similar mechanisms for O-glycosylated proteins 
cannot be excluded.  
4.10  Previous immunological studies 
Studies dedicated to the development of MUC1-based cancer vaccines mainly were oriented 
toward non-glycosylated peptides.  
Several groups have identified the STAPPAHGV peptide in cellular systems as a ligand for 
HLA-A11 and –A2 restricted CTLs. (Apostolopoulos V et al., 1997b; Domenech n et al., 
1995). The recognition of MUC1 tandem repeat epitopes by CTLs from breast cancer patients 
was reported to occur in an MHC-unrestricted manner (Jerome KR et al., 1991). Clustering of 
T-cell receptors that bind to the repetitive peptide of MUC1 apparently triggers the activation 
of T-cells. 
Murine transgenic models were used as an attractive model system to study immunogenicity 
of MUC1 and to perform tumor rejection studies. Apostolopolus V identified (1997) several 
MUC1 VNTR-derived peptides containing the DTR or GST motifs as recognized by mouse 
CTLs and confirmed the binding of SAPDTRPAP(GalNAc) glycopeptide and peptide to the 
mouse H2Kb allele. The majority of studies on MUC1 immunogenicity, performed in 
animals, used wild-type mice or rats as recipients of various MUC1-based vaccines. Since 
human MUC1 is xenogenic to these animals, results cannot be directly correlated to human 
models. 
Human HLA-class I- as well as human MUC1-transgenic mice were developed. Several 
MUC1-based vaccines were evaluated in the mouse systems (Apostolopoulos V et al., 1996, 
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1994, Acress B et al., 2000). In a study by Soares MM (2001) tumor rejection in MUC1 Tg 
mice immunised with MUC1 VNTR peptide was reported. The vaccination of MUC1 
transgenic mice with MUC1-bearing syngeneic tumors failed to develop effective anti-tumor 
response (Rowse GJ et al., 1998), possibly due to the inability to process fully glycosylated 
MUC1 antigen.  
From the non-VNTR part of the protein several MHC class I binding peptides were identified, 
demonstrating that immunogenicity of MUC1 is not restricted to the tandem repeat region. In 
some cases stimulation of MUC1-specific CTLs from healthy donors was shown (Brossart P 
et al., 1999; Carmon L et al., 2000).   
Several vaccination studies in humans were initiated based on the peptide approach 
(Apostolopoulos V et al., 2006; Karanikas V et al., 1997, 2001, Gilewski T et al., 2000, 
Brossart P et al., 2000). The vaccines succeeded in activation of humoral immune responses 
and in some cases weak cellular responses were developed. The cytotoxic T-cells were often 
of low frequency and low potency.  
4.11   MUC1 breast cancer vaccine - outlook 
The design of MUC1-based cancer vaccines is still confronted with the dilemma whether 
glycopeptides or peptides should be used for vaccination strategies. The former can be tested 
with respect to their immunogenicity in transgenic animals, but not with respect to their 
therapeutic effects. The reason for that is found in MUC1 glycosylation, which expectedly 
differs between humans and mice. Hence the immunotarget in hMUC1-tg mice is not 
authentic.  
4.11.1  Peptide-based vaccination strategy 
Available data on MUC1-based vaccination studies are extremely diverse due to variations of 
the experimental approach: mice, human cells, transgenic mice for human MUC1, transgenic 
mice for human MHC alleles, immunisations with glycopeptides, peptides, complete protein. 
The reason for this diversity lies in lacking information about the MUC1-MHC presentation 
in normal and tumor cells and the possibly existing tolerance to MUC1. Whether normal cells 
present MUC1 peptides on MHC molecules is not known. This problem relates to the use of 
nonglycosylated MUC1 in vaccination strategies and raises the following questions: (1) If 
normal cells are presenting MUC1 peptides in MHC complex, why no auto-immunity is 
noticed in vaccine trials? (2) Is the number of MHC/MUC1 peptide complexes a critical 
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parameter for T cell activation? If so, normal cells can be tolerated because they have a low 
level of MHC/MUC1 complexes and cancer cells are recognized due to higher abundance of 
the same complex originating from increased expression of MUC1? It was shown that MUC1 
peptides from the non-VNTR region are able to induce CTL activation indicating that non-
VNTR peptide specific T-cells are not depleted and are recognizing the normally expressed 
MUC1 (Pietersz GA et al., 2000). Although no auto-immunity is detected toward epithelial 
cells upon MUC1 peptide vaccination, the possibility exists that low-level immunity against 
self-MUC1 is given and boosting the immune response could increase it. (3) Is the presence 
of co-stimulatory molecules the crucial factor for T-cell activation? T-cells are reported to be 
activated only in the presence of co-stimulatory molecules and danger signals (Acres B et al., 
2000; Matzinger P et al., 1994) that are not present on normal cells. All these problems are 
still not addressed and their solving will help clear up the peptide/glycopeptide dilemma.  
4.11.2  Glycopeptide-based vaccination strategies 
The tolerance and auto-immunity problem may be avoided by glycopeptide based vaccination 
and induction of glycopeptide-specific T-cells. As the glycopeptide form is the authentic target 
on cancer cells, and it was shown that glycopeptide specific T-cells exist, the recognition of 
tumor-related forms of MUC1 possibly can be achieved. During embryonic development no 
cancer-related glycosylation should be presented to T-cells and therefore no depletion of 
cancer-associated MUC1-specific T-cells should be expected. With this approach the problem 
of tolerance as well as the problem of auto-immunity would be solved. In this case the 
question if tumor cells are able to present MUC1 glycopeptide on MHC molecules can be 
raised and up to now is not answered. We did neither succeed in the detection of MUC1 
glycopeptides on MHC class I, nor in some other GalNAc glycosylated peptides. Due to the 
sensitivity restrictions of our experimental set-up, we cannot exclude that such glycopeptides 
are actually presented. Tumor cells could process their own MUC1 over cross-presentation 
mechanisms or by retrograde Golgi-ER transport and delivery to proteasomes, where 
glycosylated MUC1 could enter the digestion machinery. The next problem to look for is if 
such a retrograde transport to proteasomes actually takes place and which form of MUC1 is 
involved.  
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4.11.3  Stimulation of MHC-unrestricted MUC1-specific recognition of 
tumor cells 
Even if no MUC1 glycopeptides are presented on tumor cell MHC complexes, glycopeptide- 
specific T-cells (stimulated by vaccination) could recognize tumor-associated MUC1 in 
MHC-unrestricted manner and trigger tumor cell lysis. Such MHC-unrestricted T-cell 
response was reported to take place in breast cancer patients (Jerome KR et al., 1991). Their 
low frequency could be increased by MUC1 glycopeptide vaccination.   
4.12  Concluding remarks 
MUC1 tandem repeat domain-derived peptides and glycopeptides were found to be processed 
by immunoproteasomes in specific manner. We identified major proteasome processing sites 
in the MUC1 tandem repeat peptide: SAP and GST, but a lower level of processing is 
observed at all other peptide bonds in the sequence. Glycosylation of the substrate generally 
reduced the proteasome digestion rate in a higher or lower degree.  Moreover, it influences the 
substrate processing in specific manner: Glycan localisation in close proximity or directly on 
the major processing sites of the sequence prevents the proteasomal cleavage within the site.  
The major cleavage sites overlapped with the major glycosylation sites of the sequence.  
Hence, we could identify peptides glycosylated at the central DTR as the best substrate for 
processing and presentation. These glycopeptides yielded high amounts of glycosylated 
fragments with the potential to bind MHC class I. Moreover, these glycopeptides have a 
potential to release the SAPDTRPAPG-GalNAc glycopeptide which we identified as a good 
ligand for the HLA-A0201 allele of MHC class I. 
The low immunity of native endogenous MUC1 originates from the overlapping of 
glycosylation and digestion sites. The naturally occurring MUC1 is glycosylated at major 
processing regions and therefore is not a suitable antigen for presentation by dendritic cells 
and the stimulation of glycopeptide-specific cytotoxic T-cells. 
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Summary  
MUC1 is a human transmembrane and secreted glycoprotein expressed in numerous epithelial 
tissues; in breast cancer tissues MUC1 is aberrantly glycosylated and a soluble form in the 
sera of cancer patients’ triggers weak immune responses. The stimulation of cellular immune 
responses toward tumor-associated MUC1 glycoprotein is a primary goal in 
immunotherapeutic anti-cancer strategies.  
For an effective activation of tumor-MUC1 specific T-cell repertoires the extracellular MUC1 
antigen should be presented by host dendritic cells in a MHC-dependent way. The generation 
of MHC class I epitopes is mainly performed by immunoproteasomes of dendritic cells. We 
performed in vitro studies to address the questions whether glycosylated MUC1 peptides are 
cleaved by IPs, and in which way the position and structure of O-linked glycans control the 
site specificity of peptide cleavage.  
In our work S↓A↓P↓ (N-terminal) and G↑S↑T↑  (C-terminal) were identified as the major 
processing sites within the non-glycosylated MUC1. These sequences are parts of the MUC1 
tandem repeat sequence (HGVTSAPDTRPAPGSTAPPA) which can be O-glycosylated on 
Thr and Ser residues. Glycosylation of the substrate in the close proximity of processing sites 
significantly reduced processing efficiency. Proteasomes were not able to digest glycopeptides 
carrying the Sialyl-Gal-GalNAc glycan, often found in the tumor associated form on MUC1 
glycoprotein. The best processed glycopeptide carried glycosylation on Thr of the central 
DTR motif, distant from major processing regions. The highest amount of glycosylated 
fragments with a potential to bind to the MHC class I groove was found in the digest of 
glycopeptides with glycosylation of Thr within the central DTR motif. 
Furthermore, the peptide SAPDTRPAPG glycosylated with GalNAc on Thr was identified in 
a cellular assay as an epitope with high affinity for the human HLA-A0201 allele. To confirm 
the processing pattern of MUC1 tandem repeat sequence obtained in vitro, cross-presentation 
of the MUC1 peptide on dendritic cells was performed, and eluted peptides from cell-derived 
exosomes corresponded to sequences found in vitro. 
These results indicate that design of a MUC1 glycopeptide-based cancer vaccine should 
include glycopeptides with GalNAc on Thr of DTR motif, because of their efficient 
degradation by immunoproteasome, production of high amount of glycosylated 8- to 11-mers 
and potential generation of MHC class I binding SAPDTRPAPG-GalNAc epitope. 
For future work, immunisation of the MUC1 transgenic mice with DTR glycosylated peptides 
is in progress.  
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Zusammenfassung 
MUC1 ist ein humanes Transmembranprotein, das auf vielen epithelialen Geweben exprimiert 
wird. Die Glykosylierung von MUC1 auf Mammakarzinomzellen weicht von derjenigen auf 
Epithelzellen ab, und eine lösliche Form des Proteins im Serum der Patientin verursacht eine 
schwache Immunantwort des Körpers. Die Stimulierung einer zellulären Immunantwort gegen 
tumorassoziiertes MUC1 ist ein primäres Ziel immunotherapeutischer Strategien gegen Krebs. 
Zur effektiven Aktivierung eines für das tumorassoziierte MUC1 spezifischen T-Zell-Repertoires 
muß das Antigen von dendritischen Zellen in einer MHC-abhängigen Weise präsentiert 
werden; MHC-Klasse I-Epitope werden hierbei durch Immunoproteasome (IP) erzeugt. In der 
vorliegenden Arbeit wurde in vitro untersucht, ob MUC1-abgeleitete Peptide durch IPs abgebaut 
werden, und inwieweit dies von Position und Struktur von O-Glykanen beeinflusst wird. 
Die Sequenzen S↓A↓P↓ (N-terminal) und G↑S↑T↑  (C-terminal) wurden als die Hauptprozessie- 
rungsregionen innerhalb der MUC1-Aminosäuresequenz identifiziert. Diese Sequenzen sind 
Bestandteile der tandem repeat-Sequenz (HGVTSAPDTRPAPGSTAPPA) innerhalb von MUC1, 
deren Serin- und Threoninreste potentielle Glykosylierungsziele sein können. Glykosylierung 
des Substrates in Nähe der Hauptprozessierungsregionen verminderte die Effizienz des 
Verdaus signifikant. Die Proteasomen konnten keine Glykopeptide verdauen, die das Glykan 
Sia-Gal-GalNAc enthielten; solche Glykopeptide werden häufig in der tumorassoziierten Form 
von MUC1 gefunden. Glykopeptide, die am Threonin des zentralen DTR-Motivs – weit entfernt 
von den Hauptprozessierungsregionen – glykosyliert waren, wurden am besten verdaut. Zugleich 
resultierte aus solchen Glykopeptiden die höchste Menge an glykosylierten Prozessierungs-
produkten, die aufgrund einer Länge von 8-11 Aminosäureresten am besten an die groove des 
MHC-Klasse I-Moleküls banden. Darüber hinaus ergab sich in einem zellulären Ansatz, daß 
das am Threonin mit GalNAc glykosylierte SAPDTRPAPG-Peptid eine hohe Affinität zum 
humanen HLA-A0201-Allel hatte. Um die in vitro gewonnenen Daten zur MUC1-Prozessierung 
zu bestätigen, wurde eine Kreuzpräsentation des MUC1-Peptides auf dendritischen Zellen 
durchgeführt. Die anschließend aus zellulären Exosomen eluierten Peptide entsprachen den 
Sequenzen, die in vitro gefunden worden waren. 
Aufgrund dieser Resultate sollten beim Design einer auf MUC1 basierten Krebsvakzine 
Glykopeptide verwendet werden, die am Threonin des DTR-Motivs mit einem GalNAc-
Molekül glykosyliert wurden. Gründe hierfür sind der effiziente Verdau dieser Peptide durch 
Immunproteasome, die Produktion einer großen Menge glykosylierter Peptide mit einer 
Länge von 8 - 11 Aminosäureresten und die mögliche Generierung von SAPDTRPAPG-
GalNAc-Epitopen, die an MHC-Klasse I-Moleküle binden. 
Im Hinblick auf zukünftige Arbeit erfolgt zur Zeit die Immunisierung transgener Mäuse mit 
Peptiden, die an der DTR-Sequenz glykosyliert sind. 
_____________________________________________________                     Bibliography                           
 
 90
Bibliography 
Abe M., Kufe D. Characterization of cis-acting elements regulating transcription of the human 
DF3 breast carcinoma-associated antigen (MUC1) gene. Proc. Natl. Acad. Sci. USA, 90: 282-
286, 1993.  
Acres B, Apostolopoulos V, Balloul JM, Wreschner D, Xing PX, Ali-Hadji D, Bizouarne N, 
Kieny MP, McKenzie IF. MUC1-specific immune responses in human MUC1 transgenic 
mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother. 2000 
Jan;48(10):588-94.  
Agrawal B, Krantz MJ, Parker J, Longenecker BM.  Expression of MUC1 mucin on activated 
human T cells: implications for a role of MUC1 in normal immune regulation. Cancer Res. 
1998 Sep 15;58(18):4079-81.  
Apostolopoulos V, Xing PX, McKenzie IF. Murine immune response to cells transfected with 
human MUC1: immunization with cellular and synthetic antigens. Cancer Res. 1994 Oct 
1;54(19):5186-93.  
Apostolopoulos V, Pietersz GA, McKenzie IF. Cell-mediated immune responses to MUC1 
fusion protein coupled to mannan. Vaccine. 1996 Jun;14(9):930-8.  
Apostolopoulos V, Haurum JS, McKenzie IF. MUC1 peptide epitopes associated with five 
different H-2 class I molecules. Eur J Immunol. 1997 Oct;27(10):2579-87.  
Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF. Induction of HLA-A2-restricted 
CTLs to the mucin 1 human breast cancer antigen. J Immunol. 1997 Dec 1;159(11):5211-8. 
(b) 
Apostolopoulos V, Yuriev E, Ramsland PA, Halton J, Osinski C, Li W, Plebanski M, Paulsen 
H, McKenzie IF. A glycopeptide in complex with MHC class I uses the GalNAc residue as an 
anchor. Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15029-34. 
Apostolopoulos V, Pietersz GA, Tsibanis A, Tsikkinis A, Drakaki H, Loveland BE, 
Piddlesden SJ, Plebanski M, Pouniotis DS, Alexis MN, McKenzie IF, Vassilaros S.  Pilot 
phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-
MUC1 [ISRCTN71711835]. Breast Cancer Res. 2006;8(3):R27.   
Baruch A, Hartmann M, Zrihan-Licht S, Greenstein S, Burstein M, Keydar I, Weiss M, 
Smorodinsky N, Wreschner DH. Preferential expression of novel MUC1 tumor antigen 
isoforms in human epithelial tumors and their tumor-potentiating function. Int J Cancer. 1997 
May 29;71(5):741-9. 
Baruch A, Hartmann M, Yoeli M, Adereth Y, Greenstein S, Stadler Y, Skornik Y, Zaretsky J, 
Smorodinsky NI, Keydar I, Wreschner DH.  The breast cancer-associated MUC1 gene 
_____________________________________________________                     Bibliography                           
 
 91
generates both a receptor and its cognate binding protein. Cancer Res. 1999 Apr 
1;59(7):1552-61.  
Baumeister W, Walz J, Zuhl F, Seemuller E.  The proteasome: paradigm of a self-
compartmentalizing protease. Cell. 1998 Feb 6;92(3):367-80. Review. 
Benaroudj N, Tarcsa E, Cascio P, Goldberg AL.  The unfolding of substrates and ubiquitin-
independent protein degradation by proteasomes. Biochimie. 2001 Mar-Apr;83(3-4):311-8. 
Review.  
Bennett EP, Hassan H, Mandel U, Mirgorodskaya E, Roepstorff P, Burchell J, Taylor-
Papadimitriou J, Hollingsworth MA, Merkx G, van Kessel AG, Eiberg H, Steffensen R, 
Clausen H. Cloning of a human UDP-N-acetyl-alpha-D-Galactosamine:polypeptide N-
acetylgalactosaminyltransferase that complements other GalNAc-transferases in complete O-
glycosylation of the MUC1 tandem repeat. J Biol Chem. 1998 Nov 13;273(46):30472-81.  
Berg JW, Hutter RVP. Breast Cancer. Cancer. 1995;75:257-269. 
Boes M, Ploegh HL. Translating cell biology in vitro to immunity in vivo. Nature. 2004 Jul 
8;430(6996):264-71. Review. 
Bramwell ME, Wiseman G, Shotton DM. Electron-microscopic studies of the CA antigen, 
epitectin. J Cell Sci. 1986 Dec;86:249-61.  
Brayman M, Thathiah A, Carson DD. MUC1: a multifunctional cell surface component of 
reproductive tissue epithelia.Reprod Biol Endocrinol. 2004 Jan 7;2:4. Review. 
Brockhausen I, Yang JM, Burchell J, Whitehouse C, Taylor-Papadimitriou J. Mechanisms 
underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem. 
1995 Oct 15;233(2):607-17. 
Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, 
Rammensee HG, Kanz L, Brugger W. Identification of HLA-A2-restricted T-cell epitopes 
derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood. 1999 
Jun 15;93(12):4309-17.  
Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-
lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 
2000 Nov 1;96(9):3102-8.  
Carmon L, El-Shami KM, Paz A, Pascolo S, Tzehoval E, Tirosh B, Koren R, Feldman M, 
Fridkin M, Lemonnier FA, Eisenbach L.  Novel breast-tumor-associated MUC1-derived 
peptides: characterization in Db-/-x beta2 microglobulin (beta2m) null mice transgenic for a 
chimeric HLA-A2.1/Db-beta2 microglobulin single chain. Int J Cancer. 2000 Feb 
1;85(3):391-7.  
_____________________________________________________                     Bibliography                           
 
 92
Chen L, Jondal M. Endolysosomal processing of exogenous antigen into major 
histocompatibility complex class I-binding peptides. Scand J Immunol. 2004 Jun;59(6):545-
52. 
Chen P and Hochstrasser M. Biogenesis, structure and function of the yeast 20S proteasome. 
EMBO J, 1995, 14, 2620–2630. 
Clausen H, Bennett EP. A family of UDP-GalNAc: polypeptide N-acetylgalactosaminyl-
transferases control the initiation of mucin-type O-linked glycosylation. Glycobiology. 1996 
Sep;6(6):635-46 
Cloosen S, Thio M, Vanclee A, van Leeuwen EB, Senden-Gijsbers BL, Oving EB, 
Germeraad WT, Bos GM. Mucin-1 is expressed on dendritic cells, both in vitro and in vivo. 
Int Immunol. 2004 Nov;16(11):1561-71. Epub 2004 Sep 20.  
Dalziel M, Whitehouse C, McFarlane I, Brockhausen I, Gschmeissner S, Schwientek T, 
Clausen H, Burchell JM, Taylor-Papadimitriou J. The relative activities of the C2GnT1 and 
ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-
associated epitope on MUC1. J Biol Chem. 2001 Apr 6;276(14):11007-15. Epub 2000 Dec 
15.  
Del-Val M, Lopez D. Multiple proteases process viral antigens for presentation by MHC class 
I molecules to CD8(+) T lymphocytes. Mol Immunol. 2002 Oct;39(3-4):235-47. Review. 
Dick TP, Nussbaum AK, Deeg M, Heinemeyer W, Groll M, Schirle M, Keilholz W, 
Stevanovic S, Wolf DH, Huber R, Rammensee HG, Schild H.   Contribution of proteasomal 
beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J Biol Chem. 
1998 Oct 2;273(40):25637-46. 
Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from 
the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol. 1995 Nov 
15;155(10):4766-74.  
Elhammer AP, Kezdy FJ, Kurosaka A. The acceptor specificity of UDP-GalNAc:polypeptide 
N-acetylgalactosaminyltransferases. Glycoconj J. 1999 Feb;16(2):171-80. Review. 
Emmerich NP, Nussbaum AK, Stevanovic S, Priemer M, Toes RE, Rammensee HG, Schild 
H. The human 26 S and 20 S proteasomes generate overlapping but different sets of peptide 
fragments from a model protein substrate. J Biol Chem. 2000 Jul 14;275(28):21140-8.  
Ferrington DA, Husom AD, Thompson LV. Altered proteasome structure, function, and 
oxidation in aged muscle. FASEB J. 2005 Apr;19(6):644-6. 
Fiebiger E, Story C, Ploegh HL, Tortorella D. Visualization of the ER-to-cytosol dislocation 
reaction of a type I membrane protein. EMBO J. 2002 Mar 1;21(5):1041-53.  
_____________________________________________________                     Bibliography                           
 
 93
Fowler J, Vinall L, Swallow D. Polymorphism of the human muc genes. Front Biosci. 2001 
Oct 1;6:D1207-15. Review. 
Gendler S J, Lancaster C A, Taylor-Papadimitriou J, Duhig T, Peat N, Burcheli J, Pemberton 
L, Lalani EN, Wilson D. Molecular cloning and expression of the human tumor associated 
polymorphic epithelial mucin PEM. J. Biol. Chem., 1990, 265: 15286-15293,. 
Gendler SJ, Spicer AP. Epithelial mucin genes. Annu Rev Physiol. 1995;57:607–634.  
Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton 
A, Norton L, Livingston PO. Vaccination of high-risk breast cancer patients with mucin-1 
(MUC1) keyhole limpet hemocyanin conjugate plus QS-21.Clin Cancer Res. 2000 
May;6(5):1693-701. 
Grinstead JS, Koganty RR, Krantz MJ, Longenecker BM, Campbell AP.   Effect of 
glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide-
antibody interactions. Biochemistry. 2002 Aug 6;41(31):9946-61.  
Groettrup M, Ruppert T, Kuehn L, Seeger M, Standera S, Koszinowski U, Kloetzel PM. The 
interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the 
peptide production by the 20 S proteasome in vitro. J Biol Chem. 1995 Oct 6;270(40):23808-
15.  
Groll M, Heinemeyer W, Jager S, Ullrich T, Bochtler M, Wolf DH, Huber R.  The catalytic 
sites of 20S proteasomes and their role in subunit maturation: a mutational and 
crystallographic study. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):10976-83 
Han I, Kudlow JE. Reduced O glycosylation of Sp1 is associated with increased proteasome 
susceptibility. Mol Cell Biol. 1997 May;17(5):2550-8. 
Hanisch FG, Muller S, Hassan H, Clausen H, Zachara N, Gooley AA, Paulsen H, Alving K, 
Peter-Katalinic J.  Dynamic epigenetic regulation of initial O-glycosylation by UDP-N-
Acetylgalactosamine:Peptide N-acetylgalactosaminyltransferases. site-specific glycosylation 
of MUC1 repeat peptide influences the substrate qualities at adjacent or distant Ser/Thr 
positions. J Biol Chem. 1999 Apr 9;274(15):9946-54.  
Hanisch FG, Muller S.  MUC1: the polymorphic appearance of a human mucin. 
Glycobiology. 2000 May;10(5):439-49. Review.´ 
Hanisch FG, Schwientek T, Von Bergwelt-Baildon MS, Schultze JL, Finn O. O-Linked 
glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach 
to the molecular aspects of MUC1 processing by dendritic cells. Eur J Immunol. 2003 
Dec;33(12):3242-54.  
Hartman M., Tsarfaty I., Hareuveni M., Keydar I., Wreschner D. H. Expression of breast 
cancer mucin, MUC1, alters cell adhesion and a MUC1 variant may act as a receptor 
_____________________________________________________                     Bibliography                           
 
 94
molecule on breast cancer cells Ioanndou-Mouzaka L. Agnantis N. J. Karydas I. eds. . 
Senology: Proceedings of the 7th International Congress on Senology, : 379-383, Excerpta 
Medica Publishers Amsterdam 1992.  
Hartman, M., Baruch, A., Ron, I., Adereth, Y., Yoeli, M., Sagi-Assif, O., Greenstein, S., 
Stadler, Y., Weiss, M., Harness, E., Yaakubovits, M., Keydar, I., Smorodinsky, N., and 
Wreschner D. H. The MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential 
expression of the novel MUC1/Y protein in breast cancer and other epithelial malignancies. 
Int. J. Cancer, 1999.  
Haurum JS, Arsequell G, Lellouch AC, Wong SY, Dwek RA, McMichael AJ, Elliott T. 
Recognition of carbohydrate by major histocompatibility complex class I-restricted, 
glycopeptide-specific cytotoxic T lymphocytes. J Exp Med. 1994 Aug 1;180(2):739-44.  
Haurum JS, Tan L, Arsequell G, Frodsham P, Lellouch AC, Moss PA, Dwek RA, McMichael 
AJ, Elliott T. Peptide anchor residue glycosylation: effect on class I major histocompatibility 
complex binding and cytotoxic T lymphocyte recognition. Eur J Immunol. 1995 
Dec;25(12):3270-6.  
Hayashi T, Takahashi T, Motoya S, Ishida T, Itoh F, Adachi M, Hinoda Y, Imai K. MUC1 
mucin core protein binds to the domain 1 of ICAM-1. Digestion. 2001;63 Suppl 1:87-92.  
Hearn AR, de Haan L, Pemberton AJ, Hirst TR, Rivett AJ.  Trafficking of exogenous peptides 
into proteasome-dependent major histocompatibility complex class I pathway following 
enterotoxin B subunit-mediated delivery. J Biol Chem. 2004 Dec 3;279(49):51315-22. 
Heuser C, Ganser M, Hombach A, Brand H, Denton G, Hanisch FG, Abken H.  An anti-
MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-
positive tumour cells. Br J Cancer. 2003 Sep 15;89(6):1130-9. 
Hilkens J, Kroezen V, Bonfrer JM, De Jong-Bakker M, Bruning PF.  MAM-6 antigen, a new 
serum marker for breast cancer monitoring. Cancer Res. 1986 May;46(5):2582-7.  
Hilkens J, Ligtenberg MJ, Vos HL, Litvinov SV. Cell membrane-associated mucins and their 
adhesion-modulating property. Trends Biochem Sci. 1992 Sep;17(9):359-63. Review 
Hiller MM, Finger A, Schweiger M, Wolf DH. ER degradation of a misfolded luminal protein 
by the cytosolic ubiquitin-proteasome pathway. Science. 1996 Sep 20;273(5282):1725-8. 
Hiltbold EM, Ciborowski P, Finn OJ. Naturally processed class II epitope from the tumor 
antigen MUC1 primes human CD4+ T cells. Cancer Res. 1998 Nov 15;58(22):5066-70. 
Hiltbold EM, Alter MD, Ciborowski P, Finn OJ. Presentation of MUC1 tumor antigen by 
class I MHC and CTL function correlate with the glycosylation state of the protein taken Up 
by dendritic cells. Cell Immunol. 1999 Jun 15;194(2):143-9. 
_____________________________________________________                     Bibliography                           
 
 95
Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ. The mechanism of 
unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and 
processing by dendritic cells.J Immunol. 2000 Oct 1;165(7):3730-41. 
Ignatius R, Mahnke K, Rivera M, Hong K, Isdell F, Steinman RM, Pope M, Stamatatos L.  
Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells 
initiates CD8(+) T-cell responses in vivo. Blood. 2000 Nov 15;96(10):3505-13.  
Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, Bast 
RC Jr, Finn OJ.  Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma 
recognize an epitope present on the protein core of a mucin molecule preferentially expressed 
by malignant cells. Cancer Res. 1991 Jun 1;51(11):2908-16.  
Jondal M, Schirmbeck R, Reimann J. MHC class I-restricted CTL responses to exogenous 
antigens.Immunity. 1996 Oct;5(4):295-302. Review. 
Karaivanova VK, Spiro RG. Effect of proteasome inhibitors on the release into the cytosol of 
free polymannose oligosaccharides from glycoproteins. Glycobiology. 2000 Jul;10(7):727-35.  
Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, Xing PX, 
Jamieson G, Pietersz G, Tait B, Broadbent R, Thynne G, McKenzie IF.   Antibody and T cell 
responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J 
Clin Invest. 1997 Dec 1;100(11):2783-92. 
Karanikas V, Colau D, Baurain JF, Chiari R, Thonnard J, Gutierrez-Roelens I, Goffinet C, 
Van Schaftingen EV, Weynants P, Boon T, Coulie PG. High frequency of cytolytic T 
lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers 
in the blood of a lung carcinoma patient with long survival. Cancer Res. 2001 May 
1;61(9):3718-24.  
Karsten U, Diotel C, Klich G, Paulsen H, Goletz S, Muller S, Hanisch FG.  Enhanced binding 
of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific 
glycosylation. Cancer Res. 1998 Jun 15;58(12):2541-9. 
Karsten U, Serttas N, Paulsen H, Danielczyk A, Goletz S. Binding patterns of DTR-specific 
antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin 
(MUC1). Glycobiology. 2004 Aug;14(8):681-92. 
Karsten U, von Mensdorff-Pouilly S, Goletz S. What makes MUC1 a tumor antigen? Tumour 
Biol. 2005 Jul-Aug;26(4):217-20. Review. 
Kesmir C, Nussbaum AK, Schild H, Detours V, Brunak S. Prediction of proteasome cleavage 
motifs by neural networks. Protein Eng. 2002 Apr;15(4):287-96.  
Kim W, Spear ED, Ng DT. Yos9p detects and targets misfolded glycoproteins for ER-
associated degradation. Mol Cell. 2005 Sep 16;19(6):753-64.  
_____________________________________________________                     Bibliography                           
 
 96
Kinarsky L, Suryanarayanan G, Prakash O, Paulsen H, Clausen H, Hanisch FG, 
Hollingsworth MA, Sherman S. Conformational studies on the MUC1 tandem repeat 
glycopeptides: implication for the enzymatic O-glycosylation of the mucin protein core. 
Glycobiology. 2003 Dec;13(12):929-39. 
Kohlgraf KG, Gawron AJ, Higashi M, VanLith ML, Shen X, Caffrey TC, Anderson JM, 
Hollingsworth MA. Tumor-specific immunity in MUC1.Tg mice induced by immunization 
with peptide vaccines from the cytoplasmic tail of CD227 (MUC1). Cancer Immunol 
Immunother. 2004 Dec;53(12):1068-84.  
Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ.  Humoral immunity against a tandem 
repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer 
patients. Cancer Res. 1994 Jun 1;54(11):2856-60.  
Lagow E, DeSouza MM, Carson DD. Mammalian reproductive tract mucins. Hum Reprod 
Update. 1999;5:280–292. 
Lee MC, Miller EA, Goldberg J, Orci L, Schekman R. Bi-directional protein transport 
between the ER and Golgi. Annu Rev Cell Dev Biol. 2004;20:87-123. Review.  
Ligtenberg M. J. L., Vos H. L., Genissen A. M. C., Hilkens J. Episialin, a carcinoma 
associated mucin, is generated by a polymorphic gene encoding splice variants with 
alternative amino termini. J. Biol. Chem., 265: 15573-15578, 1990.  
Ligtenberg MJ, Buijs F, Vos HL, Hilkens J. Suppression of cellular aggregation by high 
levels of episialin. Cancer Res. 1992 Apr 15;52(8):2318-24. 
Ligtenberg M. J. L., Kruijshaar L., Buijs F., Van Meijer M., Litvinov S. V., Hilkens J. Cell 
associated episialin is a complex containing two proteins derived from a common precursor. J. 
Biol. Chem., 1992, 267: 6171-6177. 
Ligtenberg,M.J., Kruijshaar,L., Buijs,F., van Meijer,M., Litvinov,S.V. and Hilkens,J.    Cell-
associated episialin is a complex containing two proteins derived from a common precursor., 
J. Biol. Chem. 1992, 267 (9), 6171-6177. 
Liu X, Sejbal J, Kotovych G, Koganty RR, Reddish MA, Jackson L, Gandhi SS, Mendonca 
AJ, Longenecker BM. Structurally defined synthetic cancer vaccines: analysis of structure, 
glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides. 
Glycoconj J. 1995 Oct;12(5):607-17.  
Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos 
V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF, Mitchell PL.  Mannan-MUC1-pulsed 
dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer 
Res. 2006 Feb 1;12(3 Pt 1):869-77. 
_____________________________________________________                     Bibliography                           
 
 97
Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R.  Crystal structure of the 20S 
proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science. 1995 Apr 
28;268(5210):533-9. 
Lucchiari-Hartz M, van Endert PM, Lauvau G, Maier R, Meyerhans A, Mann D, Eichmann 
K, Niedermann G.  Cytotoxic T lymphocyte epitopes of HIV-1 Nef: Generation of multiple 
definitive major histocompatibility complex class I ligands by proteasomes. J Exp Med. 2000 
Jan 17;191(2):239-52.  
Ma CP, Willy PJ, Slaughter CA, DeMartino GN. PA28, an activator of the 20 S proteasome, 
is inactivated by proteolytic modification at its carboxyl terminus. J Biol Chem. 1993 Oct 
25;268(30):22514-9. 
Matzinger P.  Tolerance, danger, and the extended family.Annu Rev Immunol. 1994;12:991-
1045. Review. 
Muller S, Goletz S, Packer N, Gooley A, Lawson AM, Hanisch FG.  Localization of O-
glycosylation sites on glycopeptide fragments from lactation-associated MUC1. All putative 
sites within the tandem repeat are glycosylation targets in vivo. J Biol Chem. 1997 Oct 
3;272(40):24780-93.  
Muller S, Alving K, Peter-Katalinic J, Zachara N, Gooley AA, Hanisch FG. High density O-
glycosylation on tandem repeat peptide from secretory MUC1 of T47D breast cancer cells. J 
Biol Chem. 1999 Jun 25;274(26):18165-72.  
Murakami Y, Matsufuji S, Kameji T, Hayashi S, Igarashi K, Tamura T, Tanaka K, Ichihara A. 
Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature. 
1992 Dec 10;360(6404):597-9.  
Niedermann G, King G, Butz S, Birsner U, Grimm R, Shabanowitz J, Hunt DF, Eichmann K. 
The proteolytic fragments generated by vertebrate proteasomes: structural relationships to 
major histocompatibility complex class I binding peptides. Proc Natl Acad Sci U S A. 1996 
Aug 6;93(16):8572-7. 
Nielsen M, Lundegaard C, Lund O, Kesmir C.  The role of the proteasome in generating 
cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal 
cleavage. Immunogenetics. 2005 Apr;57(1-2):33-41. 
Nussbaum AK, Dick TP, Keilholz W, Schirle M, Stevanovic S, Dietz K, Heinemeyer W, 
Groll M, Wolf DH, Huber R, Rammensee HG, Schild H. Cleavage motifs of the yeast 20S 
proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci U S A. 1998 
Oct 13;95(21):12504-9.  
Oosterkamp HM, Scheiner L, Stefanova MC, Lloyd KO, Finstad CL. Comparison of MUC-1 
mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new 
short variant form (MUC-1/Z). Int J Cancer. 1997 Jul 3;72(1):87-94. 
_____________________________________________________                     Bibliography                           
 
 98
Palmer M, Parker J, Modi S, Butts C, Smylie M, Meikle A, Kehoe M, MacLean G, 
Longenecker M.  Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active 
specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer. 2001 
Aug;3(1):49-57; 
Pandey P, Kharbanda S, Kufe D.  Association of the DF3/MUC1 breast cancer antigen with 
Grb2 and the Sos/Ras exchange protein. Cancer Res. 1995 Sep 15;55(18):4000-3.  
Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001 Sep;2(9):533-43. 
Review 
Perez-Vilar J, Hill RL. The structure and assembly of secreted mucins.J Biol Chem. 1999 Nov 
5;274(45):31751-4. Review 
Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF. Definition of MHC-
restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. 
Vaccine. 2000 Apr 3;18(19):2059-71.  
Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, 
Whiteside T, Osborne J, Kim H, Day R, Troetschel M, Finn OJ.  Phase I study of a MUC1 
vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and 
locally advanced pancreatic cancer. Cancer Immunol Immunother. 2005 Mar;54(3):254-64. 
Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol 
Today. 1996 Mar;17(3):131-7. Review.  
Rock KL, York IA, Goldberg AL. Post-proteasomal antigen processing for major 
histocompatibility complex class I presentation. Nat Immunol. 2004 Jul;5(7):670-7. Review.  
Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ.  Tolerance and 
immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res. 1998 Jan 
15;58(2):315-21.  
Schmidtke G, Kraft R, Kostka S, Henklein P, Frömmel C, Löwe J, Huber R, Kloetzel PM and 
Schmidt M. Analysis of mammalian 20S proteasome biogenesis: the maturation of -subunits 
is an ordered two-step mechanism involving autocatalysis. EMBO J, 1996, 15, 6887–6898. 
Scholl SM, Balloul JM, Le Goc G, Bizouarne N, Schatz C, Kieny MP, von Mensdorff-Pouilly 
S, Vincent-Salomon A, Deneux L, Tartour E, Fridman W, Pouillart P, Acres B.  Recombinant 
vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast 
cancer. J Immunother. 2000 Sep-Oct;23(5):570-80.  
Schroeder JA, Thompson MC, Gardner MM, Gendler SJ.  Transgenic MUC1 interacts with 
epidermal growth factor receptor and correlates with mitogen-activated protein kinase 
activation in the mouse mammary gland. J Biol Chem. 2001 Apr 20;276(16):13057-64. 
_____________________________________________________                     Bibliography                           
 
 99
Seemuller E, Lupas A, Stock D, Lowe J, Huber R, Baumeister W. Proteasome from 
Thermoplasma acidophilum: a threonine protease. Science. 1995 Apr 28;268(5210):579-82.  
Seemüller E, Lupas A and Baumeister W. Autocatalytic processing of the 20S proteasome. 
Nature, 1996, 382, 468–470.  
Seifert U, Maranon C, Shmueli A, Desoutter JF, Wesoloski L, Janek K, Henklein P, Diescher 
S, Andrieu M, de la Salle H, Weinschenk T, Schild H, Laderach D, Galy A, Haas G, Kloetzel 
PM, Reiss Y, Hosmalin A.  An essential role for tripeptidyl peptidase in the generation of an 
MHC class I epitope. Nat Immunol. 2003 Apr;4(4):375-9. 
Shen L, Sigal LJ, Boes M, Rock KL. Important role of cathepsin S in generating peptides for 
TAP-independent MHC class I crosspresentation in vivo. Immunity. 2004 Aug;21(2):155-65.  
Shimizu Y, Shaw S.  Cell adhesion. Mucins in the mainstream. Nature. 1993 Dec 
16;366(6456):630-1. 
Smorodinsky N, Weiss M, Hartmann ML, Baruch A, Harness E, Yaakobovitz M, Keydar I, 
Wreschner DH. Detection of a secreted MUC1/SEC protein by MUC1 isoform specific 
monoclonal antibodies. Biochem Biophys Res Commun. 1996 Nov 1;228(1):115-21. 
Snyder LA, Goletz TJ, Gunn GR, Shi FF, Harris MC, Cochlin K, McCauley C, McCarthy SG, 
Branigan PJ, Knight DM.  A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and 
increased survival in MUC1 transgenic mice. Vaccine. 2006 Apr 12;24(16):3340-52. 
Soares MM, Mehta V, Finn OJ.  Three different vaccines based on the 140-amino acid MUC1 
peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector 
mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor 
rejection. J Immunol. 2001 Jun 1;166(11):6555-63. 
Spicer A. P., Rowse G. J., Lidner T-K., Gendler S. J. Delayed mammary tumor progression in 
MUC-1 null mice. J. Biol. Chem., 270: 30093-30101, 1995 
Stepensky D, Tzehoval E, Vadai E, Eisenbach L. O-glycosylated versus non-glycosylated 
MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clin 
Exp Immunol. 2006 Jan;143(1):139-49.  
Storkus WJ, Zeh HJ 3rd, Salter RD, Lotze MT. Identification of T-cell epitopes: rapid 
isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother. 
1993 Aug;14(2):94-103.  
Suzuki T, Park H, Kwofie MA, Lennarz WJ. Rad23 provides a link between the Png1 
deglycosylating enzyme and the 26 S proteasome in yeast. J Biol Chem. 2001 Jun 
15;276(24):21601-7. 
_____________________________________________________                     Bibliography                           
 
 100
Tanaka Y, Koido S, Ohana M, Liu C, Gong J. Induction of impaired antitumor immunity by 
fusion of MHC class II-deficient dendritic cells with tumor cells. J Immunol. 2005 Feb 
1;174(3):1274-80.  
Ten Hagen KG, Tetaert D, Hagen FK, Richet C, Beres TM, Gagnon J, Balys MM, 
VanWuyckhuyse B, Bedi GS, Degand P, Tabak LA. Characterization of a UDP-
GalNAc:polypeptide N-acetylgalactosaminyltransferase that displays glycopeptide N-
acetylgalactosaminyltransferase activity. J Biol Chem. 1999 Sep 24;274(39):27867-74. 
Toes RE, Nussbaum AK, Degermann S, Schirle M, Emmerich NP, Kraft M, Laplace C, 
Zwinderman A, Dick TP, Muller J, Schonfisch B, Schmid C, Fehling HJ, Stevanovic S, 
Rammensee HG, Schild H.  Discrete cleavage motifs of constitutive and immunoproteasomes 
revealed by quantitative analysis of cleavage products. J Exp Med. 2001 Jul 2;194(1):1-12.  
Unno M, Mizushima T, Morimoto Y, Tomisugi Y, Tanaka K, Yasuoka N, Tsukihara T.  The 
structure of the mammalian 20S proteasome at 2.75 A resolution. Structure. 2002 
May;10(5):609-18.  
Vlad AM, Muller S, Cudic M, Paulsen H, Otvos L Jr, Hanisch FG, Finn OJ.   Complex 
carbohydrates are not removed during processing of glycoproteins by dendritic cells: 
processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility 
complex class II-restricted T cells. J Exp Med. 2002 Dec 2;196(11):1435-46.  
Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from 
discovery to clinical applications. Adv Immunol. 2004;82:249-93. Review. 
von Mensdorff-Pouilly S, Petrakou E, Kenemans P, van Uffelen K, Verstraeten AA, 
Snijdewint FG, van Kamp GJ, Schol DJ, Reis CA, Price MR, Livingston PO, Hilgers J.  
Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and 
n-acetylgalactosamine (GalNAc) peptides. Int J Cancer. 2000 Jun 1;86(5):702-12.  
Walz G, Aruffo A, Kolanus W, Bevilacqua M, Seed B.  Recognition by ELAM-1 of the 
sialyl-Lex determinant on myeloid and tumor cells. Science. 1990 Nov 23;250(4984):1132-5.  
Wandall HH, Hassan H, Mirgorodskaya E, Kristensen AK, Roepstorff P, Bennett EP, Nielsen 
PA, Hollingsworth MA, Burchell J, Taylor-Papadimitriou J, Clausen H.  Substrate 
specificities of three members of the human UDP-N-acetyl-alpha-D-
galactosamine:Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -
T3. J Biol Chem. 1997 Sep 19;272(38):23503-14. 
Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) 
overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J 
Cell Biol. 1995;129:255–265. 
_____________________________________________________                     Bibliography                           
 
 101
Wesseling J, van der Valk SW, Hilkens J.  A mechanism for inhibition of E-cadherin-
mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol 
Cell. 1996 Apr;7(4):565-77.  
Whitby FG, Masters EI, Kramer L, Knowlton JR, Yao Y, Wang CC, Hill CP. Structural basis 
for the activation of 20S proteasomes by 11S regulators. Nature. 2000 Nov 2;408(6808):115-
20.  
Whitehouse C, Burchell J, Gschmeissner S, Brockhausen I, Lloyd KO, Taylor-Papadimitriou 
J. A transfected sialyltransferase that is elevated in breast cancer and localizes to the 
medial/trans-Golgi apparatus inhibits the development of core-2-based O-glycans. J Cell Biol. 
1997 Jun 16;137(6):1229-41.  
Wierecky J, Mueller M, Brossart P. Dendritic cell-based cancer immunotherapy targeting 
MUC-1. Cancer Immunol Immunother. 2006 Jan;55(1):63-7. 
Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM, Hantschel M, 
Brugger W, Schroder S, Horger MS, Kanz L, Brossart P.  Immunologic and clinical responses 
after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. 
Cancer Res. 2006 Jun 1;66(11):5910-8.  
Wiertz EJ, Tortorella D, Bogyo M, Yu J, Mothes W, Jones TR, Rapoport TA, Ploegh HL. 
Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the 
proteasome for destruction. Nature. 1996 Dec 5;384(6608):432-8.  
Wilkinson RW, Ross EL, Lee-MacAry AE, Laylor R, Burchell J, Taylor-Papadimitriou J, 
Snary D. A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype 
response to human MUC1. Br J Cancer. 2000 Nov;83(9):1202-8.  
Wreschner D. H., Hareuveni M., Tsarfaty I., Smorodinsky N., Horev J., Zaretsky J., Kotkes 
P., Weiss M., Lathe R., Dion A. S., Keydar I. Human epithelial tumor antigen cDNA 
sequences—differential splicing may generate multiple protein forms. Eur. J. Biochem., 189: 
463-473, 1990.[Abstract]  
Wreschner DH, Zrihan-Licht S, Baruch A, Sagiv D, Hartman ML, Smorodinsky N, Keydar I. 
Does a novel form of the breast cancer marker protein, MUC1, act as a receptor molecule that 
modulates signal transduction? Adv Exp Med Biol. 1994;353:17-26.  
Yamamoto M, Bharti A, Li Y, Kufe D. Interaction of the DF3/MUC1 breast carcinoma-
associated antigen and beta-catenin in cell adhesion. J Biol Chem. 1997 May 
9;272(19):12492-4. 
Yamamoto K, Ueno T, Kawaoka T, Hazama S, Fukui M, Suehiro Y, Hamanaka Y, Ikematsu 
Y, Imai K, Oka M, Hinoda Y. MUC1 peptide vaccination in patients with advanced pancreas 
or biliary tract cancer.Anticancer Res. 2005 Sep-Oct;25(5):3575-9.  
_____________________________________________________                     Bibliography                           
 
 102
Ye Y, Shibata Y, Yun C, Ron D, Rapoport TA. A membrane protein complex mediates retro-
translocation from the ER lumen into the cytosol. Nature. 2004 Jun 24;429(6994):841-7. 
Yoshida Y. Expression and assay of glycoprotein-specific ubiquitin ligases. Methods 
Enzymol. 2005;398:159-69. 
Yuen CT, Lawson AM, Chai W, Larkin M, Stoll MS, Stuart AC, Sullivan FX, Ahern TJ, 
Feizi T.  Novel sulfated ligands for the cell adhesion molecule E-selectin revealed by the 
neoglycolipid technology among O-linked oligosaccharides on an ovarian cystadenoma 
glycoprotein. Biochemistry. 1992 Sep 29;31(38):9126-31. 
Zhang K, Baeckstrom D, Brevinge H, Hansson GC. Secreted MUC1 mucins lacking their 
cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of 
colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing 
endothelial cells. J Cell Biochem. 1996 Mar 15;60(4):538-49. 
Zotter S, Hageman PC, Lossnitzer A, Mooi WJ, Hilgers J. Tissue and tumor distribution of 
human polymorphic epithelial mucin. In Hilgers J, Zotter S. (eds), Polymorphic Epithelial 
Mucin and CA125-bearing Glycoprotein As Tumor-Associated Antigens. Cancer Rev., Vol 
11/12, pp. 55-101  
Zrihan-Licht S, Baruch A, Elroy-Stein O, Keydar I, Wreschner DH. Tyrosine phosphorylation 
of the MUC1 breast cancer membrane proteins. Cytokine receptor-like molecules. FEBS Lett. 
1994 Dec 12;356(1):130-6.  
Zrihan-Licht S, Vos HL, Baruch A, Elroy-Stein O, Sagiv D, Keydar I, Hilkens J, Wreschner 
DH. Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem 
repeats, expressed in human breast cancer tissue. Eur J Biochem. 1994 Sep 1;224(2):787-95.  
                                                                                                                                                                               
 
 103
 
 
 
 
Erklärung 
 
 
Ich versichere, dass ich die von mir vorgelegte Dissertation selbständig angefertigt, die 
benutzten Quellen und Hilfsmittel vollständig angegeben und die Stellen der Arbeit -
einschließlich Tabellen und Abbildungen -, die anderen Werke im Wortlaut oder dem Sinn 
nach entnommen sind, in jedem Einzelfall als Entlehnung kenntlich gemacht habe; dass diese 
Dissertation noch keiner anderen Fakultät oder Universität zur Prüfung vorgelegen hat; dass 
sie noch nicht veröffentlicht ist, sowie, dass ich eine Veröffentlichung vor Abschluss des 
Promotionsverfahrens nicht vornehmen werde. Die Bestimmungen dieser Promotionsordnung 
sind mir bekannt. Die von mir vorgelegte Dissertation ist von Herrn Prof. Dr. Franz-Georg 
Hanisch betreut worden. 
 
 
 
 
 
Köln, den 20.08.2006. 
Tanja Ninković 
 
 
 
Publications: 
Hanisch FG, Ninkovic T. Immunology of O-glycosylated Proteins: Approaches to the design 
of a MUC1 Glycopeptide-Based Tumor Vaccine, Current Protein and Peptide Science, 2006, 
7, 307-315 
Ninkovic T, Pisarev V, Hanisch FG. Processing of MUC1 tumor antigen in MHC class I 
pathway, Mucin in Health and Disease, 8th International Workshop on Carcinoma-associated 
Mucins, Robinson College, Cambridge (UK), 8 – 13 July 2005; Oral and poster presentation 
Ninkovic T, Hansich FG. Processing of O-glycosylated MUC1 glycopeptides by 
immunoproteasomed for presentation in the MHC class I pathway, Joint meeting of the 
Glycobiology Society, Wageningen, Netherlands, Nov 2004. Poster and oral presentation 
 
 
                                                                                                                                                                               
 
 104
Lebenslauf/Curriculum Vitae 
 
 
Persönliche Daten: 
 
Name,Vorname:  Ninković, Tanja 
Anschrift:   Kapitelstr 21 
   51103 Köln 
Geburtsdatum:  03.09.1977. 
Geburtsort:   Jugoslawien/Serbien 
Staatsangehörigkeit: Serbin 
Familienstand:  ledig 
Eltern:   Radovan Ninković und Vesna Ninković 
 
Schulausbildung: 
 
1984-1992   Grundschule, Belgrad 
1992-1996   Naturwissenschaftliches Gymnasium, Belgrad 
 
Studium 
1996-2002   Biologische Fakultät, Universität Belgrad, 
   Institut für Molekularbiologie und Physiologie 
   Hauptstudiengang: Experimentelle Biomedizin 
   Abschluss mit der Durchschnittsnote 9,31 (auf einer Skala von 6 bis 10) 
   Diplomprüfung mit der Note 10 
   Diplomarbeit: “Die Rolle des c-myc Onkogens in der malignen  
   Transformation des oralen Mucus“ 
Feb 2003 -Okt 2006 Dissertation bei Prof. Dr. Franz-Georg Hanisch am Institut für  
   Biochemie der Medizinischen Fakultät der Universität zu Köln mit dem 
   Ziel derPromotion an der Math. Nat. Fakultät der Universität zu Köln 
 
Köln den 20.08.06,  
 
 
Tanja Ninković 
 
 
                                                                                                                                                                               
 
 105
Curriculum Vitae 
 
 
Personal details 
 
Name, Surname:  Ninković, Tanja 
Adress:   Kapitelstr 21 
   51103 Köln 
Date of birth:   03.09.1977. 
Place of birth:  Yugoslavia/Serbia 
Citizenship:  Serbian 
Family state:  Not married 
Parents:   Radovan Ninković and Vesna Ninković 
 
School education: 
 
1984-1992   Primary School 
1992-1996   Grammar school, section“ Natural Sciences“, Belgrade 
 
Studies: 
1996-2002   Faculty of Biology, University of Belgrade, 
   Institute for Molecular Biology and Physiology 
   Orientation: Experimenthal Biomedicine 
   Finnished with average mark 9,31 (on the scale from 6 to 10) 
   Master theses marked with 10 
   Title of the Master thesis: “The role of c-myc oncogene in malignant 
   transformation of the oral mucus” 
Doctoral studies: 
Feb 2003 -Okt 2006 PhD studies in the group of Prof. Dr. Franz-Georg Hanisch at Center for 
   Biochemistry, Medical Faculty, University of Cologne  
 
 
 
 
Köln 20. Aug 2006,  
 
 
Tanja Ninković 
                                                                                                                                                                               
 
 106
 
